14. Literaturverzeichnis – Breast Cancer

1. Nilsen, E. S., Myrhaug, H. T., Johansen, M., Oliver, S., Oxman, A. D., Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material, Cochrane Database Syst Rev, 2006. p. Cd004563.

2. Gysels, M., Higginson, I. J., Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials, Support Care Cancer, 2007. 15(1): p. 7-20.

3. Wofford, J. L., Smith, E. D., Miller, D. P., The multimedia computer for office-based patient education: a systematic review, Patient Educ Couns, 2005. 59(2): p. 148-57.

4. Beauchamp, Tom L, Childress, James F, Principles of biomedical ethicsOxford University Press, USA, 2001.

5. Sieber, W. J., Kaplan, R. M., Informed adherence: the need for shared medical decision making, Control Clin Trials, 2000. 21(5 Suppl): p. 233s-40s.

6. Weinstein, James N, Editorial: The missing piece: Embracing shared decision making to reform health careLWW, 2000.

7. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, Bmj, 2004. 328(7444): p. 864.

8. Dissemination, NHS Centre for Reviews and, Effective Health Care: Informing, communicating and sharing decision with people who have cancer.Latimer Trend & Company Ltd., 2000.

9. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23(27): p. 6623-30.

10. Katz, S. J., Lantz, P. M., Janz, N. K., Fagerlin, A., Schwartz, K., Liu, L., et.al. Patient involvement in surgery treatment decisions for breast cancer, J Clin Oncol, 2005. 23(24): p. 5526-33.

11. Wagner, Katja, Koller, M, Keil, Astrid, Trott, Diana, Engenhart-Cabillic, Rita, Pfab, R, et.al. Strahlentherapie bei chirurgischen und nichtchirurgischen Patienten Therapieerwartungen, Lebensqualität und Arzteinschätzungen, Der Chirurg, 1998. 69(3): p. 252-258.

12. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73(3): p. 511-8.

13. Steinbach, K., van Oorschot, B. Anselm, R. Leppert, K. Schweitzer, S. Hausmann, C. Köhler, N., Wer soll entscheiden?, Deutsches Ärzteblatt, 2004. 101(41): p. A-2741.

14. Albert, U-S, Koller, M, Wagner, U, Schulz, K-D, Survival chances and psychological aspects of quality of life in patients with localized early stage breast cancer, Inflammation Research, 2004. 53: p. S136-S141.

15. Chouliara, Z., Kearney, N., Stott, D., Molassiotis, A., Miller, M., Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature, Ann Oncol, 2004. 15(11): p. 1596-602.

16. Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., Tattersall, M. H., Communicating prognosis in cancer care: a systematic review of the literature, Ann Oncol, 2005. 16(7): p. 1005-53.

17. Center, D.-H.M., Available from:  http://www.dartmouth-hitchcock.org/about_dh/project_search.html, 2016., Available, from:, , , http://www.dartmouth-hitchcock.org/about_dh/project_search.html, , .

18. Berger-Hoger, B., Liethmann, K., Muhlhauser, I., Haastert, B., Steckelberg, A., Informed shared decision-making supported by decision coaches for women with ductal carcinoma in situ: study protocol for a cluster randomized controlled trial, Trials, 2015. 16: p. 452.

19. Rahn, A. C., Kopke, S., Kasper, J., Vettorazzi, E., Muhlhauser, I., Heesen, C., Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial, Trials, 2015. 16: p. 106.

20. Albert, U-S, Schulz, K-D, Alt, D, Beck, V, Doherty, J, Holsteg, K, et.al. Eine Leitlinie für Leitlinien: die methodische Entwicklung und Anwendung der Leitlinie Fraueninformation, Zentralblatt für Gynäkologie, 2003. 125(12): p. 484-493.

21. O'connor, Annette M, Rostom, Alaa, Fiset, Valerie, Tetroe, Jacqueline, Entwistle, Vikki, Llewellyn-Thomas, Hilary, et.al. Decision aids for patients facing health treatment or screening decisions: systematic review, Bmj, 1999. 319(7212): p. 731-734.

22. Klemperer, D, Lang, B, Koch, K, Bastian, H, Brunsmann, F, Burkhardt, M, et.al. Gute Praxis Gesundheitsinformation, Z Evid Fortbild Qual Gesundh wesen (ZEFQ), 2010. 104: p. 66-68.

23. Bruera, E., Willey, J. S., Palmer, J. L., Rosales, M., Treatment decisions for breast carcinoma: patient preferences and physician perceptions, Cancer, 2002. 94(7): p. 2076-80.

24. Butow, P., Harrison, J. D., Choy, E. T., Young, J. M., Spillane, A., Evans, A., Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan, Cancer, 2007. 110(9): p. 1937-44.

25. Elkin, E. B., Kim, S. H., Casper, E. S., Kissane, D. W., Schrag, D., Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions, J Clin Oncol, 2007. 25(33): p. 5275-80.

26. Ford, S., Schofield, T., Hope, T., Observing decision-making in the general practice consultation: who makes which decisions?, Health Expect, 2006. 9(2): p. 130-7.

27. Politi, M. C., Han, P. K., Col, N. F., Communicating the uncertainty of harms and benefits of medical interventions, Med Decis Making, 2007. 27(5): p. 681-95.

28. NICE, The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment, 2009 [addendum 2014].

29. Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et.al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 2014. 32(24): p. 2595-603.

30. NICE, The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment, 2009 (Update 2014).

31. Runowicz, Carolyn D, Leach, Corinne R, Henry, N Lynn, Henry, Karen S, Mackey, Heather T, Cowens‐Alvarado, Rebecca L, et.al. American Cancer society/American society of clinical oncology breast Cancer survivorship care guideline, CA: a cancer journal for clinicians, 2016. 66(1): p. 43-73.

32. Du, S., Hu, L., Dong, J., Xu, G., Jin, S., Zhang, H., et.al. Patient education programs for cancer-related fatigue: A systematic review, Patient Educ Couns, 2015. 98(11): p. 1308-19.

33. Gesundheit, Bundesministeriumfür, Patientenrechte in Deutschland. Leitfaden für Patientinnen/Patienten und Ärztinnen/Ärzte., 2007.

34. Schwartz, Alan, Crockett, Rachel A, Sutton, Stephen, Walter, Fiona M, Clinch, Megan, Marteau, Theresa M, et.al. Impact on decisions to start or continue medicines of providing information to patients about possible benefits and/or harms: a systematic review and meta-analysis, Medical Decision Making, 2011. 31(5): p. 767-777.

35. Butow, P. N., Maclean, M., Dunn, S. M., Tattersall, M. H., Boyer, M. J., The dynamics of change: cancer patients' preferences for information, involvement and support, Ann Oncol, 1997. 8(9): p. 857-63.

36. Degner, L. F., Kristjanson, L. J., Bowman, D., Sloan, J. A., Carriere, K. C., O'Neil, J., et.al. Information needs and decisional preferences in women with breast cancer, Jama, 1997. 277(18): p. 1485-92.

37. Leinster, Samuel J, Ashcroft, Jennifer J, Slade, Peter, Dewey, Michael E, Mastectomy versus conservative surgery: psychosocial effects of the patient's choice of treatment, Journal of Psychosocial Oncology, 1989. 7(1-2): p. 179-192.

38. Hundertmark-Mayser, J, Thiel, W., Selbsthilfe, in Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes Gemeinsam getragen von RKI und Destatis Berlin, 2015. p. 369-374.

39. Nickel, Stefan, Werner, Silke, Kofahl, Christopher, Gesundheitsbezogene Selbsthilfe in Deutschland–Entwicklungen, Wirkungen, Perspektiven. Deskriptiver Ergebnis-Bericht zu der Befragung von Kontaktpersonen der Selbsthilfegruppen, 2014.

40. Albert, Ute Susann, Altland, H, Duda, V, Stufe-3-Leitlinie Brustkrebs-Früherkennung in DeutschlandZuckschwerdt München, 2008.

41. Group., Duke Evidence Synthesis, Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines.Duke Clinical Research Institute, Durham, NC: Guidelines Development Group, 2014.

42. Organization, World Health, WHO position paper on mammography screeningWorld Health Organization, 2014.

43. RKI., Krebs in Deutschland 2011/2012Robert Koch Institut, 2015.

44. Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., et.al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies, J Med Screen, 2012. 19 Suppl 1: p. 14-25.

45. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., et.al. Breast-cancer screening--viewpoint of the IARC Working Group, N Engl J Med, 2015. 372(24): p. 2353-8.

46. Oeffinger, K. C., Fontham, E. T., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. C., et.al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society, Jama, 2015. 314(15): p. 1599-614.

47. Tabar, L., Yen, A. M., Wu, W. Y., Chen, S. L., Chiu, S. Y., Fann, J. C., et.al. Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs, Breast J, 2015. 21(1): p. 13-20.

48. Simbrich, A., Wellmann, I., Heidrich, J., Heidinger, O., Hense, H. W., Trends in advanced breast cancer incidence rates after implementation of a mammography screening program in a German population, Cancer Epidemiol, 2016. 44: p. 44-51.

49. Malek, D, Kääb-Sanyal, V, Evaluationsbericht 2011. Zusammenfassung der Ergebnisse des Mammographie-Screening-Programms in Deutschland., 2011.

50. Bromham, N., Schmidt-Hansen, M., Astin, M., Hasler, E., Reed, M. W., Axillary treatment for operable primary breast cancer, Cochrane Database Syst Rev, 2017. 1: p. Cd004561.

51. Nelson, H. D., Pappas, M., Cantor, A., Griffin, J., Daeges, M., Humphrey, L., Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation, Ann Intern Med, 2016. 164(4): p. 256-67.

52. Myers, E. R., Moorman, P., Gierisch, J. M., Havrilesky, L. J., Grimm, L. J., Ghate, S., et.al. Benefits and Harms of Breast Cancer Screening: A Systematic Review, Jama, 2015. 314(15): p. 1615-34.

53. Bleyer, A., Welch, H. G., Effect of three decades of screening mammography on breast-cancer incidence, N Engl J Med, 2012. 367(21): p. 1998-2005.

54. Helvie, Mark A, Chang, Joanne T, Hendrick, R Edward, Banerjee, Mousumi, Reduction in late‐stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer, Cancer, 2014. 120(17): p. 2649-2656.

55. Duffy, S. W., Dibden, A., Michalopoulos, D., Offman, J., Parmar, D., Jenkins, J., et.al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study, Lancet Oncol, 2016. 17(1): p. 109-14.

56. van Luijt, P. A., Heijnsdijk, E. A., Fracheboud, J., Overbeek, L. I., Broeders, M. J., Wesseling, J., et.al. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening, Breast Cancer Res, 2016. 18(1): p. 47.

57. Perry, N., Broeders, M., de Wolf, C., Tornberg, S., Holland, R., von Karsa, L., European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document, Ann Oncol, 2008. 19(4): p. 614-22.

58. (ECIBC), European Commission Initiative on Breast Cancer, Evidencereport update, 2016.

59. Azavedo, E., Zackrisson, S., Mejare, I., Heibert Arnlind, M., Is single reading with computer-aided detection (CAD) as good as double reading in mammography screening? A systematic review, BMC Med Imaging, 2012. 12: p. 22.

60. Lehman, C. D., Wellman, R. D., Buist, D. S., Kerlikowske, K., Tosteson, A. N., Miglioretti, D. L., Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection, JAMA Intern Med, 2015. 175(11): p. 1828-37.

61. Swedish Council on Health Technology, Assessment, SBU Systematic Review Summaries, in Computer-Aided Detection (CAD) in Mammography Screening, 2011, Swedish Council on Health Technology Assessment (SBU) Copyright (c) 2011 by the Swedish Council on Health Technology Assessment.: Stockholm.

62. Obi, N., Waldmann, A., Schafer, F., Schreer, I., Katalinic, A., Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients, Cancer Epidemiol, 2011. 35(3): p. 286-92.

63. Lehman, C. D., Lee, A. Y., Lee, C. I., Imaging management of palpable breast abnormalities, AJR Am J Roentgenol, 2014. 203(5): p. 1142-53.

64. Miglioretti, D. L., Zhu, W., Kerlikowske, K., Sprague, B. L., Onega, T., Buist, D. S., et.al. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status, JAMA Oncol, 2015. 1(8): p. 1069-77.

65. Siu, A. L., Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, 2016. 164(4): p. 279-96.

66. Fügemann, H, Kääb-Sanyal, V, Mammographie-Screening: Nutzen-Schaden-Abwägung im internationalen Vergleich, Dtsch Arztebl, 2016. 113(3): p. A74-A78.

67. Erstellung von Patientenleitlinien zu S3-Leitlinien/NVL im Rahmen der Leitlinienprogramme., 2017.

68. (IARC)., International Agency for Research on Cancer, Breast Cancer Screening. IARC Handbook of Cancer Prevention., 2016. 15:

69. Pace, L. E., Keating, N. L., A systematic assessment of benefits and risks to guide breast cancer screening decisions, Jama, 2014. 311(13): p. 1327-35.

70. Nelson, H. D., Fu, R., Cantor, A., Pappas, M., Daeges, M., Humphrey, L., Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation, Ann Intern Med, 2016. 164(4): p. 244-55.

71. Moss, S. M., Wale, C., Smith, R., Evans, A., Cuckle, H., Duffy, S. W., Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial, Lancet Oncol, 2015. 16(9): p. 1123-32.

72. Hodgson, Robert, Heywang-Köbrunner, Sylvia H, Harvey, Susan C, Edwards, Mary, Shaikh, Javed, Arber, Mick, et.al. Systematic review of 3D mammography for breast cancer screening, The Breast, 2016. 27: p. 52-61.

73. Melnikow, J., Fenton, J. J., Whitlock, E. P., Miglioretti, D. L., Weyrich, M. S., Thompson, J. H., et.al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force, Ann Intern Med, 2016. 164(4): p. 268-78.

74. Skaane, P., Bandos, A. I., Eben, E. B., Jebsen, I. N., Krager, M., Haakenaasen, U., et.al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images, Radiology, 2014. 271(3): p. 655-63.

75. Lang, K., Andersson, I., Rosso, A., Tingberg, A., Timberg, P., Zackrisson, S., Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmo Breast Tomosynthesis Screening Trial, a population-based study, Eur Radiol, 2016. 26(1): p. 184-90.

76. Group., Duke Evidence Synthesis, Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines.Duke Clinical Research Institute, Durham, NC: Guidelines Development Group, 2014.

77. Siu, A. L., Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, 2016. 164(4): p. 279-96.

78. (IARC)., International Agency for Research on Cancer, Breast Cancer Screening. IARC Handbook of Cancer Prevention., 2016. 15:

79. Melnikow, J., Fenton, J. J., Whitlock, E. P., Miglioretti, D. L., Weyrich, M. S., Thompson, J. H., et.al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force, Ann Intern Med, 2016. 164(4): p. 268-78.

80. Golatta, M., Franz, D., Harcos, A., Junkermann, H., Rauch, G., Scharf, A., et.al. Interobserver reliability of automated breast volume scanner (ABVS) interpretation and agreement of ABVS findings with hand held breast ultrasound (HHUS), mammography and pathology results, Eur J Radiol, 2013. 82(8): p. e332-6.

81. Golatta, Michael, Baggs, Christina, Schweitzer-Martin, Mirjam, Domschke, Christoph, Schott, Sarah, Harcos, Aba, et.al. Evaluation of an automated breast 3D-ultrasound system (ABUS) by comparing it with hand-held ultrasound (HHUS) and mammography, Archives of gynecology and obstetrics, 2014. 291:

82. Wojcinski, S., Gyapong, S., Farrokh, A., Soergel, P., Hillemanns, P., Degenhardt, F., Diagnostic performance and inter-observer concordance in lesion detection with the automated breast volume scanner (ABVS), BMC Med Imaging, 2013. 13: p. 36.

83. Choi, W. J., Cha, J. H., Kim, H. H., Shin, H. J., Kim, H., Chae, E. Y., et.al. Comparison of automated breast volume scanning and hand- held ultrasound in the detection of breast cancer: an analysis of 5,566 patient evaluations, Asian Pac J Cancer Prev, 2014. 15(21): p. 9101-5.

84. Shin, H. J., Kim, H. H., Cha, J. H., Current status of automated breast ultrasonography, Ultrasonography, 2015. 34(3): p. 165-72.

85. Brem, R. F., Tabar, L., Duffy, S. W., Inciardi, M. F., Guingrich, J. A., Hashimoto, B. E., et.al. Assessing improvement in detection of breast cancer with three-dimensional automated breast US in women with dense breast tissue: the SomoInsight Study, Radiology, 2015. 274(3): p. 663-73.

86. Hellgren, Roxanna, Dickman, Paul, Leifland, Karin, Saracco, Ariel, Hall, Per, Celebioglu, Fuat, Comparison of handheld ultrasound and automated breast ultrasound in women recalled after mammography screening, Acta Radiologica, 2016. p. 0284185116665421.

87. Wilczek, B., Wilczek, H. E., Rasouliyan, L., Leifland, K., Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: Report from a hospital-based, high-volume, single-center breast cancer screening program, Eur J Radiol, 2016. 85(9): p. 1554-63.

88. Giger, M. L., Inciardi, M. F., Edwards, A., Papaioannou, J., Drukker, K., Jiang, Y., et.al. Automated Breast Ultrasound in Breast Cancer Screening of Women With Dense Breasts: Reader Study of Mammography-Negative and Mammography-Positive Cancers, AJR Am J Roentgenol, 2016. 206(6): p. 1341-50.

89. Houssami, N., Abraham, L. A., Kerlikowske, K., Buist, D. S., Irwig, L., Lee, J., et.al. Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening, Cancer Epidemiol Biomarkers Prev, 2013. 22(5): p. 946-61.

90. Kerlikowske, Karla, Zhu, Weiwei, Tosteson, Anna NA, Sprague, Brian L, Tice, Jeffrey A, Lehman, Constance D, et.al. Identifying women with dense breasts at high risk for interval cancer: a cohort study, Annals of internal medicine, 2015. 162(10): p. 673-681.

91. Brentnall, A. R., Harkness, E. F., Astley, S. M., Donnelly, L. S., Stavrinos, P., Sampson, S., et.al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort, Breast Cancer Res, 2015. 17(1): p. 147.

92. Ohuchi, N., Suzuki, A., Sobue, T., Kawai, M., Yamamoto, S., Zheng, Y. F., et.al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial, Lancet, 2016. 387(10016): p. 341-8.

93. Tagliafico, Alberto S, Calabrese, Massimo, Mariscotti, Giovanna, Durando, Manuela, Tosto, Simona, Monetti, Francesco, et.al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial, Journal of Clinical Oncology, 2016. 34(16): p. 1882-1888.

94. Caumo, Francesca, Bernardi, Daniela, Ciatto, Stefano, Macaskill, Petra, Pellegrini, Marco, Brunelli, Silvia, et.al. Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: increased breast cancer detection evident for screening centres in a population-based trial, The Breast, 2014. 23(1): p. 76-80.

95. McCormack, V. A., dos Santos Silva, I., Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2006. 15(6): p. 1159-69.

96. Gail, M. H., Mai, P. L., Comparing breast cancer risk assessment models, J Natl Cancer Inst, 2010. 102(10): p. 665-8.

97. D'Orsi, CJ, Bassett, LW, Berg, WA, al., et, BIRADS: Mammography, 4th edition, American College of Radiology, 2003.

98. Radiology, American College of, Breast imaging reporting and data system atlas, Breast Imaging Atlas., Reston, VA: American College of Radiology, 2013.

99. Carney, P. A., Miglioretti, D. L., Yankaskas, B. C., Kerlikowske, K., Rosenberg, R., Rutter, C. M., et.al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography, Ann Intern Med, 2003. 138(3): p. 168-75.

100. Kast, K., Rhiem, K., Wappenschmidt, B., Hahnen, E., Hauke, J., Bluemcke, B., et.al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer, J Med Genet, 2016. 53(7): p. 465-71.

101. NICE, Familial Breast Cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer., 2015.

102. Moyer, V. A., Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 2014. 160(4): p. 271-81.

103. Mavaddat, N., Rebbeck, T. R., Lakhani, S. R., Easton, D. F., Antoniou, A. C., Incorporating tumour pathology information into breast cancer risk prediction algorithms, Breast Cancer Res, 2010. 12(3): p. R28.

104. Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., et.al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, J Clin Oncol, 2015. 33(4): p. 304-11.

105. Schmidt, M., Thomssen, C., Untch, M., Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis, Oncol Res Treat, 2016. 39(3): p. 102-10.

106. Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkas, K., Roberts, J., et.al. Breast-cancer risk in families with mutations in PALB2, N Engl J Med, 2014. 371(6): p. 497-506.

107. Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., et.al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene, Nat Genet, 2010. 42(5): p. 410-4.

108. Legare, F., Stacey, D., Turcotte, S., Cossi, M. J., Kryworuchko, J., Graham, I. D., et.al. Interventions for improving the adoption of shared decision making by healthcare professionals, Cochrane Database Syst Rev, 2014. p. Cd006732.

109. Stacey, D., Legare, F., Col, N. F., Bennett, C. L., Barry, M. J., Eden, K. B., et.al. Decision aids for people facing health treatment or screening decisions, Cochrane Database Syst Rev, 2014. p. Cd001431.

110. Stacey, D., Samant, R., Bennett, C., Decision making in oncology: a review of patient decision aids to support patient participation, CA Cancer J Clin, 2008. 58(5): p. 293-304.

111. Kopke, S., Gerlach, A., [Informed decisions], Pflege Z, 2012. 65(4): p. 220-3.

112. Mühlhauser, I., Steckelberg, A., Evidenzbasierte Patienteninformation: Wünsche der Betroffenen., Deutsches Ärzteblatt, 2009. 106(51-52): p. A-2554–A-2556.

113. Lühnen J, Albrecht M, Mühlhauser I, A, Steckelberg, Leitlinie evidenzbasierte Gesundheitsinformation., 2017.

114. Arbeitsgruppe, GPGI, Gute Praxis Gesundheitsinformation, Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2016. 110: p. 85-92.

115. Honrado, E., Osorio, A., Palacios, J., Benitez, J., Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations, Oncogene, 2006. 25(43): p. 5837-45.

116. Lühnen J, Albrecht M, Mühlhauser I, A, Steckelberg, Leitlinie evidenzbasierte Gesundheitsinformation., 2017.

117. Stacey, D., Kryworuchko, J., Bennett, C., Murray, M. A., Mullan, S., Legare, F., Decision coaching to prepare patients for making health decisions: a systematic review of decision coaching in trials of patient decision AIDS, Med Decis Making, 2012. 32(3): p. E22-33.

118. Neumeyer-Gromen, Angela, Bodemer, Nicolai, Müller, Stephanie M, Gigerenzer, Gerd, Ermöglichen Medienberichte und Broschüren informierte Entscheidungen zur Gebärmutterhalskrebsprävention?, Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, 2011. 54(11): p. 1197-1210.

119. Lakhani, S. R., Ellis, I., Schnitt, S., Tan, P. H., Van de Vijver, M., WHO Classification of Tumours of the BreastIARC Press, 2012.

120. Stacey, D., Kryworuchko, J., Bennett, C., Murray, M. A., Mullan, S., Legare, F., Decision coaching to prepare patients for making health decisions: a systematic review of decision coaching in trials of patient decision AIDS, Med Decis Making, 2012. 32(3): p. E22-33.

121. Honrado, E., Osorio, A., Palacios, J., Benitez, J., Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations, Oncogene, 2006. 25(43): p. 5837-45.

122. Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., et.al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, J Clin Oncol, 2008. 26(26): p. 4282-8.

123. Evans, D. G., Clayton, R., Donnai, P., Shenton, A., Lalloo, F., Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk, Eur J Hum Genet, 2009. 17(11): p. 1381-5.

124. Gadzicki, D., Schubert, A., Fischer, C., Milde, S., Lehmann, U., Steinemann, D., et.al. Histopathological criteria and selection algorithms for BRCA1 genetic testing, Cancer Genet Cytogenet, 2009. 189(2): p. 105-11.

125. Young, S. R., Pilarski, R. T., Donenberg, T., Shapiro, C., Hammond, L. S., Miller, J., et.al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer, BMC Cancer, 2009. 9: p. 86.

126. Evans, D. G., Lennard, F., Pointon, L. J., Ramus, S. J., Gayther, S. A., Sodha, N., et.al. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study, Cancer Epidemiol Biomarkers Prev, 2009. 18(7): p. 2123-31.

127. Evans, D. G., Kesavan, N., Lim, Y., Gadde, S., Hurley, E., Massat, N. J., et.al. MRI breast screening in high-risk women: cancer detection and survival analysis, Breast Cancer Res Treat, 2014. 145(3): p. 663-72.

128. Phi, X. A., Saadatmand, S., De Bock, G. H., Warner, E., Sardanelli, F., Leach, M. O., et.al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis, Br J Cancer, 2016. 114(6): p. 631-7.

129. (ASC), American Cancer Society, Breast cancer early detection and diagnosis. American Cancer Society screenings recommendation for women at higher than average risk., 2016.

130. Robays, Jo, Stordeur, Sabine, Hulstaert, Frank, Van Maerken, Tom, Claes, Kathleen, Janin, Nicolas, et.al. Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li-Fraumeni syndrome and Cowden syndrome, KCE Report, 2015. 236:

131. Passaperuma, K., Warner, E., Causer, P. A., Hill, K. A., Messner, S., Wong, J. W., et.al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations, Br J Cancer, 2012. 107(1): p. 24-30.

132. Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., et.al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening, Ann Oncol, 2016. 27(suppl 5): p. v103-v110.

133. Obdeijn, I. M., Winter-Warnars, G. A., Mann, R. M., Hooning, M. J., Hunink, M. G., Tilanus-Linthorst, M. M., Should we screen BRCA1 mutation carriers only with MRI? A multicenter study, Breast Cancer Res Treat, 2014. 144(3): p. 577-82.

134. Saadatmand, S., Obdeijn, I. M., Rutgers, E. J., Oosterwijk, J. C., Tollenaar, R. A., Woldringh, G. H., et.al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC), Int J Cancer, 2015. 137(7): p. 1729-38.

135. Audeh, M. W., Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition, Pharmgenomics Pers Med, 2014. 7: p. 307-16.

136. Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., et.al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat, 2014. 147(2): p. 401-5.

137. Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et.al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy, J Clin Oncol, 2010. 28(3): p. 375-9.

138. Liu, M., Mo, Q. G., Wei, C. Y., Qin, Q. H., Huang, Z., He, J., Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis, Oncol Lett, 2013. 5(3): p. 983-991.

139. Telli, M., Optimizing chemotherapy in triple-negative breast cancer: the role of platinum, Am Soc Clin Oncol Educ Book, 2014. p. e37-42.

140. Turner, N. C., Tutt, A. N., Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?, Breast Cancer Res, 2012. 14(6): p. 115.

141. Lafarge, S., Sylvain, V., Ferrara, M., Bignon, Y. J., Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway, Oncogene, 2001. 20(45): p. 6597-606.

142. Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., et.al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis, Cancer Res, 2003. 63(19): p. 6221-8.

143. Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A, et.al. Germline mutation status, pathological complete response and disease-free survival rates in triple-negative breast cancer (GeparSixto trial), A Randomized Clinical Trial., JAMA Oncology in press, 2017.

144. Tutt, Andrew, Ellis, Paul, Kilburn, Lucy, Gilett, Cheryl, Pinder, Sarah, Abraham, Jacinta, et.al. Abstract S3-01: the TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)AACR, 2015.

145. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et.al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 2005. 434(7035): p. 913-7.

146. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et.al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 2005. 434(7035): p. 917-21.

147. Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., et.al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review, Clin Cancer Res, 2016. 22(15): p. 3971-81.

148. De Felice, F., Marchetti, C., Musella, A., Palaia, I., Perniola, G., Musio, D., et.al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis, Ann Surg Oncol, 2015. 22(9): p. 2876-80.

149. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et.al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, Jama, 2010. 304(9): p. 967-75.

150. Evans, D. G., Ingham, S. L., Baildam, A., Ross, G. L., Lalloo, F., Buchan, I., et.al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer, Breast Cancer Res Treat, 2013. 140(1): p. 135-42.

151. Lindor, N. M., Goldgar, D. E., Tavtigian, S. V., Plon, S. E., Couch, F. J., BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management, Oncologist, 2013. 18(5): p. 518-24.

152. Heemskerk-Gerritsen, B. A., Menke-Pluijmers, M. B., Jager, A., Tilanus-Linthorst, M. M., Koppert, L. B., Obdeijn, I. M., et.al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis, Ann Oncol, 2013. 24(8): p. 2029-35.

153. Lostumbo, L., Carbine, N. E., Wallace, J., Prophylactic mastectomy for the prevention of breast cancer, Cochrane Database Syst Rev, 2010. p. Cd002748.

154. Meijers-Heijboer, H., van Geel, B., van Putten, W. L., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B., et.al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med, 2001. 345(3): p. 159-64.

155. Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van 't Veer, L., Garber, J. E., et.al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 2004. 22(6): p. 1055-62.

156. Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., et.al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study, J Clin Oncol, 2008. 26(8): p. 1331-7.

157. Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et.al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 2004. 22(12): p. 2328-35.

158. Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T., Evans, G., Isaacs, C., et.al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study, Lancet Oncol, 2006. 7(3): p. 223-9.

159. Kotsopoulos, Joanne, Huzarski, Tomasz, Gronwald, Jacek, Singer, Christian F, Moller, Pal, Lynch, Henry T, et.al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers, JNCI: Journal of the National Cancer Institute, 2017. 109(1):

160. Heemskerk-Gerritsen, B. A., Seynaeve, C., van Asperen, C. J., Ausems, M. G., Collee, J. M., van Doorn, H. C., et.al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst, 2015. 107(5):

161. Robson, M., Svahn, T., McCormick, B., Borgen, P., Hudis, C. A., Norton, L., et.al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series, Cancer, 2005. 103(1): p. 44-51.

162. Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., et.al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 2009. 27(35): p. 5887-92.

163. Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., et.al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers, Gynecol Oncol, 2005. 96(1): p. 222-6.

164. Rhiem, K., Engel, C., Graeser, M., Zachariae, S., Kast, K., Kiechle, M., et.al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study, Breast Cancer Res, 2012. 14(6): p. R156.

165. van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R., van Asperen, C. J., Rutgers, E. J., et.al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers, Br J Cancer, 2005. 93(3): p. 287-92.

166. Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et.al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis, Int J Cancer, 2015. 136(3): p. 668-77.

167. Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., et.al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer, J Clin Oncol, 2006. 24(16): p. 2437-43.

168. Fakkert, I. E., Mourits, M. J., Jansen, L., van der Kolk, D. M., Meijer, K., Oosterwijk, J. C., et.al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers, Cancer Prev Res (Phila), 2012. 5(11): p. 1291-7.

169. van den Broek, A. J., van 't Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., et.al. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers, J Clin Oncol, 2016. 34(5): p. 409-18.

170. Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Musio, D., et.al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health, 2014. 14: p. 150.

171. Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Kim-Sing, C., Olopade, O. I., et.al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers, JAMA Oncol, 2015. 1(3): p. 306-13.

172. Plon, S. E., Eccles, D. M., Easton, D., Foulkes, W. D., Genuardi, M., Greenblatt, M. S., et.al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, 2008. 29(11): p. 1282-91.

173. Boughey, J. C., Hoskin, T. L., Degnim, A. C., Sellers, T. A., Johnson, J. L., Kasner, M. J., et.al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer, Ann Surg Oncol, 2010. 17(10): p. 2702-9.

174. Fayanju, O. M., Stoll, C. R., Fowler, S., Colditz, G. A., Margenthaler, J. A., Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis, Ann Surg, 2014. 260(6): p. 1000-10.

175. Speroff, L., The meaning of mammographic breast density in users of postmenopausal hormone therapy, Maturitas, 2002. 41(3): p. 171-5.

176. Morrow, M., Chatterton, R. T., Jr., Rademaker, A. W., Hou, N., Jordan, V. C., Hendrick, R. E., et.al. A prospective study of variability in mammographic density during the menstrual cycle, Breast Cancer Res Treat, 2010. 121(3): p. 565-74.

177. Scaranelo, A. M., Carrillo, M. C., Fleming, R., Jacks, L. M., Kulkarni, S. R., Crystal, P., Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density, Radiology, 2013. 267(3): p. 692-700.

178. Chiarelli, A. M., Prummel, M. V., Muradali, D., Shumak, R. S., Majpruz, V., Brown, P., et.al. Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection, Breast Cancer Res Treat, 2015. 154(2): p. 377-87.

179. Houssami, N., Hayes, D. F., Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer?, CA Cancer J Clin, 2009. 59(5): p. 290-302.

180. Kerlikowske, K., Zhu, W., Hubbard, R. A., Geller, B., Dittus, K., Braithwaite, D., et.al. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy, JAMA Intern Med, 2013. 173(9): p. 807-16.

181. Banks, E., Reeves, G., Beral, V., Bull, D., Crossley, B., Simmonds, M., et.al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect, Breast Cancer Res, 2006. 8(1): p. R8.

182. Holm, J., Humphreys, K., Li, J., Ploner, A., Cheddad, A., Eriksson, M., et.al. Risk factors and tumor characteristics of interval cancers by mammographic density, J Clin Oncol, 2015. 33(9): p. 1030-7.

183. Nothacker, M., Duda, V., Hahn, M., Warm, M., Degenhardt, F., Madjar, H., et.al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review, BMC Cancer, 2009. 9: p. 335.

184. Hendrick, R. E., Radiation doses and cancer risks from breast imaging studies, Radiology, 2010. 257(1): p. 246-53.

185. NZGG, Management of Early Breast Cancer - Evidence-based Best Practice Guideline, New Zealand Guidelines Group, 2009.

186. Zuley, M. L., Bandos, A. I., Ganott, M. A., Sumkin, J. H., Kelly, A. E., Catullo, V. J., et.al. Digital breast tomosynthesis versus supplemental diagnostic mammographic views for evaluation of noncalcified breast lesions, Radiology, 2013. 266(1): p. 89-95.

187. Morel, J. C., Iqbal, A., Wasan, R. K., Peacock, C., Evans, D. R., Rahim, R., et.al. The accuracy of digital breast tomosynthesis compared with coned compression magnification mammography in the assessment of abnormalities found on mammography, Clin Radiol, 2014. 69(11): p. 1112-6.

188. Cornford, E. J., Turnbull, A. E., James, J. J., Tsang, R., Akram, T., Burrell, H. C., et.al. Accuracy of GE digital breast tomosynthesis vs supplementary mammographic views for diagnosis of screen-detected soft-tissue breast lesions, Br J Radiol, 2016. 89(1058): p. 20150735.

189. Whelehan, P., Heywang-Kobrunner, S. H., Vinnicombe, S. J., Hacker, A., Jansch, A., Hapca, A., et.al. Clinical performance of Siemens digital breast tomosynthesis versus standard supplementary mammography for the assessment of screen-detected soft-tissue abnormalities: a multi-reader study, Clin Radiol, 2017. 72(1): p. 95.e9-95.e15.

190. Houssami, N., Skaane, P., Overview of the evidence on digital breast tomosynthesis in breast cancer detection, Breast, 2013. 22(2): p. 101-8.

191. Garcia-Leon, F. J., Llanos-Mendez, A., Isabel-Gomez, R., Digital tomosynthesis in breast cancer: A systematic review, Radiologia, 2015. 57(4): p. 333-43.

192. Bernardi, D., Macaskill, P., Pellegrini, M., Valentini, M., Fanto, C., Ostillio, L., et.al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study, Lancet Oncol, 2016. 17(8): p. 1105-13.

193. Fallenberg, E. M., Dromain, C., Diekmann, F., Renz, D. M., Amer, H., Ingold-Heppner, B., et.al. Contrast-enhanced spectral mammography: Does mammography provide additional clinical benefits or can some radiation exposure be avoided?, Breast Cancer Res Treat, 2014. 146(2): p. 371-81.

194. Fallenberg, E. M., Schmitzberger, F. F., Amer, H., Ingold-Heppner, B., Balleyguier, C., Diekmann, F., et.al. Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation, Eur Radiol, 2017. 27(7): p. 2752-2764.

195. Lobbes, M. B., Lalji, U., Houwers, J., Nijssen, E. C., Nelemans, P. J., van Roozendaal, L., et.al. Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme, Eur Radiol, 2014. 24(7): p. 1668-76.

196. Lobbes, M. B., Lalji, U. C., Nelemans, P. J., Houben, I., Smidt, M. L., Heuts, E., et.al. The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI, J Cancer, 2015. 6(2): p. 144-50.

197. Luczynska, E., Heinze-Paluchowska, S., Hendrick, E., Dyczek, S., Rys, J., Herman, K., et.al. Comparison between breast MRI and contrast-enhanced spectral mammography, Med Sci Monit, 2015. 21: p. 1358-67.

198. Tagliafico, A. S., Bignotti, B., Rossi, F., Signori, A., Sormani, M. P., Valdora, F., et.al. Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis, Breast, 2016. 28: p. 13-9.

199. Tennant, S. L., James, J. J., Cornford, E. J., Chen, Y., Burrell, H. C., Hamilton, L. J., et.al. Contrast-enhanced spectral mammography improves diagnostic accuracy in the symptomatic setting, Clin Radiol, 2016. 71(11): p. 1148-55.

200. Mueller-Schimpfle, M. P., Brandenbusch, V. C., Degenhardt, F., Duda, V., Madjar, H., Mundinger, A., et.al. The Problem of Mammographic Breast Density - The Position of the DEGUM Working Group on Breast Ultrasound, Ultraschall Med, 2016. 37(2): p. 170-5.

201. Berg, W. A., Bandos, A. I., Mendelson, E. B., Lehrer, D., Jong, R. A., Pisano, E. D., Ultrasound as the Primary Screening Test for Breast Cancer: Analysis From ACRIN 6666, J Natl Cancer Inst, 2016. 108(4):

202. Houssami, N., Irwig, L., Simpson, J. M., McKessar, M., Blome, S., Noakes, J., Sydney Breast Imaging Accuracy Study: Comparative sensitivity and specificity of mammography and sonography in young women with symptoms, AJR Am J Roentgenol, 2003. 180(4): p. 935-40.

203. Kolb, T. M., Lichy, J., Newhouse, J. H., Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations, Radiology, 2002. 225(1): p. 165-75.

204. Müller-Schimpfle, M, Graf, O, Madjar, H, al., et, Diskussionspapier - BI-RADS die 5. - eine Kurzmitteilung aus deutsch- /österreichischer Sicht, Rofo, 2016. p. 346-352.

205. Berg, W. A., Cosgrove, D. O., Dore, C. J., Schafer, F. K., Svensson, W. E., Hooley, R. J., et.al. Shear-wave elastography improves the specificity of breast US: the BE1 multinational study of 939 masses, Radiology, 2012. 262(2): p. 435-49.

206. Madjar, H., Prompeler, H., Wolfahrt, R., Bauknecht, T., Pfleiderer, A., [Color Doppler flow data of breast tumors], Ultraschall Med, 1994. 15(2): p. 69-73.

207. Svensson, W. E., Pandian, A. J., Hashimoto, H., The use of breast ultrasound color Doppler vascular pattern morphology improves diagnostic sensitivity with minimal change in specificity, Ultraschall Med, 2010. 31(5): p. 466-74.

208. Wilczek, B., Wilczek, H. E., Rasouliyan, L., Leifland, K., Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: Report from a hospital-based, high-volume, single-center breast cancer screening program, Eur J Radiol, 2016. 85(9): p. 1554-63.

209. Giger, M. L., Inciardi, M. F., Edwards, A., Papaioannou, J., Drukker, K., Jiang, Y., et.al. Automated Breast Ultrasound in Breast Cancer Screening of Women With Dense Breasts: Reader Study of Mammography-Negative and Mammography-Positive Cancers, AJR Am J Roentgenol, 2016. 206(6): p. 1341-50.

210. Giuliano, V., Giuliano, C., Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts, Clin Imaging, 2013. 37(3): p. 480-6.

211. Krekel, N. M., Haloua, M. H., Lopes Cardozo, A. M., de Wit, R. H., Bosch, A. M., de Widt-Levert, L. M., et.al. Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): a multicentre, randomised controlled trial, Lancet Oncol, 2013. 14(1): p. 48-54.

212. Eggemann, H., Ignatov, T., Beni, A., Costa, S. D., Ignatov, A., Ultrasonography-guided breast-conserving surgery is superior to palpation-guided surgery for palpable breast cancer, Clin Breast Cancer, 2014. 14(1): p. 40-5.

213. Eggemann, H., Ignatov, T., Beni, A., Costa, S. D., Ortmann, O., Ignatov, A., Intraoperative Ultrasound in the Treatment of Breast Cancer, Geburtshilfe Frauenheilkd, 2013. 73(10): p. 1028-1034.

214. Wurstlein, R., Degenhardt, F., Duda, V., Madjar, H., Merz, E., Mundinger, A., et.al. [Evaluation of the nationwide DEGUM breast ultrasound training program], Ultraschall Med, 2014. 35(4): p. 345-9.

215. Bennani-Baiti, B., Bennani-Baiti, N., Baltzer, P. A., Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis, PLoS One, 2016. 11(8): p. e0160346.

216. Fancellu, A., Turner, R. M., Dixon, J. M., Pinna, A., Cottu, P., Houssami, N., Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ, Br J Surg, 2015. 102(8): p. 883-93.

217. Houssami, N., Turner, R., Morrow, M., Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes, Ann Surg, 2013. 257(2): p. 249-55.

218. Plana, M. N., Carreira, C., Muriel, A., Chiva, M., Abraira, V., Emparanza, J. I., et.al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis, Eur Radiol, 2012. 22(1): p. 26-38.

219. Di Leo, G., Trimboli, R. M., Benedek, A., Jereczek-Fossa, B. A., Fossati, P., Leonardi, M. C., et.al. MR Imaging for Selection of Patients for Partial Breast Irradiation: A Systematic Review and Meta-Analysis, Radiology, 2015. 277(3): p. 716-26.

220. Fortune-Greeley, A. K., Wheeler, S. B., Meyer, A. M., Reeder-Hayes, K. E., Biddle, A. K., Muss, H. B., et.al. Preoperative breast MRI and surgical outcomes in elderly women with invasive ductal and lobular carcinoma: a population-based study, Breast Cancer Res Treat, 2014. 143(1): p. 203-12.

221. Gonzalez, V., Sandelin, K., Karlsson, A., Aberg, W., Lofgren, L., Iliescu, G., et.al. Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study, World J Surg, 2014. 38(7): p. 1685-93.

222. Mann, R. M., Balleyguier, C., Baltzer, P. A., Bick, U., Colin, C., Cornford, E., et.al. Breast MRI: EUSOBI recommendations for women's information, Eur Radiol, 2015. 25(12): p. 3669-78.

223. Dahabreh, I. J., Wieland, L. S., Adam, G. P., Halladay, C., Lau, J., Trikalinos, T. A., AHRQ Comparative Effectiveness Reviews, in Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: An Update to the 2009 Report, 2014, Agency for Healthcare Research and Quality (US): Rockville (MD).

224. Ahn, H. S., Kim, S. M., Jang, M., La Yun, B., Kim, S. W., Kang, E., et.al. Comparison of sonography with sonographically guided fine-needle aspiration biopsy and core-needle biopsy for initial axillary staging of breast cancer, J Ultrasound Med, 2013. 32(12): p. 2177-84.

225. Ganott, M. A., Zuley, M. L., Abrams, G. S., Lu, A. H., Kelly, A. E., Sumkin, J. H., et.al. Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer, ISRN Oncol, 2014. 2014: p. 703160.

226. Rao, R., Lilley, L., Andrews, V., Radford, L., Ulissey, M., Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration versus core needle biopsy, Ann Surg Oncol, 2009. 16(5): p. 1170-5.

227. Rautiainen, S., Masarwah, A., Sudah, M., Sutela, A., Pelkonen, O., Joukainen, S., et.al. Axillary lymph node biopsy in newly diagnosed invasive breast cancer: comparative accuracy of fine-needle aspiration biopsy versus core-needle biopsy, Radiology, 2013. 269(1): p. 54-60.

228. Bolivar, A. V., Alonso-Bartolome, P., Garcia, E. O., Ayensa, F. G., Ultrasound-guided core needle biopsy of non-palpable breast lesions: a prospective analysis in 204 cases, Acta Radiol, 2005. 46(7): p. 690-5.

229. Fishman, J. E., Milikowski, C., Ramsinghani, R., Velasquez, M. V., Aviram, G., US-guided core-needle biopsy of the breast: how many specimens are necessary?, Radiology, 2003. 226(3): p. 779-82.

230. Schulz-Wendtland, R., Aichinger, U., Kramer, S., Tartsch, M., Kuchar, I., Magener, A., et.al. [Sonographical breast biopsy: how many core biopsy specimens are needed?], Rofo, 2003. 175(1): p. 94-8.

231. Bruening, W., Fontanarosa, J., Tipton, K., Treadwell, J. R., Launders, J., Schoelles, K., Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions, Ann Intern Med, 2010. 152(4): p. 238-46.

232. Diaz, L. K., Wiley, E. L., Venta, L. A., Are malignant cells displaced by large-gauge needle core biopsy of the breast?, AJR Am J Roentgenol, 1999. 173(5): p. 1303-13.

233. Knight, R., Horiuchi, K., Parker, S. H., Ratzer, E. R., Fenoglio, M. E., Risk of needle-track seeding after diagnostic image-guided core needle biopsy in breast cancer, Jsls, 2002. 6(3): p. 207-9.

234. Department of Health, National Clinical Guideline - Diagnosis, staging and treatment of patients with Breast Cancer. National Clinical Guideline No. 7., 2015.

235. Department of Health, National Clinical Guideline - Diagnosis, staging and treatment of patients with Breast Cancer. National Clinical Guideline No. 7., 2015.

236. Brennan, M., Houssami, N., Newly diagnosed early breast cancer - an update on pre-operative assessment and staging, Aust Fam Physician, 2012. 41(11): p. 871-4.

237. Virnig, B. A., Tuttle, T. M., Shamliyan, T., Kane, R. L., Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes, J Natl Cancer Inst, 2010. 102(3): p. 170-8.

238. Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V., Sun, P., Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ, JAMA Oncol, 2015. 1(7): p. 888-96.

239. Morrow, M., Katz, S. J., Addressing Overtreatment in DCIS: What Should Physicians Do Now?, J Natl Cancer Inst, 2015. 107(12): p. djv290.

240. Lebeau, A., Kuhn, T., Updates in the treatment of ductal carcinoma in situ of the breast, Curr Opin Obstet Gynecol, 2016. 28(1): p. 49-58.

241. Van Zee, K. J., Barrio, A. V., Tchou, J., Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ, JAMA Oncol, 2016. 2(3): p. 397-8.

242. Sanders, M. E., Schuyler, P. A., Simpson, J. F., Page, D. L., Dupont, W. D., Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up, Mod Pathol, 2015. 28(5): p. 662-9.

243. Collins, L. C., Tamimi, R. M., Baer, H. J., Connolly, J. L., Colditz, G. A., Schnitt, S. J., Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study, Cancer, 2005. 103(9): p. 1778-84.

244. Shamliyan, T., Wang, S. Y., Virnig, B. A., Tuttle, T. M., Kane, R. L., Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ, J Natl Cancer Inst Monogr, 2010. 2010(41): p. 121-9.

245. Tunon-de-Lara, C., Lemanski, C., Cohen-Solal-Le-Nir, C., de Lafontan, B., Charra-Brunaud, C., Gonzague-Casabianca, L., et.al. Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk, Eur J Surg Oncol, 2010. 36(12): p. 1165-71.

246. Lagios, MD, Pathologic procedures for mammographically-detected ductal carcinomain situ, in Ductal carcinoma in situ of the breast., Silverstein, Mel E. Recht Abram E. Lagios Michael D. , Editor. 2002, Lippincott Williams & Wilkins: Philadelphia. p. 189–193.

247. Lakhani, S. R.%A Ellis, I%A Schnitt, S%A Tan, P. H.%A Vijver, MJ van de, WHO Classification of Tumours of the BreastIARC Press, World Health Organization classification of tumours, 2012. p. 240 p..

248. Rakovitch, E., Nofech-Mozes, S., Hanna, W., Baehner, F. L., Saskin, R., Butler, S. M., et.al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone, Breast Cancer Res Treat, 2015. 152(2): p. 389-98.

249. Wang, S. Y., Shamliyan, T., Virnig, B. A., Kane, R., Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis, Breast Cancer Res Treat, 2011. 127(1): p. 1-14.

250. Pinder, S. E., Duggan, C., Ellis, I. O., Cuzick, J., Forbes, J. F., Bishop, H., et.al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial, Br J Cancer, 2010. 103(1): p. 94-100.

251. Solin, L. J., Gray, R., Baehner, F. L., Butler, S. M., Hughes, L. L., Yoshizawa, C., et.al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast, J Natl Cancer Inst, 2013. 105(10): p. 701-10.

252. McCormick, B., Winter, K., Hudis, C., Kuerer, H. M., Rakovitch, E., Smith, B. L., et.al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation, J Clin Oncol, 2015. 33(7): p. 709-15.

253. Wehner, P., Lagios, M. D., Silverstein, M. J., DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines, Ann Surg Oncol, 2013. 20(10): p. 3175-9.

254. Pang, J. M., Gorringe, K. L., Fox, S. B., Ductal carcinoma in situ - update on risk assessment and management, Histopathology, 2016. 68(1): p. 96-109.

255. Dillon, M. F., Mc Dermott, E. W., O'Doherty, A., Quinn, C. M., Hill, A. D., O'Higgins, N., Factors affecting successful breast conservation for ductal carcinoma in situ, Ann Surg Oncol, 2007. 14(5): p. 1618-28.

256. Maffuz, A., Barroso-Bravo, S., Najera, I., Zarco, G., Alvarado-Cabrero, I., Rodriguez-Cuevas, S. A., Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ, J Exp Clin Cancer Res, 2006. 25(2): p. 223-7.

257. Sigal-Zafrani, B., Lewis, J. S., Clough, K. B., Vincent-Salomon, A., Fourquet, A., Meunier, M., et.al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications, Mod Pathol, 2004. 17(1): p. 81-8.

258. Kantor, O., Winchester, D. J., Breast conserving therapy for DCIS--does size matter?, J Surg Oncol, 2014. 110(1): p. 75-81.

259. MacDonald, H. R., Silverstein, M. J., Mabry, H., Moorthy, B., Ye, W., Epstein, M. S., et.al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins, Am J Surg, 2005. 190(4): p. 521-5.

260. Asjoe, F. T., Altintas, S., Huizing, M. T., Colpaert, C., Marck, E. V., Vermorken, J. B., et.al. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis, Breast J, 2007. 13(4): p. 359-67.

261. Lagios, M. D., Margolin, F. R., Westdahl, P. R., Rose, M. R., Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence, Cancer, 1989. 63(4): p. 618-24.

262. Pinder, S. E., Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation, Mod Pathol, 2010. 23 Suppl 2: p. S8-13.

263. Lester, S. C., Bose, S., Chen, Y. Y., Connolly, J. L., de Baca, M. E., Fitzgibbons, P. L., et.al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast, Arch Pathol Lab Med, 2009. 133(1): p. 15-25.

264. Marinovich, M. L., Azizi, L., Macaskill, P., Irwig, L., Morrow, M., Solin, L. J., et.al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis, Ann Surg Oncol, 2016. 23(12): p. 3811-3821.

265. NICE, Early and locally advanced breast cancer overview, National Institute for Health and Care Excellence, 2016.

266. SIGN, Treatment of primary breast cancer. SIGN 134, Scottish Intercollegiate Guidelines Network, 2013.

267. , National Comprehensive Cancer Network, Breast cancer. Version 2.2016, 2016.

268. Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., et.al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ, J Clin Oncol, 2016. 34(33): p. 4040-4046.

269. Macdonald, H. R., Silverstein, M. J., Lee, L. A., Ye, W., Sanghavi, P., Holmes, D. R., et.al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast, Am J Surg, 2006. 192(4): p. 420-2.

270. Hughes, L. L., Wang, M., Page, D. L., Gray, R., Solin, L. J., Davidson, N. E., et.al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 2009. 27(32): p. 5319-24.

271. Rudloff, U., Brogi, E., Reiner, A. S., Goldberg, J. I., Brockway, J. P., Wynveen, C. A., et.al. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy, Ann Surg, 2010. 251(4): p. 583-91.

272. Silverstein, M. J., Lagios, M. D., Groshen, S., Waisman, J. R., Lewinsky, B. S., Martino, S., et.al. The influence of margin width on local control of ductal carcinoma in situ of the breast, N Engl J Med, 1999. 340(19): p. 1455-61.

273. Dunne, C., Burke, J. P., Morrow, M., Kell, M. R., Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ, J Clin Oncol, 2009. 27(10): p. 1615-20.

274. Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., et.al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 2016. 14(3): p. 324-54.

275. Lyman, G. H., Temin, S., Edge, S. B., Newman, L. A., Turner, R. R., Weaver, D. L., et.al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 2014. 32(13): p. 1365-83.

276. Shapiro-Wright, H. M., Julian, T. B., Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ, J Natl Cancer Inst Monogr, 2010. 2010(41): p. 145-9.

277. Tunon-de-Lara, C., Chauvet, M. P., Baranzelli, M. C., Baron, M., Piquenot, J., Le-Bouedec, G., et.al. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study, Ann Surg Oncol, 2015. 22(12): p. 3853-60.

278. Trentin, C., Dominelli, V., Maisonneuve, P., Menna, S., Bazolli, B., Luini, A., et.al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases, Breast, 2012. 21(5): p. 635-40.

279. Chin-Lenn, L., Mack, L. A., Temple, W., Cherniak, W., Quinn, R. R., Ravani, P., et.al. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy, Ann Surg Oncol, 2014. 21(1): p. 66-73.

280. Schulz, S., Sinn, P., Golatta, M., Rauch, G., Junkermann, H., Schuetz, F., et.al. Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy, Breast, 2013. 22(4): p. 537-42.

281. Yen, T. W., Hunt, K. K., Ross, M. I., Mirza, N. Q., Babiera, G. V., Meric-Bernstam, F., et.al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ, J Am Coll Surg, 2005. 200(4): p. 516-26.

282. Kim, J., Han, W., Lee, J. W., You, J. M., Shin, H. C., Ahn, S. K., et.al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision, Breast, 2012. 21(5): p. 641-5.

283. Prendeville, S., Ryan, C., Feeley, L., O'Connell, F., Browne, T. J., O'Sullivan, M. J., et.al. Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast, Breast, 2015. 24(3): p. 197-200.

284. Nicholson, S., Hanby, A., Clements, K., Kearins, O., Lawrence, G., Dodwell, D., et.al. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS, Eur J Surg Oncol, 2015. 41(1): p. 86-93.

285. Goodwin, A., Parker, S., Ghersi, D., Wilcken, N., Post-operative radiotherapy for ductal carcinoma in situ of the breast, Cochrane Database Syst Rev, 2013. p. Cd000563.

286. Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., et.al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial, J Clin Oncol, 2014. 32(32): p. 3613-8.

287. Sagara, Y., Freedman, R. A., Vaz-Luis, I., Mallory, M. A., Wong, S. M., Aydogan, F., et.al. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study, J Clin Oncol, 2016. 34(11): p. 1190-6.

288. Early Breast Cancer Trialists' Collaborative, Group%A Correa, C.%A McGale, P.%A Taylor, C.%A Wang, Y.%A Clarke, M.%A Davies, C.%A Peto, R.%A Bijker, N.%A Solin, L.%A Darby, S., Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast, J Natl Cancer Inst Monogr, 2010. 2010(41): p. 162-77.

289. Stuart, K. E., Houssami, N., Taylor, R., Hayen, A., Boyages, J., Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis, BMC Cancer, 2015. 15: p. 890.

290. Subhedar, P., Olcese, C., Patil, S., Morrow, M., Van Zee, K. J., Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years, Ann Surg Oncol, 2015. 22(10): p. 3273-81.

291. Miller, K. L., Marks, L. B., Barrier, R. C., Jr., Leight, G. S., Clough, R. W., Prosnitz, R. G., et.al. Increased sectioning of pathologic specimens with ductal carcinoma in situ of the breast: are there clinical consequences?, Clin Breast Cancer, 2003. 4(3): p. 198-202.

292. Rutgers, E. J., Quality control in the locoregional treatment of breast cancer, Eur J Cancer, 2001. 37(4): p. 447-53.

293. Sagara, Y., Mallory, M. A., Wong, S., Aydogan, F., DeSantis, S., Barry, W. T., et.al. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study, JAMA Surg, 2015. 150(8): p. 739-45.

294. Cante, D., Franco, P., Sciacero, P., Girelli, G., Marra, A. M., Pasquino, M., et.al. Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series, Med Oncol, 2014. 31(2): p. 838.

295. Nilsson, C., Valachis, A., The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies, Radiother Oncol, 2015. 114(1): p. 50-5.

296. Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., et.al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24, J Clin Oncol, 2012. 30(12): p. 1268-73.

297. Staley, H., McCallum, I., Bruce, J., Postoperative tamoxifen for ductal carcinoma in situ, Cochrane Database Syst Rev, 2012. 10: p. Cd007847.

298. Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., et.al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS, J Natl Cancer Inst, 2011. 103(6): p. 478-88.

299. Cuzick, J., Sestak, I., Pinder, S. E., Ellis, I. O., Forsyth, S., Bundred, N. J., et.al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial, Lancet Oncol, 2011. 12(1): p. 21-9.

300. Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., et.al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, Lancet, 2016. 387(10021): p. 866-73.

301. Morrow, M., Refining the use of endocrine therapy for ductal carcinoma in situ, J Clin Oncol, 2012. 30(12): p. 1249-51.

302. Guerrieri-Gonzaga, A., Lazzeroni, M., Botteri, E., Serrano, D., Rotmensz, N., Varricchio, M. C., et.al. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study, Ann Oncol, 2013. 24(7): p. 1859-66.

303. Calhoun, B. C., Collins, L. C., Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature, Histopathology, 2016. 68(1): p. 138-51.

304. Ellis, I. O., Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology, Mod Pathol, 2010. 23 Suppl 2: p. S1-7.

305. (EUREF), European Reference Organisation for Quality Assured Breast Screening and Diagnostic Service, European guidelines for quality assurance in breast cancer screening and diagnosis.Wells, C. A., 2017.

306. Collins, L. C., Aroner, S. A., Connolly, J. L., Colditz, G. A., Schnitt, S. J., Tamimi, R. M., Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies, Cancer, 2016. 122(4): p. 515-20.

307. Buckley, E., Sullivan, T., Farshid, G., Hiller, J., Roder, D., Risk profile of breast cancer following atypical hyperplasia detected through organized screening, Breast, 2015. 24(3): p. 208-12.

308. Hartmann, L. C., Radisky, D. C., Frost, M. H., Santen, R. J., Vierkant, R. A., Benetti, L. L., et.al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study, Cancer Prev Res (Phila), 2014. 7(2): p. 211-7.

309. Degnim, A. C., Visscher, D. W., Berman, H. K., Frost, M. H., Sellers, T. A., Vierkant, R. A., et.al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study, J Clin Oncol, 2007. 25(19): p. 2671-7.

310. Page, D. L., Dupont, W. D., Rogers, L. W., Rados, M. S., Atypical hyperplastic lesions of the female breast. A long-term follow-up study, Cancer, 1985. 55(11): p. 2698-708.

311. Youn, I., Kim, M. J., Moon, H. J., Kim, E. K., Absence of Residual Microcalcifications in Atypical Ductal Hyperplasia Diagnosed via Stereotactic Vacuum-Assisted Breast Biopsy: Is Surgical Excision Obviated?, J Breast Cancer, 2014. 17(3): p. 265-9.

312. Mesurolle, B., Perez, J. C., Azzumea, F., Lemercier, E., Xie, X., Aldis, A., et.al. Atypical ductal hyperplasia diagnosed at sonographically guided core needle biopsy: frequency, final surgical outcome, and factors associated with underestimation, AJR Am J Roentgenol, 2014. 202(6): p. 1389-94.

313. Khoury, T., Chen, X., Wang, D., Kumar, P., Qin, M., Liu, S., et.al. Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions, Histopathology, 2015. 67(1): p. 106-20.

314. Caplain, A., Drouet, Y., Peyron, M., Peix, M., Faure, C., Chassagne-Clement, C., et.al. Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution, Am J Surg, 2014. 208(2): p. 260-7.

315. Eby, P. R., Ochsner, J. E., DeMartini, W. B., Allison, K. H., Peacock, S., Lehman, C. D., Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge, AJR Am J Roentgenol, 2009. 192(1): p. 229-34.

316. Degnim, A. C., King, T. A., Surgical management of high-risk breast lesions, Surg Clin North Am, 2013. 93(2): p. 329-40.

317. Yu, Y. H.A Liang, C.A Yuan, X. Z., Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review, Breast Cancer Res Treat, 2010. 120(2): p. 469-79.

318. Sneige, N., Lim, S. C., Whitman, G. J., Krishnamurthy, S., Sahin, A. A., Smith, T. L., et.al. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision, Am J Clin Pathol, 2003. 119(2): p. 248-53.

319. Ely, K. A., Carter, B. A., Jensen, R. A., Simpson, J. F., Page, D. L., Core biopsy of the breast with atypical ductal hyperplasia: a probabilistic approach to reporting, Am J Surg Pathol, 2001. 25(8): p. 1017-21.

320. Nguyen, C. V., Albarracin, C. T., Whitman, G. J., Lopez, A., Sneige, N., Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision, Ann Surg Oncol, 2011. 18(3): p. 752-61.

321. Allison, K. H., Eby, P. R., Kohr, J., DeMartini, W. B., Lehman, C. D., Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade, Hum Pathol, 2011. 42(1): p. 41-50.

322. Wagoner, M. J., Laronga, C., Acs, G., Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ in subsequent excision, Am J Clin Pathol, 2009. 131(1): p. 112-21.

323. Kohr, J. R., Eby, P. R., Allison, K. H., DeMartini, W. B., Gutierrez, R. L., Peacock, S., et.al. Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications, Radiology, 2010. 255(3): p. 723-30.

324. Morrow, M., Schnitt, S. J., Norton, L., Current management of lesions associated with an increased risk of breast cancer, Nat Rev Clin Oncol, 2015. 12(4): p. 227-38.

325. Page, D. L., Kidd, T. E., Jr., Dupont, W. D., Simpson, J. F., Rogers, L. W., Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease, Hum Pathol, 1991. 22(12): p. 1232-9.

326. Dabbs, D. J., Schnitt, S. J., Geyer, F. C., Weigelt, B., Baehner, F. L., Decker, T., et.al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry, Am J Surg Pathol, 2013. 37(7): p. e1-11.

327. Ottesen, G. L., Graversen, H. P., Blichert-Toft, M., Zedeler, K., Andersen, J. A., Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group, Am J Surg Pathol, 1993. 17(1): p. 14-21.

328. Andersen, J. A., Lobular carcinoma in situ. A long-term follow-up in 52 cases, Acta Pathol Microbiol Scand A, 1974. 82(4): p. 519-33.

329. Middleton, L. P., Palacios, D. M., Bryant, B. R., Krebs, P., Otis, C. N., Merino, M. J., Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis, Am J Surg Pathol, 2000. 24(12): p. 1650-6.

330. Cancer_Australia, Clinical guidance for the management of lobular carcinoma in situ, 2016.

331. Nakhlis, F., Gilmore, L., Gelman, R., Bedrosian, I., Ludwig, K., Hwang, E. S., et.al. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020), Ann Surg Oncol, 2016. 23(3): p. 722-8.

332. Bagaria, S. P., Shamonki, J., Kinnaird, M., Ray, P. S., Giuliano, A. E., The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?, Ann Surg Oncol, 2011. 18(7): p. 1845-51.

333. Ross, D. S., Hoda, S. A., Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases, Am J Surg Pathol, 2011. 35(5): p. 750-6.

334. Reis-Filho, J. S., Simpson, P. T., Jones, C., Steele, D., Mackay, A., Iravani, M., et.al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity, J Pathol, 2005. 207(1): p. 1-13.

335. Masannat, Y. A., Bains, S. K., Pinder, S. E., Purushotham, A. D., Challenges in the management of pleomorphic lobular carcinoma in situ of the breast, Breast, 2013. 22(2): p. 194-6.

336. Brogi, E., Murray, M. P., Corben, A. D., Lobular carcinoma, not only a classic, Breast J, 2010. 16 Suppl 1: p. S10-4.

337. Sinn, H. P., Helmchen, B., Heil, J., Aulmann, S., [Lobular neoplasms and invasive lobular breast cancer], Pathologe, 2014. 35(1): p. 45-53.

338. Schnitt, S. J., Vincent-Salomon, A., Columnar cell lesions of the breast, Adv Anat Pathol, 2003. 10(3): p. 113-24.

339. Abdel-Fatah, T. M., Powe, D. G., Hodi, Z., Reis-Filho, J. S., Lee, A. H., Ellis, I. O., Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family, Am J Surg Pathol, 2008. 32(4): p. 513-23.

340. Brandt, S. M., Young, G. Q., Hoda, S. A., The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions, Adv Anat Pathol, 2008. 15(3): p. 140-6.

341. Aulmann, S., Braun, L., Mietzsch, F., Longerich, T., Penzel, R., Schirmacher, P., et.al. Transitions between flat epithelial atypia and low-grade ductal carcinoma in situ of the breast, Am J Surg Pathol, 2012. 36(8): p. 1247-52.

342. Sinn, H. P., Breast cancer precursors: lessons learned from molecular genetics, J Mol Med (Berl), 2009. 87(2): p. 113-5.

343. Lopez-Garcia, M. A., Geyer, F. C., Lacroix-Triki, M., Marchio, C., Reis-Filho, J. S., Breast cancer precursors revisited: molecular features and progression pathways, Histopathology, 2010. 57(2): p. 171-92.

344. Becker, A. K., Gordon, P. B., Harrison, D. A., Hassell, P. R., Hayes, M. M., van Niekerk, D., et.al. Flat ductal intraepithelial neoplasia 1A diagnosed at stereotactic core needle biopsy: is excisional biopsy indicated?, AJR Am J Roentgenol, 2013. 200(3): p. 682-8.

345. Dialani, V., Venkataraman, S., Frieling, G., Schnitt, S. J., Mehta, T. S., Does isolated flat epithelial atypia on vacuum-assisted breast core biopsy require surgical excision?, Breast J, 2014. 20(6): p. 606-14.

346. Calhoun, B. C., Sobel, A., White, R. L., Gromet, M., Flippo, T., Sarantou, T., et.al. Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies, Mod Pathol, 2015. 28(5): p. 670-6.

347. Yu, C. C., Ueng, S. H., Cheung, Y. C., Shen, S. C., Kuo, W. L., Tsai, H. P., et.al. Predictors of underestimation of malignancy after image-guided core needle biopsy diagnosis of flat epithelial atypia or atypical ductal hyperplasia, Breast J, 2015. 21(3): p. 224-32.

348. Lerwill, M. F., Flat epithelial atypia of the breast, Arch Pathol Lab Med, 2008. 132(4): p. 615-21.

349. Pinder, S. E., Provenzano, E., Reis-Filho, J. S., Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for management, Pathology, 2007. 39(2): p. 208-16.

350. Villa, A., Chiesa, F., Massa, T., Friedman, D., Canavese, G., Baccini, P., et.al. Flat epithelial atypia: comparison between 9-gauge and 11-gauge devices, Clin Breast Cancer, 2013. 13(6): p. 450-4.

351. Chester, R., Bokinni, O., Ahmed, I., Kasem, A., UK national survey of management of breast lobular carcinoma in situ, Ann R Coll Surg Engl, 2015. 97(8): p. 574-7.

352. Shin, S. J., Lal, A., De Vries, S., Suzuki, J., Roy, R., Hwang, E. S., et.al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ, Hum Pathol, 2013. 44(10): p. 1998-2009.

353. Wen, X., Cheng, W., Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors, Ann Surg Oncol, 2013. 20(1): p. 94-101.

354. Liberman, L., Tornos, C., Huzjan, R., Bartella, L., Morris, E. A., Dershaw, D. D., Is surgical excision warranted after benign, concordant diagnosis of papilloma at percutaneous breast biopsy?, AJR Am J Roentgenol, 2006. 186(5): p. 1328-34.

355. Skandarajah, A. R., Field, L., Yuen Larn Mou, A., Buchanan, M., Evans, J., Hart, S., et.al. Benign papilloma on core biopsy requires surgical excision, Ann Surg Oncol, 2008. 15(8): p. 2272-7.

356. Shouhed, D., Amersi, F. F., Spurrier, R., Dang, C., Astvatsaturyan, K., Bose, S., et.al. Intraductal papillary lesions of the breast: clinical and pathological correlation, Am Surg, 2012. 78(10): p. 1161-5.

357. Holley, S. O., Appleton, C. M., Farria, D. M., Reichert, V. C., Warrick, J., Allred, D. C., et.al. Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy, Radiology, 2012. 265(2): p. 379-84.

358. Mulligan, A. M., O'Malley, F. P., Papillary lesions of the breast: a review, Adv Anat Pathol, 2007. 14(2): p. 108-19.

359. Rageth, C. J., O'Flynn, E. A., Comstock, C., Kurtz, C., Kubik, R., Madjar, H., et.al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions), Breast Cancer Res Treat, 2016. 159(2): p. 203-13.

360. Ni, Y. B., Tse, G. M., Pathological criteria and practical issues in papillary lesions of the breast - a review, Histopathology, 2016. 68(1): p. 22-32.

361. Ueng, S. H., Mezzetti, T., Tavassoli, F. A., Papillary neoplasms of the breast: a review, Arch Pathol Lab Med, 2009. 133(6): p. 893-907.

362. Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., et.al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 2014. 32(14): p. 1507-15.

363. Committee, National Clinical Effectiveness, Diagnosis, staging and treatment of patients with breast cancer: national clinical guideline no. 7, 2015.

364. Houssami, N., Macaskill, P., Marinovich, M. L., Morrow, M., The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis, Ann Surg Oncol, 2014. 21(3): p. 717-30.

365. Buchholz, T. A., Somerfield, M. R., Griggs, J. J., El-Eid, S., Hammond, M. E., Lyman, G. H., et.al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline, J Clin Oncol, 2014. 32(14): p. 1502-6.

366. Jones, H. A., Antonini, N., Hart, A. A., Peterse, J. L., Horiot, J. C., Collin, F., et.al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial, J Clin Oncol, 2009. 27(30): p. 4939-47.

367. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005. 365(9472): p. 1687-717.

368. Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., et.al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23, J Clin Oncol, 2001. 19(4): p. 931-42.

369. Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et.al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, N Engl J Med, 2002. 347(16): p. 1227-32.

370. Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., et.al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer, N Engl J Med, 2002. 347(16): p. 1233-41.

371. Wald, N. J., Murphy, P., Major, P., Parkes, C., Townsend, J., Frost, C., UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening, Bmj, 1995. 311(7014): p. 1189-93.

372. Weaver, D. L., Krag, D. N., Ashikaga, T., Harlow, S. P., O'Connell, M., Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study, Cancer, 2000. 88(5): p. 1099-107.

373. McCahill, L. E., Single, R. M., Aiello Bowles, E. J., Feigelson, H. S., James, T. A., Barney, T., et.al. Variability in reexcision following breast conservation surgery, Jama, 2012. 307(5): p. 467-75.

374. Brackstone, M., Fletcher, G. G., Dayes, I. S., Madarnas, Y., SenGupta, S. K., Verma, S., Locoregional therapy of locally advanced breast cancer: a clinical practice guideline, Curr Oncol, 2014. 22(Suppl 1): p. S54-66.

375. Fisher, B., Anderson, S., Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project, World J Surg, 1994. 18(1): p. 63-9.

376. Voogd, A. C., Nielsen, M., Peterse, J. L., Blichert-Toft, M., Bartelink, H., Overgaard, M., et.al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials, J Clin Oncol, 2001. 19(6): p. 1688-97.

377. Jaeger, K, Rudde-Teufel, C, Ladra, J, Fehler und Gefahren bei der brusterhaltenden Therapie, Chir AZ, 2000. 1: p. 130-134.

378. Gentilini, O., Botteri, E., Rotmensz, N., Da Lima, L., Caliskan, M., Garcia-Etienne, C. A., et.al. Conservative surgery in patients with multifocal/multicentric breast cancer, Breast Cancer Res Treat, 2009. 113(3): p. 577-83.

379. Lynch, S. P., Lei, X., Hsu, L., Meric-Bernstam, F., Buchholz, T. A., Zhang, H., et.al. Breast cancer multifocality and multicentricity and locoregional recurrence, Oncologist, 2013. 18(11): p. 1167-73.

380. Neri, A., Marrelli, D., Megha, T., Bettarini, F., Tacchini, D., De Franco, L., et.al. "Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases", BMC Surg, 2015. 15: p. 1.

381. Patani, N., Carpenter, R., Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer, Breast J, 2010. 16(3): p. 222-32.

382. Shaikh, T., Tam, T. Y., Li, T., Hayes, S. B., Goldstein, L., Bleicher, R., et.al. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type, Breast J, 2015. 21(2): p. 121-6.

383. Tan, M. P., Sitoh, N. Y., Sim, A. S., Breast conservation treatment for multifocal and multicentric breast cancers in women with small-volume breast tissue, ANZ J Surg, 2014.

384. Wolters, R., Wockel, A., Janni, W., Novopashenny, I., Ebner, F., Kreienberg, R., et.al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients, Breast Cancer Res Treat, 2013. 142(3): p. 579-90.

385. Yerushalmi, R., Tyldesley, S., Woods, R., Kennecke, H. F., Speers, C., Gelmon, K. A., Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?, Ann Oncol, 2012. 23(4): p. 876-81.

386. Blamey, R. W., The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). BASO Breast Specialty Group, Eur J Surg Oncol, 1998. 24(6): p. 464-76.

387. Blichert-Toft, M., Smola, M. G., Cataliotti, L., O'Higgins, N., Principles and guidelines for surgeons--management of symptomatic breast cancer. On behalf of the European Society of Surgical Oncology, Ann Chir Gynaecol, 1998. 87(1): p. 101-9.

388. O'Higgins, N., Linos, D. A., Blichert-Toft, M., Cataliotti, L., de Wolf, C., Rochard, F., et.al. European guidelines for quality assurance in the surgical management of mammographically detected lesions, Eur J Surg Oncol, 1998. 24(2): p. 96-8.

389. Bartelink, H., Horiot, J. C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., et.al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial, J Clin Oncol, 2007. 25(22): p. 3259-65.

390. Hoffmann, J., Wallwiener, D., Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients, BMC Cancer, 2009. 9: p. 108.

391. De La Cruz, L., Moody, A. M., Tappy, E. E., Blankenship, S. A., Hecht, E. M., Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review, Ann Surg Oncol, 2015. 22(10): p. 3241-9.

392. Endara, M., Chen, D., Verma, K., Nahabedian, M. Y., Spear, S. L., Breast reconstruction following nipple-sparing mastectomy: a systematic review of the literature with pooled analysis, Plast Reconstr Surg, 2013. 132(5): p. 1043-54.

393. Lanitis, S., Tekkis, P. P., Sgourakis, G., Dimopoulos, N., Al Mufti, R., Hadjiminas, D. J., Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies, Ann Surg, 2010. 251(4): p. 632-9.

394. Piper, M., Peled, A. W., Foster, R. D., Moore, D. H., Esserman, L. J., Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications, Ann Plast Surg, 2013. 70(4): p. 435-7.

395. Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. H., Nelson, D. O., Clarke, C. A., Gomez, S. L., Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011, Jama, 2014. 312(9): p. 902-14.

396. Potter, S., Brigic, A., Whiting, P. F., Cawthorn, S. J., Avery, K. N., Donovan, J. L., et.al. Reporting clinical outcomes of breast reconstruction: a systematic review, J Natl Cancer Inst, 2011. 103(1): p. 31-46.

397. SIGN 2013, Scottish Intercollegiate Guidelines Network. Treatment of primary breast cancer – a national clinical guideline., SIGN publication no. 134

398. Audretsch, Werner P, Rezai, Mahdi, Kolotas, Christos, Zamboglou, Nikolaos, Schnabel, Thomas, Bojar, Hans, Tumor-specific immediate reconstruction in breast cancer patients, Perspectives in plastic surgery, 1998. 11(01): p. 71-100.

399. Calabrese, C, Distante, V, Orzalesi, L, Immediate reconstruction with mammaplasty in conservative breast cancer treatment: Long-term results. Focus Rec Breast Cancer Surg, Osp Ital Chir, 2001. 7: p. 38-46.

400. Kroll, S. S., Khoo, A., Singletary, S. E., Ames, F. C., Wang, B. G., Reece, G. P., et.al. Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up, Plast Reconstr Surg, 1999. 104(2): p. 421-5.

401. Bohmert, H., Gabka, CJ., Plastic and reconstructive surgery of the breast, Thieme.

402. Plastische ChirurgieKrupp, S., 1994.

403. Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., et.al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 2010. 11(10): p. 927-33.

404. Houssami, N., Ciatto, S., Turner, R. M., Cody, H. S., 3rd, Macaskill, P., Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla, Ann Surg, 2011. 254(2): p. 243-51.

405. Straver, M. E., Meijnen, P., van Tienhoven, G., van de Velde, C. J., Mansel, R. E., Bogaerts, J., et.al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer, J Clin Oncol, 2010. 28(5): p. 731-7.

406. Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., et.al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial, Jama, 2011. 305(6): p. 569-75.

407. Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., et.al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial, Lancet Oncol, 2013. 14(4): p. 297-305.

408. Classe, J. M., Bordes, V., Campion, L., Mignotte, H., Dravet, F., Leveque, J., et.al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study, J Clin Oncol, 2009. 27(5): p. 726-32.

409. Xing, Y., Foy, M., Cox, D. D., Kuerer, H. M., Hunt, K. K., Cormier, J. N., Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer, Br J Surg, 2006. 93(5): p. 539-46.

410. Kuehn, Thorsten, Bauerfeind, Ingo, Fehm, Tanja, Fleige, Barbara, Hausschild, Maik, Helms, Gisela, et.al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study, The lancet oncology, 2013. 14(7): p. 609-618.

411. Boughey, J. C., Suman, V. J., Mittendorf, E. A., Ahrendt, G. M., Wilke, L. G., Taback, B., et.al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial, Jama, 2013. 310(14): p. 1455-61.

412. Giuliano, A. E., Ballman, K., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., et.al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial, Ann Surg, 2016. 264(3): p. 413-20.

413. Gartlehner, G., Chapman, A., Strobelberger, M., Kerschner, B., Thaler, K., Griebler, U., et.al. Vergleichende Wirksamkeit und Sicherheit von alleiniger Sentinel-Lymphknoten-Biopsie oder kompletter Axilladissektion bei Sentinel-positivem Mammakarzinom: Systematische Übersichtsarbeit., 2011.

414. Martelli, G., Boracchi, P., De Palo, M., Pilotti, S., Oriana, S., Zucali, R., et.al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up, Ann Surg, 2005. 242(1): p. 1-6; discussion 7-9.

415. Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., Rey, P., et.al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93, J Clin Oncol, 2006. 24(3): p. 337-44.

416. Veronesi, U., Marubini, E., Mariani, L., Valagussa, P., Zucali, R., The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial, Eur J Cancer, 1999. 35(9): p. 1320-5.

417. Veronesi, U., Orecchia, R., Zurrida, S., Galimberti, V., Luini, A., Veronesi, P., et.al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy, Ann Oncol, 2005. 16(3): p. 383-8.

418. Vogt, H., Schmidt, M., Bares, R., Brenner, W., Grunwald, F., Kopp, J., et.al. [Procedure guideline for sentinel lymph node diagnosis], Nuklearmedizin, 2010. 49(4): p. 167-72; quiz N19.

419. Caudle, A. S., Yang, W. T., Krishnamurthy, S., Mittendorf, E. A., Black, D. M., Gilcrease, M. Z., et.al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection, J Clin Oncol, 2016. 34(10): p. 1072-8.

420. Amendoeira, I., Apostolikas, N., Bellocq, J. P., Bianchi, S., Boecker, W., Borisch, B., et.al. Quality assurance guidelines for pathology: Cytological and histological non-operative procedures, in European guidelines for quality assurance in breast cancer screening and diagnosis, Perry, N.Broeders, M.de Wolf, C.Störnberg, S.Holland, R. and von Karsa, L., Editors. 2006, European Communities. p. 221-256.

421. Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., et.al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 2010. 28(16): p. 2784-95.

422. Lester, S., Bose, S., Chen, Y. Y., Connolly, J. L., De Baca, M. E., Fitzgibbons, P., et.al. Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of the Breast. InvasiveBreast 3.2.0.0College of American Pathologists, 2013. p. 1-37.

423. Lester, S. E., Bose, S., Chen, Y. Y., Connolly, J. L., De Baca, M. E., Fitzgibbons, P., et.al. Protocol for the Examination of Specimens from Patients with Ductal Carcinoma In Situ (DCIS) of the Breast. DCIS 3.2.0.0College of American Pathologists, 2013. p. 1-20.

424. Ellis, I. O., Al-Sam, S., Anderson, N., Carder, P., Deb, R., Girling, A., et.al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. G 148 LRThe Royal College of Pathologists, 2016. p. 1-160.

425. Lee, A. H., Anderson, N., Carder, P., Cooke, J., Deb, R., Ellis, I. O., et.al. Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. G 150The Royal College of Pathologists, 2016. p. 1-74.

426. Wolff, A. C., Hammond, M. E., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., et.al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 2013. 31(31): p. 3997-4013.

427. Lyman, G. H., Temin, S., Edge, S. B., Newman, L. A., Turner, R. R., Weaver, D. L., et.al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 2014. 32(13): p. 1365-83.

428. Wells, C. A., Bellocq, J. P., Boecker, W., Borisch, B., Bruun Rasmussen, B., Callagy, G., et.al. Pathology update. Quality assurance guidelines for pathology., in European guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed.-Supplements., Perry, N.Broeders, M.De Wolf, C.Törnberg, S.Holland, R. and Von Karsa, L., Editors. 2013, European Commission, Office for Official Publications of the European Union.: Luxembourg.

429. Brierley, James, Gospodarowicz, M. K., Wittekind, Ch (Hrsg.), TNM classification of malignant tumoursJohn Wiley & Sons, Inc., 2017.

430. Jorns, J. M., Visscher, D., Sabel, M., Breslin, T., Healy, P., Daignaut, S., et.al. Intraoperative frozen section analysis of margins in breast conserving surgery significantly decreases reoperative rates: one-year experience at an ambulatory surgical center, Am J Clin Pathol, 2012. 138(5): p. 657-69.

431. Schnitt, S. J., Morrow, M., Should intraoperative frozen section evaluation of breast lumpectomy margins become routine practice?, Am J Clin Pathol, 2012. 138(5): p. 635-8.

432. Cserni, G., Amendoeira, I., Apostolikas, N., Bellocq, J. P., Bianchi, S., Bussolati, G., et.al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines, Eur J Cancer, 2003. 39(12): p. 1654-67.

433. Langer, I., Guller, U., Berclaz, G., Koechli, O. R., Moch, H., Schaer, G., et.al. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study, Breast Cancer Res Treat, 2009. 113(1): p. 129-36.

434. Rakha, E. A., Ellis, I. O., An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens, J Clin Pathol, 2007. 60(12): p. 1300-6.

435. Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., et.al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 2014. 32(14): p. 1507-15.

436. Schnitt, S. J., Abner, A., Gelman, R., Connolly, J. L., Recht, A., Duda, R. B., et.al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy, Cancer, 1994. 74(6): p. 1746-51.

437. Sinn, H. P., Anton, H. W., Magener, A., von Fournier, D., Bastert, G., Otto, H. F., Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy, Eur J Cancer, 1998. 34(5): p. 646-53.

438. Schnitt, S. J., Connolly, J. L., Khettry, U., Mazoujian, G., Brenner, M., Silver, B., et.al. Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy, Cancer, 1987. 59(4): p. 675-81.

439. Elston, C. W., Ellis, I. O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 1991. 19(5): p. 403-10.

440. Andrade, V. P., Gobbi, H., Accuracy of typing and grading invasive mammary carcinomas on core needle biopsy compared with the excisional specimen, Virchows Arch, 2004. 445(6): p. 597-602.

441. Badoual, C., Maruani, A., Ghorra, C., Lebas, P., Avigdor, S., Michenet, P., Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions, Breast, 2005. 14(1): p. 22-7.

442. Burge, C. N., Chang, H. R., Apple, S. K., Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?, Breast, 2006. 15(2): p. 167-72.

443. Cahill, R. A., Walsh, D., Landers, R. J., Watson, R. G., Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy, Ann Surg Oncol, 2006. 13(1): p. 45-51.

444. Di Loreto, C., Puglisi, F., Rimondi, G., Zuiani, C., Anania, G., Della Mea, V., et.al. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas, Eur J Cancer, 1996. 32A(10): p. 1693-700.

445. Harris, G. C., Denley, H. E., Pinder, S. E., Lee, A. H., Ellis, I. O., Elston, C. W., et.al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma, Am J Surg Pathol, 2003. 27(1): p. 11-5.

446. Ough, M., Velasco, J., Hieken, T. J., A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression, Am J Surg, 2011. 201(5): p. 692-4.

447. Park, S. Y., Kim, K. S., Lee, T. G., Park, S. S., Kim, S. M., Han, W., et.al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer, Am J Surg, 2009. 197(2): p. 266-9.

448. Richter-Ehrenstein, C., Muller, S., Noske, A., Schneider, A., Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients, Int J Surg Pathol, 2009. 17(4): p. 323-6.

449. Sharifi, S., Peterson, M. K., Baum, J. K., Raza, S., Schnitt, S. J., Assessment of pathologic prognostic factors in breast core needle biopsies, Mod Pathol, 1999. 12(10): p. 941-5.

450. Usami, S., Moriya, T., Amari, M., Suzuki, A., Ishida, T., Sasano, H., et.al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy, Jpn J Clin Oncol, 2007. 37(4): p. 250-5.

451. Kwok, T. C., Rakha, E. A., Lee, A. H., Grainge, M., Green, A. R., Ellis, I. O., et.al. Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation, Histopathology, 2010. 57(2): p. 212-9.

452. O'Shea, A. M., Rakha, E. A., Hodi, Z., Ellis, I. O., Lee, A. H., Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens, Histopathology, 2011. 59(3): p. 543-8.

453. Lee, A. H., Rakha, E. A., Hodi, Z., Ellis, I. O., Re-audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast, Histopathology, 2012. 60(7): p. 1166-7.

454. Christgen, M., Langer, F., Kreipe, H., [Histological grading of breast cancer], Pathologe, 2016. 37(4): p. 328-36.

455. Committee, The Consensus Conference, Consensus Conference on the classification of ductal carcinoma in situ., Cancer, 1997. 80(9): p. 1798-802.

456. Cserni, G., Bori, R., Sejben, I., Voros, A., Kaiser, L., Hamar, S., et.al. Unifocal, multifocal and diffuse carcinomas: a reproducibility study of breast cancer distribution, Breast, 2013. 22(1): p. 34-8.

457. Tot, T., Gere, M., Pekar, G., Tarjan, M., Hofmeyer, S., Hellberg, D., et.al. Breast cancer multifocality, disease extent, and survival, Hum Pathol, 2011. 42(11): p. 1761-9.

458. Faverly, D. R., Burgers, L., Bult, P., Holland, R., Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications, Semin Diagn Pathol, 1994. 11(3): p. 193-8.

459. Gujam, F. J., Going, J. J., Edwards, J., Mohammed, Z. M., McMillan, D. C., The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer, Crit Rev Oncol Hematol, 2014. 89(2): p. 231-41.

460. Rakha, E. A., Martin, S., Lee, A. H., Morgan, D., Pharoah, P. D., Hodi, Z., et.al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma, Cancer, 2012. 118(15): p. 3670-80.

461. Lee, A. K., Loda, M., Mackarem, G., Bosari, S., DeLellis, R. A., Heatley, G. J., et.al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome, Cancer, 1997. 79(4): p. 761-71.

462. Leitner, S. P., Swern, A. S., Weinberger, D., Duncan, L. J., Hutter, R. V., Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0), Cancer, 1995. 76(11): p. 2266-74.

463. Schnitt, Stuart J., Collins, Laura C., Biopsy interpretation of the breastWolters Kluwer Health/Lippincott Williams & Wilkins, Biopsy interpretation series, 2013. p. xi, 540 p..

464. Zaorsky, N. G., Patil, N., Freedman, G. M., Tuluc, M., Differentiating lymphovascular invasion from retraction artifact on histological specimen of breast carcinoma and their implications on prognosis, J Breast Cancer, 2012. 15(4): p. 478-80.

465. NICE, Early and locally advanced breast cancer: diagnosis and treatment. CG80National Institute for Health and Care Excellence (NICE), 2009 (last update 2017). p. 1-26.

466. NZGG, Management of Early Breast CancerNew Zealand Guidelines Group (NZGG), Evidence-based Best Practice Guideline, 2009. p. 1-255.

467. Nothacker, M., Lelgemann, M., Giersiepen, K., S, Weinbrenner, Evidenzbericht 2007 zur S3-Leitlinie Brustkrebsfrüherkennung in Deutschland.Ärztliches Zentrum für Qualität in der der Medizin (ÄZQ), 2007. p. 1-281.

468. Wolff, A. C., Hammond, M. E., Hicks, D. G., Allison, K. H., Bartlett, J. M., Bilous, M., et.al. Reply to E.A. Rakha et al, J Clin Oncol, 2015. 33(11): p. 1302-4.

469. Rüschoff, J., Lebeau, A., Kreipe, H., Sinn, P., Gerharz, C. D., Koch, W., et.al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany, Mod Pathol, 2017. 30(2): p. 217-226.

470. Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., et.al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 2015. 26(8): p. 1533-46.

471. Curigliano, G., Burstein, H. J., E, P. Winer, Gnant, M., Dubsky, P., Loibl, S., et.al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017, Ann Oncol, 2017. 28(8): p. 1700-1712.

472. Nofech-Mozes, S., Vella, E. T., Dhesy-Thind, S., Hagerty, K. L., Mangu, P. B., Temin, S., et.al. Systematic review on hormone receptor testing in breast cancer, Appl Immunohistochem Mol Morphol, 2012. 20(3): p. 214-63.

473. Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., et.al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype, Ann Surg Oncol, 2013. 20(1): p. 87-93.

474. Iwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., et.al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry, J Clin Oncol, 2012. 30(7): p. 729-34.

475. Prabhu, J. S., Korlimarla, A., Desai, K., Alexander, A., Raghavan, R., Anupama, C., et.al. A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors, J Cancer, 2014. 5(2): p. 156-65.

476. Sanford, R. A., Song, J., Gutierrez-Barrera, A. M., Profato, J., Woodson, A., Litton, J. K., et.al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors, Cancer, 2015. 121(19): p. 3422-7.

477. Yi, M., Huo, L., Koenig, K. B., Mittendorf, E. A., Meric-Bernstam, F., Kuerer, H. M., et.al. Which threshold for ER positivity? a retrospective study based on 9639 patients, Ann Oncol, 2014. 25(5): p. 1004-11.

478. Nofech-Mozes, S., Vella, E. T., Dhesy-Thind, S., Hanna, W. M., Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer, Clin Oncol (R Coll Radiol), 2012. 24(10): p. 684-96.

479. Harvey, J. M., Clark, G. M., Osborne, C. K., Allred, D. C., Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 1999. 17(5): p. 1474-81.

480. Remmele, W., Stegner, H. E., [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue], Pathologe, 1987. 8(3): p. 138-40.

481. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., et.al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 2007. 25(1): p. 118-45.

482. Wolff, A. C., Hammond, M. E., Hayes, D. F., Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria, J Natl Cancer Inst, 2012. 104(12): p. 957-8.

483. Rakha, E. A., Pigera, M., Shin, S. J., D'Alfonso, T., Ellis, I. O., Lee, A. H., Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?, Histopathology, 2016. 69(1): p. 20-4.

484. Petrelli, F., Viale, G., Cabiddu, M., Barni, S., Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients, Breast Cancer Res Treat, 2015. 153(3): p. 477-91.

485. Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., et.al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2016. 34(10): p. 1134-50.

486. Mengel, M., von Wasielewski, R., Wiese, B., Rudiger, T., Muller-Hermelink, H. K., Kreipe, H., Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial, J Pathol, 2002. 198(3): p. 292-9.

487. Varga, Z., Diebold, J., Dommann-Scherrer, C., Frick, H., Kaup, D., Noske, A., et.al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists, PLoS One, 2012. 7(5): p. e37379.

488. Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., et.al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, 2011. 103(22): p. 1656-64.

489. Leung, Samuel C. Y., Nielsen, Torsten O., Zabaglo, Lila, Arun, Indu, Badve, Sunil S., Bane, Anita L., et.al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration, Npj Breast Cancer, 2016. 2: p. 16014.

490. Polley, M. Y., Leung, S. C., Gao, D., Mastropasqua, M. G., Zabaglo, L. A., Bartlett, J. M., et.al. An international study to increase concordance in Ki67 scoring, Mod Pathol, 2015. 28(6): p. 778-86.

491. Varga, Z., Cassoly, E., Li, Q., Oehlschlegel, C., Tapia, C., Lehr, H. A., et.al. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study, PLoS One, 2015. 10(4): p. e0123435.

492. Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., et.al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment, J Clin Oncol, 2016. 34(20): p. 2341-9.

493. Nitz, U., Gluz, O., Huober, J., Kreipe, H. H., Kates, R. E., Hartmann, A., et.al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression, Ann Oncol, 2014. 25(8): p. 1551-7.

494. Inwald, E. C., Klinkhammer-Schalke, M., Hofstadter, F., Zeman, F., Koller, M., Gerstenhauer, M., et.al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry, Breast Cancer Res Treat, 2013. 139(2): p. 539-52.

495. O'Shaughnessy, J., Koeppen, H., Xiao, Y., Lackner, M. R., Paul, D., Stokoe, C., et.al. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine, Clin Cancer Res, 2015. 21(19): p. 4305-11.

496. Sonnenblick, A., Francis, P. A., Azim, H. A., Jr., de Azambuja, E., Nordenskjold, B., Gutierez, J., et.al. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer, Eur J Cancer, 2015. 51(12): p. 1481-9.

497. Christgen, M., Winkens, W., Kreipe, H. H., [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67], Pathologe, 2014. 35(1): p. 54-60.

498. Denkert, C., Budczies, J., von Minckwitz, G., Wienert, S., Loibl, S., Klauschen, F., Strategies for developing Ki67 as a useful biomarker in breast cancer, Breast, 2015. 24 Suppl 2: p. S67-72.

499. Klauschen, F., Wienert, S., Schmitt, W. D., Loibl, S., Gerber, B., Blohmer, J. U., et.al. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study, Clin Cancer Res, 2015. 21(16): p. 3651-7.

500. Christgen, M., von Ahsen, S., Christgen, H., Langer, F., Kreipe, H., The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer, Hum Pathol, 2015. 46(9): p. 1341-9.

501. Bundred, N. J., Prognostic and predictive factors in breast cancer, Cancer Treat Rev, 2001. 27(3): p. 137-42.

502. Carter, C. L., Allen, C., Henson, D. E., Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, 1989. 63(1): p. 181-7.

503. Page, D. L., Jensen, R. A., Simpson, J. F., Routinely available indicators of prognosis in breast cancer, Breast Cancer Res Treat, 1998. 51(3): p. 195-208.

504. Page, D. L., Rogers, L. W., Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia, Hum Pathol, 1992. 23(10): p. 1095-7.

505. Rakha, E. A., Agarwal, D., Green, A. R., Ashankyty, I., Ellis, I. O., Ball, G., et.al. Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer, Histopathology, 2017. 70(4): p. 622-631.

506. Rosen, P. P., Groshen, S., Kinne, D. W., Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study, J Clin Oncol, 1991. 9(9): p. 1650-61.

507. Rosen, P. P., Groshen, S., Kinne, D. W., Norton, L., Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up, J Clin Oncol, 1993. 11(11): p. 2090-100.

508. Brierley, James, Gospodarowicz, M. K., Wittekind, Ch (Hrsg.), TNM classification of malignant tumoursJohn Wiley & Sons, Inc., 2017.

509. Fisher, E. R., Redmond, C., Fisher, B., Bass, G., Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients, Cancer, 1990. 65(9 Suppl): p. 2121-8.

510. Elston, C. W., Ellis, I. O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 1991. 19(5): p. 403-10.

511. Rakha, E. A., El-Sayed, M. E., Lee, A. H., Elston, C. W., Grainge, M. J., Hodi, Z., et.al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma, J Clin Oncol, 2008. 26(19): p. 3153-8.

512. Schwartz, Arnold M., Henson, Donald Earl, Chen, Dechang, Rajamarthandan, Sivasankari, Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161 708 Cases of Breast Cancer From the SEER Program, Archives of Pathology & Laboratory Medicine, 2014. 138(8): p. 1048-1052.

513. Colleoni, M., Rotmensz, N., Maisonneuve, P., Sonzogni, A., Pruneri, G., Casadio, C., et.al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer, Ann Oncol, 2007. 18(10): p. 1632-40.

514. Buus, R., Sestak, I., Kronenwett, R., Denkert, C., Dubsky, P., Krappmann, K., et.al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy, J Natl Cancer Inst, 2016. 108(11):

515. Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., et.al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, N Engl J Med, 2016. 375(8): p. 717-29.

516. Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., et.al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer, N Engl J Med, 2015. 373(21): p. 2005-14.

517. Giuliano, A. E., Connolly, J. L., Edge, S. B., Mittendorf, E. A., Rugo, H. S., Solin, L. J., et.al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 2017.

518. Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., et.al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients, Eur J Cancer, 2013. 49(8): p. 1825-35.

519. Schmidt, M., Dogan, G., Battista, M., Lenhard, H. G., Lebrecht, A., Hönig, A., et.al. Zusammenhang zwischen urokinase-typ Plasminogen Aktivator (uPA)/Plasminogen Aktivator Inhibitor-1 (PAI-1) und intrinsischen Subtypen beim frühen Mammakarzinom, Geburtshilfe Frauenheilkd, 2014. 74(S 01): p. PO_Onko07_18.

520. Witzel, I., Milde-Langosch, K., Schmidt, M., Karn, T., Becker, S., Wirtz, R., et.al. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer, Onco Targets Ther, 2014. 7: p. 2205-13.

521. IQWiG, Bestimmung der Antigenexpressionslevel von uPA und PAI-1 beim primären Mammakarzinom mit intermediärem Rückfallrisiko nach R0-Primäroperation. D13-02Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2014. p. 1-78.

522. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et.al. Molecular portraits of human breast tumours, Nature, 2000. 406(6797): p. 747-52.

523. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et.al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 2001. 98(19): p. 10869-74.

524. Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., et.al. Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 2009. 27(8): p. 1160-7.

525. Cheang, M. C., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., et.al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 2009. 101(10): p. 736-50.

526. Hugh, J., Hanson, J., Cheang, M. C., Nielsen, T. O., Perou, C. M., Dumontet, C., et.al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial, J Clin Oncol, 2009. 27(8): p. 1168-76.

527. Prat, A., Cheang, M. C., Martin, M., Parker, J. S., Carrasco, E., Caballero, R., et.al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 2013. 31(2): p. 203-9.

528. Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B., et.al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 2013. 24(9): p. 2206-23.

529. Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B., Senn, H. J., et.al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 2011. 22(8): p. 1736-47.

530. Prat, A., Adamo, B., Cheang, M. C., Anders, C. K., Carey, L. A., Perou, C. M., Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, Oncologist, 2013. 18(2): p. 123-33.

531. Early Breast Cancer Trialists' Collaborative, Group, Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., et.al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 2012. 379(9814): p. 432-44.

532. Koppelmans, V., Breteler, M. M., Boogerd, W., Seynaeve, C., Gundy, C., Schagen, S. B., Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy, J Clin Oncol, 2012. 30(10): p. 1080-6.

533. Lange, M., Heutte, N., Rigal, O., Noal, S., Kurtz, J. E., Levy, C., et.al. Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment, Oncologist, 2016.

534. Shapiro, C. L., Recht, A., Side effects of adjuvant treatment of breast cancer, N Engl J Med, 2001. 344(26): p. 1997-2008.

535. Tao, J. J., Visvanathan, K., Wolff, A. C., Long term side effects of adjuvant chemotherapy in patients with early breast cancer, Breast, 2015. 24 Suppl 2: p. S149-53.

536. Mayer, E. L., Early and late long-term effects of adjuvant chemotherapy, Am Soc Clin Oncol Educ Book, 2013. p. 9-14.

537. Simon, R. M., Paik, S., Hayes, D. F., Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 2009. 101(21): p. 1446-52.

538. Dubsky, P., Brase, J. C., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., et.al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients, Br J Cancer, 2013. 109(12): p. 2959-64.

539. Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., et.al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer, Ann Oncol, 2013. 24(3): p. 640-7.

540. Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C. F., et.al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors, Clin Cancer Res, 2011. 17(18): p. 6012-20.

541. Martin, M., Brase, J. C., Calvo, L., Krappmann, K., Ruiz-Borrego, M., Fisch, K., et.al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial, Breast Cancer Res, 2014. 16(2): p. R38.

542. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et.al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 2004. 351(27): p. 2817-26.

543. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., et.al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, 2006. 24(23): p. 3726-34.

544. Wolmark, N., Mamounas, E. P., Baehner, F. L., Butler, S. M., Tang, G., Jamshidian, F., et.al. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14, J Clin Oncol, 2016. 34(20): p. 2350-8.

545. Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T., et.al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, 2010. 11(1): p. 55-65.

546. Sgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., et.al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population, Lancet Oncol, 2013. 14(11): p. 1067-76.

547. Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stoger, H., Jakesz, R., et.al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer, Clin Cancer Res, 2014. 20(5): p. 1298-305.

548. Martin, M., Prat, A., Rodriguez-Lescure, A., Caballero, R., Ebbert, M. T., Munarriz, B., et.al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer, Breast Cancer Res Treat, 2013. 138(2): p. 457-66.

549. Gnant, M., Filipits, M., Greil, R., Stoeger, H., Rudas, M., Bago-Horvath, Z., et.al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone, Ann Oncol, 2014. 25(2): p. 339-45.

550. Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., et.al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype, Ann Oncol, 2015. 26(8): p. 1685-91.

551. Bartlett, J. M., Bayani, J., Marshall, A., Dunn, J. A., Campbell, A., Cunningham, C., et.al. Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others, J Natl Cancer Inst, 2016. 108(9):

552. Stein, R. C., Dunn, J. A., Bartlett, J. M., Campbell, A. F., Marshall, A., Hall, P., et.al. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer, Health Technol Assess, 2016. 20(10): p. xxiii-xxix, 1-201.

553. Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., et.al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, 2013. 31(22): p. 2783-90.

554. Martin, M., Brase, J. C., Ruiz, A., Prat, A., Kronenwett, R., Calvo, L., et.al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study, Breast Cancer Res Treat, 2016. 156(1): p. 81-9.

555. Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., et.al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update, J Clin Oncol, 2017. 35(24): p. 2838-2847.

556. IQWiG, Biomarkerbasierte Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom. Abschlussbericht. Version 1.0. D14-01Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2016. IQWIG-Bericht Nr. 457: p. 1-225.

557. Fitzal, F., Filipits, M., Rudas, M., Greil, R., Dietze, O., Samonigg, H., et.al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial, Br J Cancer, 2015. 112(8): p. 1405-10.

558. Sestak, I, Buus, R, Cuzick, J, Dubsky, P, Kronenwett, R, Ferree, S, et.al. Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC, Cancer Research, 2017. 77(4 Supplement): p. S6-05-S6-05.

559. Early Breast Cancer Trialists' Collaborative, Group, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., et.al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 2011. 378(9793): p. 771-84.

560. Freedman, O. C., Fletcher, G. G., Gandhi, S., Mates, M., Dent, S. F., Trudeau, M. E., et.al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline, Curr Oncol, 2015. 22(Suppl 1): p. S95-S113.

561. Early Breast Cancer Trialists' Collaborative, Group, Ovarian ablation for early breast cancer, Cochrane Database Syst Rev, 2000. p. CD000485.

562. Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., Mamounas, E., Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy, Eur J Cancer, 2012. 48(18): p. 3342-54.

563. von Minckwitz, G., Untch, M., Nuesch, E., Loibl, S., Kaufmann, M., Kummel, S., et.al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 2011. 125(1): p. 145-56.

564. Amoroso, V., Generali, D., Buchholz, T., Cristofanilli, M., Pedersini, R., Curigliano, G., et.al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013), J Natl Cancer Inst Monogr, 2015. 2015(51): p. 90-6.

565. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., et.al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 2014. 384(9938): p. 164-72.

566. Berruti, A., Amoroso, V., Gallo, F., Bertaglia, V., Simoncini, E., Pedersini, R., et.al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies, J Clin Oncol, 2014. 32(34): p. 3883-91.

567. Denkert, C., Loibl, S., Muller, B. M., Eidtmann, H., Schmitt, W. D., Eiermann, W., et.al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial, Ann Oncol, 2013. 24(11): p. 2786-93.

568. Caldarella, A., Crocetti, E., Paci, E., Ki67 in breast cancer: a useful prognostic marker?, Ann Oncol, 2014. 25(2): p. 542.

569. Denkert, C., von Minckwitz, G., Reply to Ki67 in breast cancer: a useful prognostic marker!, Ann Oncol, 2014. 25(2): p. 542-3.

570. Ingold Heppner, B., Untch, M., Denkert, C., Pfitzner, B. M., Lederer, B., Schmitt, W., et.al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer, Clin Cancer Res, 2016. 22(23): p. 5747-5754.

571. Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., et.al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00, Breast Cancer Res Treat, 2016. 158(2): p. 323-31.

572. Wang, K., Xu, J., Zhang, T., Xue, D., Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis, Oncotarget, 2016. 7(28): p. 44288-44298.

573. Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., et.al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Ann Oncol, 2015. 26(2): p. 259-71.

574. Lee, A. H., Villena Salinas, N. M., Hodi, Z., Rakha, E. A., Ellis, I. O., The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification, J Clin Pathol, 2012. 65(12): p. 1097-9.

575. Thomas, J., Evans, A., Macartney, J., Pinder, S. E., Hanby, A., Ellis, I., et.al. Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project, Br J Cancer, 2010. 102(2): p. 285-93.

576. Lebeau, A., [Prognostic factors in ductal carcinoma in situ], Pathologe, 2006. 27(5): p. 326-36.

577. Kühn, T., Bembenek, A., Decker, T., Munz, D. L., Sautter-Bihl, M. L., Untch, M., et.al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance, Cancer, 2005. 103(3): p. 451-61.

578. Cserni, G., Gregori, D., Merletti, F., Sapino, A., Mano, M. P., Ponti, A., et.al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer, Br J Surg, 2004. 91(10): p. 1245-52.

579. Viale, G., Maiorano, E., Pruneri, G., Mastropasqua, M. G., Valentini, S., Galimberti, V., et.al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy, Ann Surg, 2005. 241(2): p. 319-25.

580. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., et.al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005. 366(9503): p. 2087-106.

581. Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., et.al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet, 2011. 378(9804): p. 1707-16.

582. Potter, R., Gnant, M., Kwasny, W., Tausch, C., Handl-Zeller, L., Pakisch, B., et.al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer, Int J Radiat Oncol Biol Phys, 2007. 68(2): p. 334-40.

583. Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., et.al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343, J Clin Oncol, 2013. 31(19): p. 2382-7.

584. Kunkler, I. H., Williams, L. J., Jack, W. J., Cameron, D. A., Dixon, J. M., Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial, Lancet Oncol, 2015. 16(3): p. 266-73.

585. Blamey, R. W., Bates, T., Chetty, U., Duffy, S. W., Ellis, I. O., George, D., et.al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial, Eur J Cancer, 2013. 49(10): p. 2294-302.

586. Fyles, Anthony W, McCready, David R, Manchul, Lee A, Trudeau, Maureen E, Merante, Patricia, Pintilie, Melania, et.al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer, New England Journal of Medicine, 2004. 351(10): p. 963-970.

587. Kauer-Dorner, D., Potter, R., Resch, A., Handl-Zeller, L., Kirchheiner, K., Meyer-Schell, K., et.al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial, Radiother Oncol, 2012. 102(1): p. 96-101.

588. Sedlmayer, F., Sautter-Bihl, M. L., Budach, W., Dunst, J., Fastner, G., Feyer, P., et.al. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer, Strahlenther Onkol, 2013. 189(10): p. 825-33.

589. Bantema-Joppe, E. J., Vredeveld, E. J., de Bock, G. H., Busz, D. M., Woltman-van Iersel, M., Dolsma, W. V., et.al. Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence, Radiother Oncol, 2013. 108(2): p. 269-72.

590. Pötter, Richard, Gnant, Michael, Kwasny, Werner, Tausch, Christoph, Handl-Zeller, Leonore, Pakisch, Brigitte, et.al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer, International Journal of Radiation Oncology* Biology* Physics, 2007. 68(2): p. 334-340.

591. Matuschek, C., Bolke, E., Haussmann, J., Mohrmann, S., Nestle-Kramling, C., Gerber, P. A., et.al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials, Radiat Oncol, 2017. 12(1): p. 60.

592. Hancke, K., Denkinger, M. D., Konig, J., Kurzeder, C., Wockel, A., Herr, D., et.al. Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study, Ann Oncol, 2010. 21(4): p. 748-53.

593. Houssami, N., Macaskill, P., Marinovich, M. L., Dixon, J. M., Irwig, L., Brennan, M. E., et.al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy, Eur J Cancer, 2010. 46(18): p. 3219-32.

594. Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., et.al. Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 2013. 368(11): p. 987-98.

595. Poortmans, Philip M, Collette, Sandra, Kirkove, Carine, Van Limbergen, Erik, Budach, Volker, Struikmans, Henk, et.al. Internal mammary and medial supraclavicular irradiation in breast cancer, New England Journal of Medicine, 2015. 373(4): p. 317-327.

596. Thorsen, L. B., Offersen, B. V., Dano, H., Berg, M., Jensen, I., Pedersen, A. N., et.al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer, J Clin Oncol, 2016. 34(4): p. 314-20.

597. Whelan, Timothy J, Olivotto, Ivo A, Parulekar, Wendy R, Ackerman, Ida, Chua, Boon H, Nabid, Abdenour, et.al. Regional nodal irradiation in early-stage breast cancer, New England Journal of Medicine, 2015. 373(4): p. 307-316.

598. Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., et.al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831, J Clin Oncol, 2009. 27(16): p. 2638-44.

599. Donovan, E., Bleakley, N., Denholm, E., Evans, P., Gothard, L., Hanson, J., et.al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy, Radiother Oncol, 2007. 82(3): p. 254-64.

600. Mukesh, M. B., Barnett, G. C., Wilkinson, J. S., Moody, A. M., Wilson, C., Dorling, L., et.al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis, J Clin Oncol, 2013. 31(36): p. 4488-95.

601. McCormick, B., Hunt, M., Intensity-modulated radiation therapy for breast: is it for everyone?, Semin Radiat Oncol, 2011. 21(1): p. 51-4.

602. Staffurth, J, A review of the clinical evidence for intensity-modulated radiotherapy, Clinical oncology, 2010. 22(8): p. 643-657.

603. Bartlett, F. R., Colgan, R. M., Donovan, E. M., McNair, H. A., Carr, K., Evans, P. M., et.al. The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery, Radiother Oncol, 2015. 114(1): p. 66-72.

604. Berrington de Gonzalez, A., Curtis, R. E., Kry, S. F., Gilbert, E., Lamart, S., Berg, C. D., et.al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries, Lancet Oncol, 2011. 12(4): p. 353-60.

605. Wiltink, Lisette M, Nout, Remi A, Fiocco, Marta, Meershoek-Klein Kranenbarg, Elma, Jürgenliemk-Schulz, Ina M, Jobsen, Jan J, et.al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials, Journal of Clinical Oncology, 2014. 33(15): p. 1640-1646.

606. Owen, J. R., Ashton, A., Bliss, J. M., Homewood, J., Harper, C., Hanson, J., et.al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial, Lancet Oncol, 2006. 7(6): p. 467-71.

607. Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., et.al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials, Lancet Oncol, 2013. 14(11): p. 1086-94.

608. Whelan, Timothy J, Pignol, Jean-Philippe, Levine, Mark N, Julian, Jim A, MacKenzie, Robert, Parpia, Sameer, et.al. Long-term results of hypofractionated radiation therapy for breast cancer, New England Journal of Medicine, 2010. 362(6): p. 513-520.

609. Yarnold, J., Ashton, A., Bliss, J., Homewood, J., Harper, C., Hanson, J., et.al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial, Radiother Oncol, 2005. 75(1): p. 9-17.

610. Bentzen, S. M., Agrawal, R. K., Aird, E. G., Barrett, J. M., Barrett-Lee, P. J., Bliss, J. M., et.al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet Oncol, 2008. 9(4): p. 331-41.

611. Trialists' Group, The START, The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, The Lancet, 2008. 371(9618): p. 1098-1107.

612. Shaitelman, S. F., Schlembach, P. J., Arzu, I., Ballo, M., Bloom, E. S., Buchholz, D., et.al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial, JAMA Oncol, 2015. 1(7): p. 931-41.

613. Agrawal, R. K., Alhasso, A., Barrett-Lee, P. J., Bliss, J. M., Bliss, P., Bloomfield, D., et.al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015), Radiother Oncol, 2011. 100(1): p. 93-100.

614. Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., et.al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial, Radiother Oncol, 2016. 120(1): p. 114-8.

615. Zhou, Z. R., Mei, X., Chen, X. X., Yang, Z. Z., Hou, J., Zhang, L., et.al. Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer, Surg Oncol, 2015. 24(3): p. 200-11.

616. Bane, A. L., Whelan, T. J., Pond, G. R., Parpia, S., Gohla, G., Fyles, A. W., et.al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy, Ann Oncol, 2014. 25(5): p. 992-8.

617. Galecki, J., Hicer-Grzenkowicz, J., Grudzien-Kowalska, M., Michalska, T., Zalucki, W., Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer--a review, Acta Oncol, 2006. 45(3): p. 280-4.

618. Antonini, N., Jones, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., et.al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882, Radiother Oncol, 2007. 82(3): p. 265-71.

619. Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., et.al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial, Lancet Oncol, 2015. 16(1): p. 47-56.

620. Vrieling, C., van Werkhoven, E., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., et.al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial, JAMA Oncol, 2017. 3(1): p. 42-48.

621. Romestaing, P., Lehingue, Y., Carrie, C., Coquard, R., Montbarbon, X., Ardiet, J. M., et.al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France, J Clin Oncol, 1997. 15(3): p. 963-8.

622. Collette, S., Collette, L., Budiharto, T., Horiot, J. C., Poortmans, P. M., Struikmans, H., et.al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost', Eur J Cancer, 2008. 44(17): p. 2587-99.

623. Poortmans, P. M., Collette, L., Bartelink, H., Struikmans, H., Van den Bogaert, W. F., Fourquet, A., et.al. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial, Cancer Radiother, 2008. 12(6-7): p. 565-70.

624. Wickberg, A., Holmberg, L., Adami, H. O., Magnuson, A., Villman, K., Liljegren, G., Sector resection with or without postoperative radiotherapy for stage I breast cancer: 20-year results of a randomized trial, J Clin Oncol, 2014. 32(8): p. 791-7.

625. Aly, M. M., Abo-Madyan, Y., Jahnke, L., Wenz, F., Glatting, G., Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH), Radiat Oncol, 2016. 11: p. 16.

626. Van Parijs, Hilde, Reynders, Truus, Heuninckx, Karina, Verellen, Dirk, Storme, Guy, De Ridder, Mark, Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost, BioMed research international, 2014. 2014:

627. McDonald, M. W., Godette, K. D., Whitaker, D. J., Davis, L. W., Johnstone, P. A., Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost, Int J Radiat Oncol Biol Phys, 2010. 77(2): p. 523-30.

628. (DEGRO), Deutsche Geselleschaft für Radioonkologie, Brustkrebs: Neue Techniken ermöglichen kürzere Bestrahlungszeiten., 2013.

629. Polgar, C., Van Limbergen, E., Potter, R., Kovacs, G., Polo, A., Lyczek, J., et.al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009), Radiother Oncol, 2010. 94(3): p. 264-73.

630. Polgar, C., Fodor, J., Major, T., Sulyok, Z., Kasler, M., Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial, Radiother Oncol, 2013. 108(2): p. 197-202.

631. Veronesi, U., Orecchia, R., Maisonneuve, P., Viale, G., Rotmensz, N., Sangalli, C., et.al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial, Lancet Oncol, 2013. 14(13): p. 1269-77.

632. Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., et.al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 2014. 383(9917): p. 603-13.

633. Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., et.al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial, Lancet, 2016. 387(10015): p. 229-38.

634. Polgar, C., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., et.al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial, Lancet Oncol, 2017. 18(2): p. 259-268.

635. Chen, P. Y., Wallace, M., Mitchell, C., Grills, I., Kestin, L., Fowler, A., et.al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation, Int J Radiat Oncol Biol Phys, 2010. 76(4): p. 991-7.

636. Herskind, C., Griebel, J., Kraus-Tiefenbacher, U., Wenz, F., Sphere of equivalence--a novel target volume concept for intraoperative radiotherapy using low-energy X rays, Int J Radiat Oncol Biol Phys, 2008. 72(5): p. 1575-81.

637. Ivanov, O., Dickler, A., Lum, B. Y., Pellicane, J. V., Francescatti, D. S., Twelve-month follow-up results of a trial utilizing Axxent electronic brachytherapy to deliver intraoperative radiation therapy for early-stage breast cancer, Ann Surg Oncol, 2011. 18(2): p. 453-8.

638. Jeruss, J. S., Kuerer, H. M., Beitsch, P. D., Vicini, F. A., Keisch, M., Update on DCIS outcomes from the American Society of Breast Surgeons accelerated partial breast irradiation registry trial, Ann Surg Oncol, 2011. 18(1): p. 65-71.

639. Livi, L., Buonamici, F. B., Simontacchi, G., Scotti, V., Fambrini, M., Compagnucci, A., et.al. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial, Int J Radiat Oncol Biol Phys, 2010. 77(2): p. 509-15.

640. Lemanski, C., Azria, D., Gourgon-Bourgade, S., Gutowski, M., Rouanet, P., Saint-Aubert, B., et.al. Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial, Int J Radiat Oncol Biol Phys, 2010. 76(3): p. 698-703.

641. Nelson, J. C., Beitsch, P. D., Vicini, F. A., Quiet, C. A., Garcia, D., Snider, H. C., et.al. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial, Am J Surg, 2009. 198(1): p. 83-91.

642. Njeh, C. F., Saunders, M. W., Langton, C. M., Accelerated Partial Breast Irradiation (APBI): A review of available techniques, Radiat Oncol, 2010. 5: p. 90.

643. Offersen, B. V., Overgaard, M., Kroman, N., Overgaard, J., Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review, Radiother Oncol, 2009. 90(1): p. 1-13.

644. Strauss, Jonathan B, Dickler, Adam, Accelerated partial breast irradiation utilizing balloon brachytherapy techniques, Radiotherapy and Oncology, 2009. 91(2): p. 157-165.

645. Wenz, Frederik, Welzel, Grit, Blank, Elena, Hermann, Brigitte, Steil, Volker, Sütterlin, Marc, et.al. Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach, International Journal of Radiation Oncology* Biology* Physics, 2010. 77(5): p. 1309-1314.

646. Strnad, V., Hildebrandt, G., Potter, R., Hammer, J., Hindemith, M., Resch, A., et.al. Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery, Int J Radiat Oncol Biol Phys, 2011. 80(1): p. 17-24.

647. Vaidya, J. S., Baum, M., Tobias, J. S., Wenz, F., Massarut, S., Keshtgar, M., et.al. Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery, Int J Radiat Oncol Biol Phys, 2011. 81(4): p. 1091-7.

648. Veronesi, U., Orecchia, R., Luini, A., Galimberti, V., Zurrida, S., Intra, M., et.al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons, Breast Cancer Res Treat, 2010. 124(1): p. 141-51.

649. Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., et.al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial, Lancet, 2010. 376(9735): p. 91-102.

650. Livi, L., Meattini, I., Marrazzo, L., Simontacchi, G., Pallotta, S., Saieva, C., et.al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial, Eur J Cancer, 2015. 51(4): p. 451-63.

651. Meattini, I., Saieva, C., Miccinesi, G., Desideri, I., Francolini, G., Scotti, V., et.al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: Health-related quality of life final analysis from the Florence phase 3 trial, Eur J Cancer, 2017. 76: p. 17-26.

652. Vaidya, J. S., Bulsara, M., Wenz, F., Coombs, N., Singer, J., Ebbs, S., et.al. Reduced Mortality With Partial-Breast Irradiation for Early Breast Cancer: A Meta-Analysis of Randomized Trials, Int J Radiat Oncol Biol Phys, 2016. 96(2): p. 259-65.

653. Keshtgar, M. R., Vaidya, J. S., Tobias, J. S., Wenz, F., Joseph, D., Stacey, C., et.al. Targeted intraoperative radiotherapy for breast cancer in patients in whom external beam radiation is not possible, Int J Radiat Oncol Biol Phys, 2011. 80(1): p. 31-8.

654. Kraus-Tiefenbacher, U., Bauer, L., Scheda, A., Schoeber, C., Schaefer, J., Steil, V., et.al. Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy, BMC Cancer, 2007. 7: p. 178.

655. McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., et.al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials, Lancet, 2014. 383(9935): p. 2127-35.

656. Wang, H., Kong, L., Zhang, C., Chen, D., Zhu, H., Yu, J., Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study, Oncotarget, 2016. 7(46): p. 75492-75502.

657. Elmore, Leisha, Deshpande, Anjali, Daly, MacKenzie, Margenthaler, Julie A, Postmastectomy radiation therapy in T3 node-negative breast cancer, Journal of Surgical Research, 2015. 199(1): p. 90-96.

658. Francis, S. R., Frandsen, J., Kokeny, K. E., Gaffney, D. K., Poppe, M. M., Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers, Breast, 2017. 32: p. 156-161.

659. Karlsson, P., Cole, B. F., Chua, B. H., Price, K. N., Lindtner, J., Collins, J. P., et.al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report, Ann Oncol, 2012. 23(11): p. 2852-8.

660. Kyndi, Marianne, Overgaard, Marie, Nielsen, Hanne M, Sørensen, Flemming B, Knudsen, Helle, Overgaard, Jens, High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c, Radiotherapy and Oncology, 2009. 90(1): p. 74-79.

661. Nagao, T., Kinoshita, T., Tamura, N., Hojo, T., Morota, M., Kagami, Y., Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy, Int J Clin Oncol, 2013. 18(1): p. 54-61.

662. Nielsen, H. M., Overgaard, M., Grau, C., Jensen, A. R., Overgaard, J., Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies, J Clin Oncol, 2006. 24(15): p. 2268-75.

663. Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., et.al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update, J Clin Oncol, 2016. 34(36): p. 4431-4442.

664. Wang, H., Zhang, C., Kong, L., Zhu, H., Yu, J., Better survival in PMRT of female breast cancer patients with >5 negative lymph nodes: A population-based study, Medicine (Baltimore), 2017. 96(4): p. e5998.

665. Headon, Hannah, Kasem, Abdul, Almukbel, Reham, Mokbel, Kefah, Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary lymph nodes: A systematic review and meta-analysis of the current literature, Molecular and Clinical Oncology, 2016. 5(4): p. 429-436.

666. Valli, M. C., Controversies in loco-regional treatment: post-mastectomy radiation for pT2-pT3N0 breast cancer arguments in favour, Crit Rev Oncol Hematol, 2012. 84 Suppl 1: p. e70-4.

667. Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., et.al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial, N Engl J Med, 1997. 337(14): p. 949-55.

668. Overgaard, M., Jensen, M. B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., et.al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial, Lancet, 1999. 353(9165): p. 1641-8.

669. Rusthoven, C. G., Rabinovitch, R. A., Jones, B. L., Koshy, M., Amini, A., Yeh, N., et.al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis, Ann Oncol, 2016. 27(5): p. 818-27.

670. Mamounas, E. P., Anderson, S. J., Dignam, J. J., Bear, H. D., Julian, T. B., Geyer, C. E., Jr., et.al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27, J Clin Oncol, 2012. 30(32): p. 3960-6.

671. Kishan, A. U., McCloskey, S. A., Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data, Ther Adv Med Oncol, 2016. 8(1): p. 85-97.

672. Kantor, O., Pesce, C., Singh, P., Miller, M., Tseng, J., Wang, C. H., et.al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy, J Surg Oncol, 2017.

673. De Felice, F., Osti, M. F., De Sanctis, V., Musio, D., Tombolini, V., Critical decision-making in radiotherapy for early stage breast cancer in a neo-adjuvant treatment era, Expert Rev Anticancer Ther, 2017. 17(5): p. 481-485.

674. McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S. W., Yu, T. K., et.al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy, Int J Radiat Oncol Biol Phys, 2007. 68(4): p. 1004-9.

675. Nagar, H., Mittendorf, E. A., Strom, E. A., Perkins, G. H., Oh, J. L., Tereffe, W., et.al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer, Int J Radiat Oncol Biol Phys, 2011. 81(3): p. 782-7.

676. Nagar, H., Boothe, D., Ginter, P. S., Sison, C., Vahdat, L., Shin, S., et.al. Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy, Clin Breast Cancer, 2015. 15(2): p. 128-34.

677. Huang, E. H., Tucker, S. L., Strom, E. A., McNeese, M. D., Kuerer, H. M., Hortobagyi, G. N., et.al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy, Int J Radiat Oncol Biol Phys, 2005. 62(2): p. 351-7.

678. Le Scodan, R., Selz, J., Stevens, D., Bollet, M. A., de la Lande, B., Daveau, C., et.al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy, Int J Radiat Oncol Biol Phys, 2012. 82(1): p. e1-7.

679. Shim, S. J., Park, W., Huh, S. J., Choi, D. H., Shin, K. H., Lee, N. K., et.al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05), Int J Radiat Oncol Biol Phys, 2014. 88(1): p. 65-72.

680. Committee, AGO Breast, Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2017., 2017.

681. Conference, St. Gallen International Breast Cancer, Primary Therapy of Early Breast Cancer., St. Gallen international consensus session on the optimal primary treatment of breast cancer 2017 at the 15th St. Gallen International Breast Cancer Conference 2017, 2017.

682. Selz, J., Le Scodan, R., Menard, J., Hennequin, C., Quero, L., [Indication of radiotherapy after neoadjuvant chemotherapy in breast cancer], Cancer Radiother, 2014. 18(3): p. 229-34.

683. Bernier, J., Post-mastectomy radiotherapy after neodjuvant chemotherapy in breast cancer patients: A review, Crit Rev Oncol Hematol, 2015. 93(3): p. 180-9.

684. Rueth, N. M., Lin, H. Y., Bedrosian, I., Shaitelman, S. F., Ueno, N. T., Shen, Y., et.al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database, J Clin Oncol, 2014. 32(19): p. 2018-24.

685. van Uden, D. J., Bretveld, R., Siesling, S., de Wilt, J. H., Blanken-Peeters, C. F., Inflammatory breast cancer in the Netherlands; improved survival over the last decades, Breast Cancer Res Treat, 2017. 162(2): p. 365-374.

686. Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., et.al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy, Int J Radiat Oncol Biol Phys, 2013. 86(5): p. 860-6.

687. Budach, W., Bolke, E., Kammers, K., Gerber, P. A., Nestle-Kramling, C., Matuschek, C., Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update, Radiat Oncol, 2015. 10: p. 258.

688. Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., et.al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology, J Clin Oncol, 2001. 19(5): p. 1539-69.

689. Yates, L., Kirby, A., Crichton, S., Gillett, C., Cane, P., Fentiman, I., et.al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes, Int J Radiat Oncol Biol Phys, 2012. 82(5): p. 2093-103.

690. Caussa, L., Kirova, Y. M., Gault, N., Pierga, J. Y., Savignoni, A., Campana, F., et.al. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study, Eur J Cancer, 2011. 47(1): p. 65-73.

691. Shaffer, R., Tyldesley, S., Rolles, M., Chia, S., Mohamed, I., Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study, Radiother Oncol, 2009. 90(1): p. 122-6.

692. Thorsen, L. B., Thomsen, M. S., Berg, M., Jensen, I., Josipovic, M., Overgaard, M., et.al. CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects, Acta Oncol, 2014. 53(8): p. 1027-34.

693. Popescu, C. C., Olivotto, I. A., Beckham, W. A., Ansbacher, W., Zavgorodni, S., Shaffer, R., et.al. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes, Int J Radiat Oncol Biol Phys, 2010. 76(1): p. 287-95.

694. Hjelstuen, Mari HB, Mjaaland, Ingvil, Vikström, Johan, Dybvik, Kjell Ivar, Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular-and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk, Acta Oncologica, 2012. 51(3): p. 333-344.

695. Donker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J., Mansel, R. E., et.al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 2014. 15(12): p. 1303-10.

696. Gruber, G., Cole, B. F., Castiglione-Gertsch, M., Holmberg, S. B., Lindtner, J., Golouh, R., et.al. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer, Ann Oncol, 2008. 19(8): p. 1393-401.

697. Jagsi, R., Chadha, M., Moni, J., Ballman, K., Laurie, F., Buchholz, T. A., et.al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial, J Clin Oncol, 2014. 32(32): p. 3600-6.

698. van Wely, B. J., Teerenstra, S., Schinagl, D. A., Aufenacker, T. J., de Wilt, J. H., Strobbe, L. J., Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy, Br J Surg, 2011. 98(3): p. 326-33.

699. Gentile, M. S., Usman, A. A., Neuschler, E. I., Sathiaseelan, V., Hayes, J. P., Small, W., Jr., Contouring Guidelines for the Axillary Lymph Nodes for the Delivery of Radiation Therapy in Breast Cancer: Evaluation of the RTOG Breast Cancer Atlas, Int J Radiat Oncol Biol Phys, 2015. 93(2): p. 257-65.

700. Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Sola, A. B., et.al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1, Radiother Oncol, 2016. 118(1): p. 205-8.

701. Nottegar, A., Veronese, N., Senthil, M., Roumen, R. M., Stubbs, B., Choi, A. H., et.al. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis, Eur J Surg Oncol, 2016. 42(7): p. 919-25.

702. Swaminathan, S., Reintgen, M., Kerivan, L., Reintgen, E., Smith, J., Reintgen, D., Extracapsular Extension in the Sentinel Lymph Node: Guidelines for Therapy, Clin Breast Cancer, 2016. 16(3): p. e65-8.

703. Bartelink, H., Rubens, R. D., van der Schueren, E., Sylvester, R., Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial, J Clin Oncol, 1997. 15(1): p. 207-15.

704. Scotti, V., Desideri, I., Meattini, I., Di Cataldo, V., Cecchini, S., Petrucci, A., et.al. Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach, Cancer Treat Rev, 2013. 39(2): p. 119-24.

705. De Lena, M., Zucali, R., Viganotti, G., Valagussa, P., Bonadonna, G., Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer, Cancer Chemother Pharmacol, 1978. 1(1): p. 53-9.

706. Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., et.al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial, J Natl Cancer Inst, 2005. 97(2): p. 116-26.

707. Merajver, S. D., Weber, B. L., Cody, R., Zhang, D., Strawderman, M., Calzone, K. A., et.al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience, J Clin Oncol, 1997. 15(8): p. 2873-81.

708. Ring, A., Webb, A., Ashley, S., Allum, W. H., Ebbs, S., Gui, G., et.al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?, J Clin Oncol, 2003. 21(24): p. 4540-5.

709. Daveau, C., Savignoni, A., Abrous-Anane, S., Pierga, J. Y., Reyal, F., Gautier, C., et.al. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?, Int J Radiat Oncol Biol Phys, 2011. 79(5): p. 1452-9.

710. Huang, E. H., Tucker, S. L., Strom, E. A., McNeese, M. D., Kuerer, H. M., Buzdar, A. U., et.al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy, J Clin Oncol, 2004. 22(23): p. 4691-9.

711. Garg, A. K., Oh, J. L., Oswald, M. J., Huang, E., Strom, E. A., Perkins, G. H., et.al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy, Int J Radiat Oncol Biol Phys, 2007. 69(5): p. 1478-83.

712. Badwe, R., Hawaldar, R., Nair, N., Kaushik, R., Parmar, V., Siddique, S., et.al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial, Lancet Oncol, 2015. 16(13): p. 1380-8.

713. Bellon, J. R., Come, S. E., Gelman, R. S., Henderson, I. C., Shulman, L. N., Silver, B. J., et.al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial, J Clin Oncol, 2005. 23(9): p. 1934-40.

714. Hickey, B. E., Francis, D., Lehman, M. H., Sequencing of chemotherapy and radiation therapy for early breast cancer, Cochrane Database Syst Rev, 2006. p. Cd005212.

715. Hickey, B. E., Francis, D. P., Lehman, M., Sequencing of chemotherapy and radiotherapy for early breast cancer, Cochrane Database Syst Rev, 2013. p. Cd005212.

716. Pinnaro, P., Rambone, R., Giordano, C., Giannarelli, D., Strigari, L., Arcangeli, G., Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy in breast cancer, Am J Clin Oncol, 2011. 34(3): p. 238-44.

717. Chen, Z., King, W., Pearcey, R., Kerba, M., Mackillop, W. J., The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature, Radiother Oncol, 2008. 87(1): p. 3-16.

718. Huang, J., Barbera, L., Brouwers, M., Browman, G., Mackillop, W. J., Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review, J Clin Oncol, 2003. 21(3): p. 555-63.

719. Li, Y. F., Chang, L., Li, W. H., Xiao, M. Y., Wang, Y., He, W. J., et.al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis, Breast, 2016. 27: p. 93-8.

720. Balduzzi, A., Leonardi, M. C., Cardillo, A., Orecchia, R., Dellapasqua, S., Iorfida, M., et.al. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy, Cancer Treat Rev, 2010. 36(6): p. 443-50.

721. Benchalal, M., Le Prise, E., de Lafontan, B., Berton-Rigaud, D., Belkacemi, Y., Romestaing, P., et.al. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group, Cancer, 2005. 104(2): p. 240-50.

722. Azria, D., Belkacemi, Y., Romieu, G., Gourgou, S., Gutowski, M., Zaman, K., et.al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial, Lancet Oncol, 2010. 11(3): p. 258-65.

723. Bourgier, C., Kerns, S., Gourgou, S., Lemanski, C., Gutowski, M., Fenoglietto, P., et.al. Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial, Ann Oncol, 2016. 27(3): p. 474-80.

724. Ishitobi, M., Komoike, Y., Motomura, K., Koyama, H., Nishiyama, K., Inaji, H., Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer, Anticancer Res, 2009. 29(11): p. 4791-4.

725. Ishitobi, M., Nakahara, S., Komoike, Y., Motomura, K., Koyama, H., Inaji, H., Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy, Anticancer Res, 2011. 31(1): p. 367-71.

726. Ishitobi, M., Shiba, M., Nakayama, T., Motomura, K., Koyama, H., Nishiyama, K., et.al. Treatment sequence of aromatase inhibitors and radiotherapy and long-term outcomes of breast cancer patients, Anticancer Res, 2014. 34(8): p. 4311-4.

727. Tsoutsou, P. G., Belkacemi, Y., Gligorov, J., Kuten, A., Boussen, H., Bese, N., et.al. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider, Oncologist, 2010. 15(11): p. 1169-78.

728. Advani, P. P., Ballman, K. V., Dockter, T. J., Colon-Otero, G., Perez, E. A., Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial, J Clin Oncol, 2016. 34(6): p. 581-7.

729. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998. 352(9132): p. 930-42.

730. Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., et.al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 2011. 378(9793): p. 771-84.

731. Fisher, B., Dignam, J., Wolmark, N., DeCillis, A., Emir, B., Wickerham, D. L., et.al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer, J Natl Cancer Inst, 1997. 89(22): p. 1673-82.

732. Thuerlimann, B, Price, KN, Castiglione, M, Coates, AS, Goldhirsch, A, Gelber, RD, et.al. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93, The Breast, 2001. 10: p. 130-138.

733. Eisen, Andrea, Fletcher, Glenn G, Gandhi, Sonal, Mates, Mihaela, Freedman, Orit C, Dent, Susan F, et.al. Optimal Systemic Therapy for Early Female Breast Cancer, Evidence-based series, 2014. p. 1-21.

734. Yi, M., Huo, L., Koenig, K. B., Mittendorf, E. A., Meric-Bernstam, F., Kuerer, H. M., et.al. Which threshold for ER positivity? a retrospective study based on 9639 patients, Ann Oncol, 2014. 25(5): p. 1004-11.

735. Gloyeske, N. C., Dabbs, D. J., Bhargava, R., Low ER+ breast cancer: Is this a distinct group?, Am J Clin Pathol, 2014. 141(5): p. 697-701.

736. Cserni, G., Francz, M., Kalman, E., Kelemen, G., Komjathy, D. C., Kovacs, I., et.al. Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?, Pathol Oncol Res, 2011. 17(3): p. 663-8.

737. Hefti, M. M., Hu, R., Knoblauch, N. W., Collins, L. C., Haibe-Kains, B., Tamimi, R. M., et.al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype, Breast Cancer Res, 2013. 15(4): p. R68.

738. Delozier, T., Switsers, O., Genot, J. Y., Ollivier, J. M., Hery, M., Namer, M., et.al. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial), Ann Oncol, 2000. 11(5): p. 515-9.

739. Veronesi, A., Miolo, G., Magri, M. D., Crivellari, D., Scalone, S., Bidoli, E., et.al. Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study, BMC Cancer, 2010. 10: p. 205.

740. Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., et.al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17, J Natl Cancer Inst, 2005. 97(17): p. 1262-71.

741. Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., et.al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update, J Clin Oncol, 2014. 32(21): p. 2255-69.

742. Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., et.al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 2013. 381(9869): p. 805-16.

743. Gray, Richard G, Rea, Daniel, Handley, Kelly, Bowden, Sarah Jane, Perry, Philip, Earl, Helena Margaret, et.al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancerAmerican Society of Clinical Oncology, 2013.

744. Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Lonati, V., Barni, S., Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials, Breast Cancer Res Treat, 2013. 140(2): p. 233-40.

745. Rea, DW, Gray, RG, Bowden, SJ, Handley, K, Earl, HM, Poole, CJ, et.al. Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer, 2013.

746. Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Lang, I., et.al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 2014. 371(2): p. 107-18.

747. Chlebowski, R. T., Pan, K., Col, N. F., Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer, Breast Cancer Res Treat, 2017. 161(2): p. 185-190.

748. Hackshaw, A., Baum, M., Fornander, T., Nordenskjold, B., Nicolucci, A., Monson, K., et.al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer, J Natl Cancer Inst, 2009. 101(5): p. 341-9.

749. Ryden, L., Heibert Arnlind, M., Vitols, S., Hoistad, M., Ahlgren, J., Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials, Breast, 2016. 26: p. 106-14.

750. Burstein, Harold J, Temin, Sarah, Anderson, Holly, Buchholz, Thomas A, Davidson, Nancy E, Gelmon, Karen E, et.al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update, Journal of Clinical Oncology, 2014. 32(21): p. 2255-2269.

751. Mamounas, EP, Bandos, H, Lembersky, BC, Geyer, CE, Fehrenbacher, L, Graham, ML, et.al. Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42AACR, 2017.

752. Van de Velde, CJH, Blok, E, Kranenbarg, E Meershoek-Klein, Putter, H, Van den Bosch, J, Maartense, E, et.al. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05), European Journal of Cancer, 2017. 72: p. S9.

753. Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., et.al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years, N Engl J Med, 2016. 375(3): p. 209-19.

754. Gnant, M., Discussion, San Antonio Breast Cancer Symposium, 2016. p. S1-06.

755. Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., Nowak, A. K., Taxanes for adjuvant treatment of early breast cancer, Cochrane Database Syst Rev, 2007. p. Cd004421.

756. Sparano, J. A., Zhao, F., Martino, S., Ligibel, J. A., Perez, E. A., Saphner, T., et.al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer, J Clin Oncol, 2015. 33(21): p. 2353-60.

757. Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., et.al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 2012. 379(9814): p. 432-44.

758. Reviews., EBM, Multi-agent chemotherapy for early breast cancer, Cochrane Database of Systematic Review., 2003.

759. Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, I. C., Wood, W. C., Weiss, R. B., et.al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B, J Natl Cancer Inst, 1998. 90(16): p. 1205-11.

760. Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Dimitrov, N., Mamounas, E., et.al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22, J Clin Oncol, 1997. 15(5): p. 1858-69.

761. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial, J Clin Oncol, 2001. 19(3): p. 602-11.

762. Fumoleau, P., Kerbrat, P., Romestaing, P., Fargeot, P., Bremond, A., Namer, M., et.al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial, J Clin Oncol, 2003. 21(2): p. 298-305.

763. Swain, S. M., Jeong, J. H., Geyer, C. E., Jr., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., et.al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer, N Engl J Med, 2010. 362(22): p. 2053-65.

764. Bonadonna, G., Zambetti, M., Valagussa, P., Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results, Jama, 1995. 273(7): p. 542-7.

765. Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., et.al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, J Clin Oncol, 2003. 21(8): p. 1431-9.

766. Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., et.al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial, J Clin Oncol, 2011. 29(29): p. 3877-84.

767. Francis, P., Crown, J., Di Leo, A., Buyse, M., Balil, A., Andersson, M., et.al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial, J Natl Cancer Inst, 2008. 100(2): p. 121-33.

768. Moebus, V., Jackisch, C., Lueck, H. J., du Bois, A., Thomssen, C., Kurbacher, C., et.al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study, J Clin Oncol, 2010. 28(17): p. 2874-80.

769. Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., et.al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial, Lancet, 2015. 385(9980): p. 1863-72.

770. Bonadonna, G., Zambetti, M., Valagussa, P., Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results, Jama, 1995. 273(7): p. 542-7.

771. Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., et.al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, J Clin Oncol, 2003. 21(8): p. 1431-9.

772. Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., et.al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial, J Clin Oncol, 2011. 29(29): p. 3877-84.

773. Francis, P., Crown, J., Di Leo, A., Buyse, M., Balil, A., Andersson, M., et.al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial, J Natl Cancer Inst, 2008. 100(2): p. 121-33.

774. Moebus, V., Jackisch, C., Lueck, H. J., du Bois, A., Thomssen, C., Kurbacher, C., et.al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study, J Clin Oncol, 2010. 28(17): p. 2874-80.

775. Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., et.al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial, Lancet, 2015. 385(9980): p. 1863-72.

776. Bria, E., Nistico, C., Cuppone, F., Carlini, P., Ciccarese, M., Milella, M., et.al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients, Cancer, 2006. 106(11): p. 2337-44.

777. Clavarezza, M., Del Mastro, L., Venturini, M., Taxane-containing chemotherapy in the treatment of early breast cancer patients, Ann Oncol, 2006. 17 Suppl 7: p. vii22-6.

778. Estevez, L. G., Munoz, M., Alvarez, I., Fernandez, Y., Garcia-Mata, J., Ruiz-Borrego, M., et.al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials, Cancer Treat Rev, 2007. 33(5): p. 474-83.

779. Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., et.al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J Clin Oncol, 2003. 21(6): p. 976-83.

780. Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., et.al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28, J Clin Oncol, 2005. 23(16): p. 3686-96.

781. Roche, H., Fumoleau, P., Spielmann, M., Canon, J. L., Delozier, T., Serin, D., et.al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial, J Clin Oncol, 2006. 24(36): p. 5664-71.

782. Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jr., Jacobs, S. A., et.al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology), J Clin Oncol, 2017. p. Jco2016714147.

783. Ejlertsen, B., Tuxen, M. K., Jakobsen, E. H., Jensen, M. B., Knoop, A. S., Hojris, I., et.al. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial, J Clin Oncol, 2017. p. Jco2017723494.

784. Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, et.al. Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→ 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancerAmerican Society of Clinical Oncology, 2017.

785. Martin, M., Segui, M. A., Anton, A., Ruiz, A., Ramos, M., Adrover, E., et.al. Adjuvant docetaxel for high-risk, node-negative breast cancer, N Engl J Med, 2010. 363(23): p. 2200-10.

786. Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., et.al. Adjuvant docetaxel for node-positive breast cancer, N Engl J Med, 2005. 352(22): p. 2302-13.

787. Martín, Miguel, Rodríguez-Lescure, Álvaro, Ruiz, Amparo, Alba, Emilio, Calvo, Lourdes, Ruiz-Borrego, Manuel, et.al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer, Journal of the National Cancer Institute, 2008. 100(11): p. 805-814.

788. Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., et.al. Weekly paclitaxel in the adjuvant treatment of breast cancer, N Engl J Med, 2008. 358(16): p. 1663-71.

789. Burnell, M., Levine, M. N., Chapman, J. A., Bramwell, V., Gelmon, K., Walley, B., et.al. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer, J Clin Oncol, 2010. 28(1): p. 77-82.

790. Jones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., McIntyre, K. J., et.al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735, J Clin Oncol, 2009. 27(8): p. 1177-83.

791. Poole, CJ, Hiller, L, Howard, HC, Dunn, JA, Canney, P, Wardley, AM, et.al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC), Journal of Clinical Oncology, 2008. 26(15_suppl): p. 506-506.

792. Joensuu, H., Kellokumpu-Lehtinen, P. L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Asola, R., et.al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial, Lancet Oncol, 2009. 10(12): p. 1145-51.

793. O'Shaughnessy, J, Paul, D, Stokoe, C, Pippen Jr, J, Blum, JL, Krekow, L, et.al. Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast CancerAACR, 2010.

794. Joensuu, H., Kellokumpu-Lehtinen, P. L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Kokko, R., et.al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial, J Clin Oncol, 2012. 30(1): p. 11-8.

795. Foukakis, T., von Minckwitz, G., Bengtsson, N. O., Brandberg, Y., Wallberg, B., Fornander, T., et.al. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial, Jama, 2016. 316(18): p. 1888-1896.

796. Swain, S. M., Tang, G., Geyer, C. E., Jr., Rastogi, P., Atkins, J. N., Donnellan, P. P., et.al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial, J Clin Oncol, 2013. 31(26): p. 3197-204.

797. Cameron, D, Barrett-Lee, P, Canney, P, Banerji, J, Bartlett, J, Bloomfield, D, et.al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC)(CRUK/05/019)AACR, 2012.

798. Berry, D. A., Ueno, N. T., Johnson, M. M., Lei, X., Caputo, J., Rodenhuis, S., et.al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials, J Clin Oncol, 2011. 29(24): p. 3214-23.

799. Farquhar, C. M., Marjoribanks, J., Lethaby, A., Basser, R., High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis, Cancer Treat Rev, 2007. 33(4): p. 325-37.

800. Farquhar, C., Marjoribanks, J., Basser, R., Hetrick, S., Lethaby, A., High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer, Cochrane Database Syst Rev, 2005. p. Cd003142.

801. Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., et.al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update, J Clin Oncol, 2006. 24(12): p. 1940-9.

802. Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Jr., Mamounas, E. P., Fisher, B., et.al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol, 2006. 24(13): p. 2019-27.

803. von Minckwitz, G., Blohmer, J. U., Raab, G., Lohr, A., Gerber, B., Heinrich, G., et.al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study, Ann Oncol, 2005. 16(1): p. 56-63.

804. Mieog, J. S., van der Hage, J. A., van de Velde, C. J., Preoperative chemotherapy for women with operable breast cancer, Cochrane Database Syst Rev, 2007. p. Cd005002.

805. Mauri, D., Pavlidis, N., Ioannidis, J. P., Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, 2005. 97(3): p. 188-94.

806. Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., et.al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 2005. 23(16): p. 3676-85.

807. Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., et.al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet, 2010. 375(9712): p. 377-84.

808. Untch, M., Fasching, P. A., Konecny, G. E., Hasmuller, S., Lebeau, A., Kreienberg, R., et.al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, 2011. 29(25): p. 3351-7.

809. Gianni, L., Pienkowski, T., Im, Y. H., Roman, L., Tseng, L. M., Liu, M. C., et.al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 2012. 13(1): p. 25-32.

810. Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., et.al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, Lancet Oncol, 2016. 17(6): p. 791-800.

811. Schneeweiss, A, Chia, S, Hickish, T, Harvey, V, Eniu, A, Hegg, R, et.al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Annals of oncology, 2013. 24(9): p. 2278-2284.

812. Korn, E. L., Sachs, M. C., McShane, L. M., Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer, Ann Oncol, 2016. 27(1): p. 10-5.

813. Bazzola, L., Foroni, C., Andreis, D., Zanoni, V., M, R. Cappelletti, Allevi, G., et.al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer, British Journal of Cancer, 2015. 112(1): p. 52-60.

814. Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F., et.al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol, 2001. 19(18): p. 3808-16.

815. Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J. U., et.al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol, 2005. 23(22): p. 5108-16.

816. Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., et.al. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis, JAMA Oncol, 2016. 2(11): p. 1477-1486.

817. Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., et.al. Trastuzumab containing regimens for early breast cancer, Cochrane Database Syst Rev, 2012. p. Cd006243.

818. Petrelli, Fausto, Barni, Sandro, Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better, Medical Oncology, 2012. 29(2): p. 503-510.

819. Bartlett, J. M., Campbell, F. M., Ibrahim, M., O'Grady, A., Kay, E., Faulkes, C., et.al. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay, Am J Clin Pathol, 2011. 135(1): p. 157-62.

820. Ellis, I. O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., et.al. Best Practice No 176: Updated recommendations for HER2 testing in the UK, J Clin Pathol, 2004. 57(3): p. 233-7.

821. Penault-Llorca, F., Bilous, M., Dowsett, M., Hanna, W., Osamura, R. Y., Ruschoff, J., et.al. Emerging technologies for assessing HER2 amplification, Am J Clin Pathol, 2009. 132(4): p. 539-48.

822. Ruschoff, J., Lebeau, A., Kreipe, H., Sinn, P., Gerharz, C. D., Koch, W., et.al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany, Mod Pathol, 2016.

823. Choritz, H., Busche, G., Kreipe, H., Quality assessment of HER2 testing by monitoring of positivity rates, Virchows Arch, 2011. 459(3): p. 283-9.

824. DKG, Erhebungsbogen PathologieDeutsche Krebsgesellschaft, 2017.

825. Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., Murray, S., Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials, Oncologist, 2008. 13(6): p. 620-30.

826. Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., et.al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial, Lancet Oncol, 2011. 12(3): p. 236-44.

827. Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., et.al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer, N Engl J Med, 2006. 354(8): p. 809-20.

828. Madarnas, Y., Trudeau, M., Franek, J. A., McCready, D., Pritchard, K. I., Messersmith, H., Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review, Cancer Treat Rev, 2008. 34(6): p. 539-57.

829. Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Davidson, N. E., Geyer, C. E., Jr., et.al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31, J Clin Oncol, 2011. 29(25): p. 3366-73.

830. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et.al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 2005. 353(16): p. 1659-72.

831. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., et.al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 2005. 353(16): p. 1673-84.

832. Slamon, D. J., Romond, E. H., Perez, E. A., Advances in adjuvant therapy for breast cancer, Clin Adv Hematol Oncol, 2006. 4(3 Suppl 7): p. suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10.

833. Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., et.al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 2007. 369(9555): p. 29-36.

834. Spielmann, M., Roche, H., Delozier, T., Canon, J. L., Romieu, G., Bourgeois, H., et.al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial, J Clin Oncol, 2009. 27(36): p. 6129-34.

835. Viani, G. A., Afonso, S. L., Stefano, E. J., De Fendi, L. I., Soares, F. V., Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials, BMC Cancer, 2007. 7: p. 153.

836. Yin, W., Jiang, Y., Shen, Z., Shao, Z., Lu, J., Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials, PLoS One, 2011. 6(6): p. e21030.

837. Fehrenbacher, L., Capra, A. M., Quesenberry, C. P., Jr., Fulton, R., Shiraz, P., Habel, L. A., Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system, J Clin Oncol, 2014. 32(20): p. 2151-8.

838. Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., et.al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller, J Clin Oncol, 2009. 27(34): p. 5700-6.

839. Park, Yeon Hee, Kim, Seung Tae, Cho, Eun Yoon, La Choi, Yoon, Ok, Oh-Nam, Baek, Hae Jin, et.al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤ 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?, Breast cancer research and treatment, 2010. 119(3): p. 653-661.

840. Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., et.al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial, Lancet, 2017. 389(10075): p. 1195-1205.

841. Pivot, X., Suter, T., Nabholtz, J. M., Pierga, J. Y., Espie, M., Lortholary, A., et.al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study, Eur J Cancer, 2015. 51(13): p. 1660-6.

842. Dang, C. T., Yu, A. F., Jones, L. W., Liu, J., Steingart, R. M., Argolo, D. F., et.al. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter, J Clin Oncol, 2016. 34(10): p. 1030-3.

843. Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Jr., Ewer, M., Keefe, D., et.al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, J Clin Oncol, 2005. 23(31): p. 7811-9.

844. Pfeilschifter, J., Diel, I. J., Osteoporosis due to cancer treatment: pathogenesis and management, J Clin Oncol, 2000. 18(7): p. 1570-93.

845. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., et.al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 2009. 360(7): p. 679-91.

846. Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., et.al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial, Lancet Oncol, 2011. 12(7): p. 631-41.

847. Hadji, P., Kauka, A., Ziller, M., Birkholz, K., Baier, M., Muth, M., et.al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study, Osteoporos Int, 2014. 25(4): p. 1369-78.

848. Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., et.al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 2015. 386(9992): p. 433-43.

849. Kalder, M., Hans, D., Kyvernitakis, I., Lamy, O., Bauer, M., Hadji, P., Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer, J Clin Densitom, 2014. 17(1): p. 66-71.

850. Hadji, P., Asmar, L., van Nes, J. G., Menschik, T., Hasenburg, A., Kuck, J., et.al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies, J Cancer Res Clin Oncol, 2011. 137(6): p. 1015-25.

851. Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thurlimann, B., et.al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial, Ann Oncol, 2009. 20(9): p. 1489-98.

852. Greep, N. C., Giuliano, A. E., Hansen, N. M., Taketani, T., Wang, H. J., Singer, F. R., The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer, Am J Med, 2003. 114(8): p. 653-9.

853. Hadji, P., Ziller, M., Maskow, C., Albert, U., Kalder, M., The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer, Eur J Cancer, 2009. 45(18): p. 3205-12.

854. Kanis, J. A., Oden, A., Johnell, O., Johansson, H., De Laet, C., Brown, J., et.al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, Osteoporos Int, 2007. 18(8): p. 1033-46.

855. Frost, S. A., Nguyen, N. D., Center, J. R., Eisman, J. A., Nguyen, T. V., Timing of repeat BMD measurements: development of an absolute risk-based prognostic model, J Bone Miner Res, 2009. 24(11): p. 1800-7.

856. Coleman, R., Cameron, D., Dodwell, D., Bell, R., Wilson, C., Rathbone, E., et.al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial, Lancet Oncol, 2014. 15(9): p. 997-1006.

857. Col, N. F., Hirota, L. K., Orr, R. K., Erban, J. K., Wong, J. B., Lau, J., Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk, J Clin Oncol, 2001. 19(8): p. 2357-63.

858. Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., et.al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 2015. 386(9992): p. 433-43.

859. Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., et.al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole, Cancer, 2012. 118(5): p. 1192-201.

860. Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., et.al. Breast-cancer adjuvant therapy with zoledronic acid, N Engl J Med, 2011. 365(15): p. 1396-405.

861. Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., et.al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study, Ann Oncol, 2010. 21(11): p. 2188-94.

862. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., et.al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 2009. 360(7): p. 679-91.

863. Hadji, P., Kauka, A., Ziller, M., Birkholz, K., Baier, M., Muth, M., et.al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study, Osteoporos Int, 2014. 25(4): p. 1369-78.

864. Pantel, K., Alix-Panabieres, C., Riethdorf, S., Cancer micrometastases, Nat Rev Clin Oncol, 2009. 6(6): p. 339-51.

865. Wilson, C., Holen, I., Coleman, R. E., Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates, Cancer Treat Rev, 2012. 38(7): p. 877-89.

866. Domschke, C., Diel, I. J., Englert, S., Kalteisen, S., Mayer, L., Rom, J., et.al. Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study, Ann Surg Oncol, 2013. 20(6): p. 1865-71.

867. Banys, M., Solomayer, E. F., Gebauer, G., Janni, W., Krawczyk, N., Lueck, H. J., et.al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial, BMC Cancer, 2013. 13: p. 480.

868. Ben-Aharon, I., Vidal, L., Rizel, S., Yerushalmi, R., Shpilberg, O., Sulkes, A., et.al. Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis, PLoS One, 2013. 8(8): p. e70044.

869. Coleman, R., Powles, T., Paterson, A., Gnant, M., Anderson, S., Diel, I., et.al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, 2015. 386(10001): p. 1353-61.

870. Coleman, R., Body, J. J., Aapro, M., Hadji, P., Herrstedt, J., Bone health in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, 2014. 25 Suppl 3: p. iii124-37.

871. Onkologie, Leitlinienprogramm, Supportive Therapie bei onkologischen PatientInnen-Konsultationsfassung, LangversionDeutsche Krebsgesellschaft, D.K., AWMF, 2016.

872. Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., et.al. Breast-cancer adjuvant therapy with zoledronic acid, N Engl J Med, 2011. 365(15): p. 1396-405.

873. Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., et.al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline, J Clin Oncol, 2016. 34(6): p. 611-35.

874. Grunfeld, E., Dhesy-Thind, S., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update), Cmaj, 2005. 172(10): p. 1319-20.

875. Hauner, D., Janni, W., Rack, B., Hauner, H., The effect of overweight and nutrition on prognosis in breast cancer, Dtsch Arztebl Int, 2011. 108(47): p. 795-801.

876. Rijnsburger, A. J., Obdeijn, I. M., Kaas, R., Tilanus-Linthorst, M. M., Boetes, C., Loo, C. E., et.al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study, Journal of Clinical Oncology, 2010. 28(36): p. 5265-73.

877. Voskuil, D. W., van Nes, J. G., Junggeburt, J. M., van de Velde, C. J., van Leeuwen, F. E., de Haes, J. C., Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients, Ann Oncol, 2010. 21(10): p. 2094-101.

878. Rock, C. L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., et.al. Nutrition and physical activity guidelines for cancer survivors, CA Cancer J Clin, 2012. 62(4): p. 243-74.

879. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., Thun, M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 2003. 348(17): p. 1625-38.

880. Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., et.al. NCCN Task Force Report: Bone Health In Cancer Care, J Natl Compr Canc Netw, 2013. 11 Suppl 3: p. S1-50; quiz S51.

881. Underwood, J. M., Townsend, J. S., Stewart, S. L., Buchannan, N., Ekwueme, D. U., Hawkins, N. A., et.al. Surveillance of demographic characteristics and health behaviors among adult cancer survivors--Behavioral Risk Factor Surveillance System, United States, 2009, MMWR Surveill Summ, 2012. 61(1): p. 1-23.

882. Ballard-Barbash, R., Friedenreich, C. M., Courneya, K. S., Siddiqi, S. M., McTiernan, A., Alfano, C. M., Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review, J Natl Cancer Inst, 2012. 104(11): p. 815-40.

883. Ewertz, M., Jensen, M. B., Gunnarsdottir, K. A., Hojris, I., Jakobsen, E. H., Nielsen, D., et.al. Effect of obesity on prognosis after early-stage breast cancer, J Clin Oncol, 2011. 29(1): p. 25-31.

884. Cheema, B. S., Kilbreath, S. L., Fahey, P. P., Delaney, G. P., Atlantis, E., Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis, Breast Cancer Res Treat, 2014. 148(2): p. 249-68.

885. Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., et.al. Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy, Br J Cancer, 2014. 111(9): p. 1718-25.

886. Irwin, M. L., Cartmel, B., Gross, C. P., Ercolano, E., Li, F., Yao, X., et.al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors, J Clin Oncol, 2015. 33(10): p. 1104-11.

887. Steindorf, K., Schmidt, M. E., Klassen, O., Ulrich, C. M., Oelmann, J., Habermann, N., et.al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life, Ann Oncol, 2014. 25(11): p. 2237-43.

888. De Groef, A., Van Kampen, M., Dieltjens, E., Christiaens, M. R., Neven, P., Geraerts, I., et.al. Effectiveness of postoperative physical therapy for upper-limb impairments after breast cancer treatment: a systematic review, Arch Phys Med Rehabil, 2015. 96(6): p. 1140-53.

889. Loh, S. Y., Musa, A. N., Methods to improve rehabilitation of patients following breast cancer surgery: a review of systematic reviews, Breast Cancer (Dove Med Press), 2015. 7: p. 81-98.

890. Crew, K. D., Capodice, J. L., Greenlee, H., Brafman, L., Fuentes, D., Awad, D., et.al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer, J Clin Oncol, 2010. 28(7): p. 1154-60.

891. Mishra, S. I., Scherer, R. W., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Gotay, C. C., et.al. Exercise interventions on health-related quality of life for cancer survivors, Cochrane Database Syst Rev, 2012. p. Cd007566.

892. Furmaniak, A. C., Menig, M., Markes, M. H., Exercise for women receiving adjuvant therapy for breast cancer, Cochrane Database Syst Rev, 2016. 9: p. Cd005001.

893. Meneses-Echavez, J. F., Gonzalez-Jimenez, E., Ramirez-Velez, R., Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis, BMC Cancer, 2015. 15: p. 77.

894. Bower, J. E., Bak, K., Berger, A., Breitbart, W., Escalante, C. P., Ganz, P. A., et.al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation, J Clin Oncol, 2014. 32(17): p. 1840-50.

895. Carayol, M., Bernard, P., Boiche, J., Riou, F., Mercier, B., Cousson-Gelie, F., et.al. Psychological effect of exercise in women with breast cancer receiving adjuvant therapy: what is the optimal dose needed?, Ann Oncol, 2013. 24(2): p. 291-300.

896. Streckmann, F., Kneis, S., Leifert, J. A., Baumann, F. T., Kleber, M., Ihorst, G., et.al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy, Ann Oncol, 2014. 25(2): p. 493-9.

897. Cartoni, C., Brunetti, G. A., Federico, V., Efficace, F., Grammatico, S., Tendas, A., et.al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma, Support Care Cancer, 2012. 20(10): p. 2621-6.

898. Gollhofer, A, Granacher, U, Taube, W, Melnyk, M, Gruber, M, Motor control and injury prevention, DEUTSCHE ZEITSCHRIFT FUR SPORTMEDIZIN, 2006. 57(11-12): p. 266-270.

899. Steimann, M, Kerschgens, C, Barth, J, Rehabilitation bei chemotherapieinduzierter Polyneuropathie, Der Onkologe, 2011. 17(10): p. 940.

900. Khan, F., Amatya, B., Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review, Eur J Phys Rehabil Med, 2012. 48(3): p. 507-22.

901. McLeod, H. L., Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy, Jama, 2015. 313(8): p. 803-4.

902. Keilani, M., Hasenoehrl, T., Neubauer, M., Crevenna, R., Resistance exercise and secondary lymphedema in breast cancer survivors-a systematic review, Support Care Cancer, 2016. 24(4): p. 1907-16.

903. Nelson, N. L., Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic Review, J Strength Cond Res, 2016. 30(9): p. 2656-65.

904. Bok, S. K., Jeon, Y., Hwang, P. S., Ultrasonographic Evaluation of the Effects of Progressive Resistive Exercise in Breast Cancer-Related Lymphedema, Lymphat Res Biol, 2016. 14(1): p. 18-24.

905. Letellier, M. E., Towers, A., Shimony, A., Tidhar, D., Breast cancer-related lymphedema: a randomized controlled pilot and feasibility study, Am J Phys Med Rehabil, 2014. 93(9): p. 751-9; quiz 760-1.

906. Cormie, P., Galvao, D. A., Spry, N., Newton, R. U., Neither heavy nor light load resistance exercise acutely exacerbates lymphedema in breast cancer survivor, Integr Cancer Ther, 2013. 12(5): p. 423-32.

907. Cormie, P., Pumpa, K., Galvao, D. A., Turner, E., Spry, N., Saunders, C., et.al. Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial, J Cancer Surviv, 2013. 7(3): p. 413-24.

908. Global, B. M. I. Mortality Collaboration, Di Angelantonio, E., Bhupathiraju Sh, N., Wormser, D., Gao, P., Kaptoge, S., et.al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet, 2016. 388(10046): p. 776-86.

909. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., Straif, K., Body Fatness and Cancer--Viewpoint of the IARC Working Group, N Engl J Med, 2016. 375(8): p. 794-8.

910. Arnold, M., Pandeya, N., Byrnes, G., Renehan, A. G., Stevens, G. A., Ezzati, M., et.al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study, Lancet Oncol, 2015. 16(1): p. 36-46.

911. Chan, D. S., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., et.al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies, Ann Oncol, 2014. 25(10): p. 1901-14.

912. Reeves, M. M., Terranova, C. O., Eakin, E. G., Demark-Wahnefried, W., Weight loss intervention trials in women with breast cancer: a systematic review, Obes Rev, 2014. 15(9): p. 749-68.

913. Demark-Wahnefried, W., Colditz, G. A., Rock, C. L., Sedjo, R. L., Liu, J., Wolin, K. Y., et.al. Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors, Breast Cancer Res Treat, 2015. 154(2): p. 329-37.

914. Batsis, J. A., Gill, L. E., Masutani, R. K., Adachi-Mejia, A. M., Blunt, H. B., Bagley, P. J., et.al. Weight Loss Interventions in Older Adults with Obesity: A Systematic Review of Randomized Controlled Trials Since 2005, J Am Geriatr Soc, 2017. 65(2): p. 257-268.

915. Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., et.al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study, J Natl Cancer Inst, 2006. 98(24): p. 1767-76.

916. Pierce, J. P., Natarajan, L., Caan, B. J., Parker, B. A., Greenberg, E. R., Flatt, S. W., et.al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial, Jama, 2007. 298(3): p. 289-98.

917. Toledo, E., Salas-Salvado, J., Donat-Vargas, C., Buil-Cosiales, P., Estruch, R., Ros, E., et.al. Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial, JAMA Intern Med, 2015. 175(11): p. 1752-60.

918. Aune, D., Chan, D. S., Greenwood, D. C., Vieira, A. R., Rosenblatt, D. A., Vieira, R., et.al. Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies, Ann Oncol, 2012. 23(6): p. 1394-402.

919. Guo, J., Wei, W., Zhan, L., Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies, Breast Cancer Res Treat, 2015. 151(1): p. 191-8.

920. Dong, J. Y., Zhang, L., He, K., Qin, L. Q., Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies, Breast Cancer Res Treat, 2011. 127(1): p. 23-31.

921. Oberritter, H, Schäbethal, K, von Ruesten, A, Boeing, H, The DGE nutrition circle—Presentation and basis of the food-related recommendations from the German Nutrition Society (DGE), Ernaehrungs Umschau international, 2013. 60(2): p. 24-29.

922. Scoccianti, C., Lauby-Secretan, B., Bello, P. Y., Chajes, V., Romieu, I., Female breast cancer and alcohol consumption: a review of the literature, Am J Prev Med, 2014. 46(3 Suppl 1): p. S16-25.

923. Force, US Preventive Services Task, Obesity in adults: screening and management, Rockville, MD: US Preventive Services Task Force, 2012.

924. Berube, S., Lemieux, J., Moore, L., Maunsell, E., Brisson, J., Smoking at time of diagnosis and breast cancer-specific survival: new findings and systematic review with meta-analysis, Breast Cancer Res, 2014. 16(2): p. R42.

925. Nechuta, S., Chen, W. Y., Cai, H., Poole, E. M., Kwan, M. L., Flatt, S. W., et.al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis, Int J Cancer, 2016. 138(9): p. 2088-97.

926. Bruce, J., Carter, D. C., Fraser, J., Patterns of recurrent disease in breast cancer, Lancet, 1970. 1(7644): p. 433-5.

927. Kurtz, J. M., Amalric, R., Brandone, H., Ayme, Y., Jacquemier, J., Pietra, J. C., et.al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis, Cancer, 1989. 63(10): p. 1912-7.

928. Dunst, J., Steil, B., Furch, S., Fach, A., Lautenschlager, C., Diestelhorst, A., et.al. Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy, Strahlenther Onkol, 2001. 177(10): p. 504-10.

929. Haffty, B. G., Fischer, D., Beinfield, M., McKhann, C., Prognosis following local recurrence in the conservatively treated breast cancer patient, Int J Radiat Oncol Biol Phys, 1991. 21(2): p. 293-8.

930. Karabali-Dalamaga, S., Souhami, R. L., O'Higgins, N. J., Soumilas, A., Clark, C. G., Natural history and prognosis of recurrent breast cancer, Br Med J, 1978. 2(6139): p. 730-3.

931. Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., Fineberg, B., Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis, Int J Radiat Oncol Biol Phys, 1992. 23(2): p. 285-91.

932. Jobsen, J. J., van der Palen, J., Meerwaldt, J. H., The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy, Eur J Cancer, 2001. 37(15): p. 1820-7.

933. Katz, A., Strom, E. A., Buchholz, T. A., Theriault, R., Singletary, S. E., McNeese, M. D., The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy, Int J Radiat Oncol Biol Phys, 2001. 50(3): p. 735-42.

934. van Tienhoven, G., Voogd, A. C., Peterse, J. L., Nielsen, M., Andersen, K. W., Mignolet, F., et.al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group, Eur J Cancer, 1999. 35(1): p. 32-8.

935. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998. 351(9114): p. 1451-67.

936. Haylock, B. J., Coppin, C. M., Jackson, J., Basco, V. E., Wilson, K. S., Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy, Int J Radiat Oncol Biol Phys, 2000. 46(2): p. 355-62.

937. Huang, E., Buchholz, T. A., Meric, F., Krishnamurthy, S., Mirza, N. Q., Ames, F. C., et.al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences, Cancer, 2002. 95(10): p. 2059-67.

938. Newman, L. A., Kuerer, H. M., Hunt, K. K., Kroll, S. S., Ames, F. C., Ross, M. I., et.al. Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction, Ann Surg Oncol, 1998. 5(7): p. 620-6.

939. Taylor, M. E., Perez, C. A., Halverson, K. J., Kuske, R. R., Philpott, G. W., Garcia, D. M., et.al. Factors influencing cosmetic results after conservation therapy for breast cancer, Int J Radiat Oncol Biol Phys, 1995. 31(4): p. 753-64.

940. Schwaibold, F., Fowble, B. L., Solin, L. J., Schultz, D. J., Goodman, R. L., The results of radiation therapy for isolated local regional recurrence after mastectomy, Int J Radiat Oncol Biol Phys, 1991. 21(2): p. 299-310.

941. Moy, L., Newell, M. S., Mahoney, M. C., Bailey, L., Barke, L. D., Carkaci, S., et.al. ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women, J Am Coll Radiol, 2014. 11(12 Pt A): p. 1160-8.

942. Shah, C., Ahlawat, S., Khan, A., Tendulkar, R. D., Wazer, D. E., Shah, S. S., et.al. The Role of MRI in the Follow-up of Women Undergoing Breast-conserving Therapy, Am J Clin Oncol, 2016. 39(3): p. 314-9.

943. Moy, L., Newell, M. S., Mahoney, M. C., Bailey, L., Barke, L. D., Carkaci, S., et.al. ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women, J Am Coll Radiol, 2014. 11(12 Pt A): p. 1160-8.

944. Shah, C., Ahlawat, S., Khan, A., Tendulkar, R. D., Wazer, D. E., Shah, S. S., et.al. The Role of MRI in the Follow-up of Women Undergoing Breast-conserving Therapy, Am J Clin Oncol, 2016. 39(3): p. 314-9.

945. Moossdorff, M., van Roozendaal, L. M., Strobbe, L. J., Aebi, S., Cameron, D. A., Dixon, J. M., et.al. Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research, J Natl Cancer Inst, 2014. 106(12):

946. Witteveen, Annemieke, Kwast, Annemiek BG, Sonke, Gabe S, IJzerman, Maarten J, Siesling, Sabine, Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval, PloS one, 2015. 10(4): p. e0120832.

947. Houssami, N, Ciatto, S, Martinelli, F, Bonardi, R, Duffy, SW, Early detection of second breast cancers improves prognosis in breast cancer survivors, Annals of oncology, 2009. 20(9): p. 1505-1510.

948. Lu, W. L., Jansen, L., Post, W. J., Bonnema, J., Van de Velde, J. C., De Bock, G. H., Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis, Breast Cancer Res Treat, 2009. 114(3): p. 403-12.

949. Houssami, N., Abraham, L. A., Miglioretti, D. L., Sickles, E. A., Kerlikowske, K., Buist, D. S., et.al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer, Jama, 2011. 305(8): p. 790-9.

950. Robertson, C., Ragupathy, S. K., Boachie, C., Fraser, C., Heys, S. D., Maclennan, G., et.al. Surveillance mammography for detecting ipsilateral breast tumour recurrence and metachronous contralateral breast cancer: a systematic review, Eur Radiol, 2011. 21(12): p. 2484-91.

951. Robertson, C., Arcot Ragupathy, S. K., Boachie, C., Dixon, J. M., Fraser, C., Hernandez, R., et.al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation, Health Technol Assess, 2011. 15(34): p. v-vi, 1-322.

952. Hölzel, Dieter, Engel, Jutta, Schmidt, Michael, Sauer, Hansjörg, Modell zur primären und sekundären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung, Strahlentherapie und Onkologie, 2001. 177(1): p. 10-24.

953. Veronesi, Umberto, Marubini, Ettore, Del Vecchio, Marcella, Manzari, Antonia, Andreola, Salvatore, Greco, Marco, et.al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events, Journal of the National Cancer Institute, 1995. 87(1): p. 19-27.

954. Deutsch, M., Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation, Int J Radiat Oncol Biol Phys, 2002. 53(3): p. 687-91.

955. Haffty, B. G., Reiss, M., Beinfield, M., Fischer, D., Ward, B., McKhann, C., Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse, J Clin Oncol, 1996. 14(1): p. 52-7.

956. Kurtz, J. M., Jacquemier, J., Amalric, R., Brandone, H., Ayme, Y., Hans, D., et.al. Is breast conservation after local recurrence feasible?, Eur J Cancer, 1991. 27(3): p. 240-4.

957. Whelan, T., Clark, R., Roberts, R., Levine, M., Foster, G., Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group, Int J Radiat Oncol Biol Phys, 1994. 30(1): p. 11-6.

958. Alpert, T. E., Kuerer, H. M., Arthur, D. W., Lannin, D. R., Haffty, B. G., Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation, Int J Radiat Oncol Biol Phys, 2005. 63(3): p. 845-51.

959. van der Sangen, M. J., van de Poll-Franse, L. V., Roumen, R. M., Rutten, H. J., Coebergh, J. W., Vreugdenhil, G., et.al. The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma, Eur J Surg Oncol, 2006. 32(1): p. 34-8.

960. Maulard, C., Housset, M., Brunel, P., Delanian, S., Taurelle, R., Baillet, F., Use of perioperative or split-course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences after conservative management of breast cancer, Am J Clin Oncol, 1995. 18(4): p. 348-52.

961. Newman, L. A., Kuerer, H. M., Advances in breast conservation therapy, J Clin Oncol, 2005. 23(8): p. 1685-97.

962. Resch, A., Fellner, C., Mock, U., Handl-Zeller, L., Biber, E., Seitz, W., et.al. Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy-- a second chance to preserve the breast, Radiology, 2002. 225(3): p. 713-8.

963. Engel, J., Eckel, R., Aydemir, U., Aydemir, S., Kerr, J., Schlesinger-Raab, A., et.al. Determinants and prognoses of locoregional and distant progression in breast cancer, Int J Radiat Oncol Biol Phys, 2003. 55(5): p. 1186-95.

964. Perez, Carlos A, Taylor, ME, Bradley, J, Mansur, D, Sanchez-Aragon, MM, Breast: Stage T1 and T2 tumors, Principles and practice of radiation oncology, 1992. 4: p. 1331-1501.

965. Feigenberg, S. J., Price Mendenhall, N., Benda, R. K., Morris, C. G., Postmastectomy radiotherapy: patterns of recurrence and long-term disease control using electrons, Int J Radiat Oncol Biol Phys, 2003. 56(3): p. 716-25.

966. Moran, M. S., Haffty, B. G., Local-regional breast cancer recurrence: prognostic groups based on patterns of failure, Breast J, 2002. 8(2): p. 81-7.

967. Schmoor, C., Sauerbrei, W., Bastert, G., Schumacher, M., Role of isolated locoregional recurrence of breast cancer: results of four prospective studies, J Clin Oncol, 2000. 18(8): p. 1696-708.

968. Wapnir, I. L., Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., et.al. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer, Ann Surg Oncol, 2008. 15(11): p. 3227-31.

969. Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., et.al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research, J Clin Oncol, 1994. 12(10): p. 2071-7.

970. Voduc, K. D., Cheang, M. C., Tyldesley, S., Gelmon, K., Nielsen, T. O., Kennecke, H., Breast cancer subtypes and the risk of local and regional relapse, J Clin Oncol, 2010. 28(10): p. 1684-91.

971. Metzger-Filho, O., Sun, Z., Viale, G., Price, K. N., Crivellari, D., Snyder, R. D., et.al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX, J Clin Oncol, 2013. 31(25): p. 3083-90.

972. Buchanan, C. L., Dorn, P. L., Fey, J., Giron, G., Naik, A., Mendez, J., et.al. Locoregional recurrence after mastectomy: incidence and outcomes, J Am Coll Surg, 2006. 203(4): p. 469-74.

973. van der Pol, C. C., van Geel, A. N., Menke-Pluymers, M. B., Schmitz, P. I., Lans, T. E., Prognostic factors in 77 curative chest wall resections for isolated breast cancer recurrence, Ann Surg Oncol, 2009. 16(12): p. 3414-21.

974. Aberizk, W. J., Silver, B., Henderson, I. C., Cady, B., Harris, J. R., The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy, Cancer, 1986. 58(6): p. 1214-8.

975. van Dongen, J. A., Bartelink, H., Fentiman, I. S., Lerut, T., Mignolet, F., Olthuis, G., et.al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer, Eur J Cancer, 1992. 28a(4-5): p. 801-5.

976. Rapiti, E., Verkooijen, H. M., Vlastos, G., Fioretta, G., Neyroud-Caspar, I., Sappino, A. P., et.al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis, J Clin Oncol, 2006. 24(18): p. 2743-9.

977. Andersson, Y., de Boniface, J., Jonsson, P. E., Ingvar, C., Liljegren, G., Bergkvist, L., et.al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer, Br J Surg, 2012. 99(2): p. 226-31.

978. Newman, L. A., Hunt, K. K., Buchholz, T., Kuerer, H. M., Vlastos, G., Mirza, N., et.al. Presentation, management and outcome of axillary recurrence from breast cancer, Am J Surg, 2000. 180(4): p. 252-6.

979. Feyerabend, T., Wiedemann, G. J., Jager, B., Vesely, H., Mahlmann, B., Richter, E., Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease, Int J Radiat Oncol Biol Phys, 2001. 49(5): p. 1317-25.

980. Sherar, M., Liu, F. F., Pintilie, M., Levin, W., Hunt, J., Hill, R., et.al. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial, Int J Radiat Oncol Biol Phys, 1997. 39(2): p. 371-80.

981. van der Zee, J., van der Holt, B., Rietveld, P. J., Helle, P. A., Wijnmaalen, A. J., van Putten, W. L., et.al. Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation, Br J Cancer, 1999. 79(3-4): p. 483-90.

982. Vernon, C. C., Hand, J. W., Field, S. B., Machin, D., Whaley, J. B., van der Zee, J., et.al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group, Int J Radiat Oncol Biol Phys, 1996. 35(4): p. 731-44.

983. Waeber, M., Castiglione-Gertsch, M., Dietrich, D., Thurlimann, B., Goldhirsch, A., Brunner, K. W., et.al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation, Ann Oncol, 2003. 14(8): p. 1215-21.

984. Yarbro, J. W., Page, D. L., Fielding, L. P., Partridge, E. E., Murphy, G. P., American Joint Committee on Cancer prognostic factors consensus conference, Cancer, 1999. 86(11): p. 2436-46.

985. Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., Martin, M., et.al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial, Lancet Oncol, 2014. 15(2): p. 156-63.

986. Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., Senkus, E., Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2012. 23 Suppl 7: p. vii11-9.

987. McCormick, B., Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences, J Natl Compr Canc Netw, 2007. 5(3): p. 345-8.

988. Nederland., Nationaal Borstkanker Overleg, Richtlijn Mammacarcinoom (Niederländische Leitlinie)., 2011.

989. Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., et.al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women, J Clin Oncol, 1998. 16(10): p. 3439-60.

990. Stockler, M, Wilcken, N, Ghersi, D, Simes, RJ, The management of advanced breast cancer: systemic reviews of randomised controlled trials regarding the use of cytotoxic chemotherapy and endocrine therapy, Woolloomooloo, NHMRC National Breast Cancer Centre, 1997.

991. Stockler, M., Wilcken, N. R., Ghersi, D., Simes, R. J., Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer, Cancer Treat Rev, 2000. 26(3): p. 151-68.

992. Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., et.al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline, J Clin Oncol, 2016. 34(25): p. 3069-103.

993. Cancer Australia. Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation, 2014.

994. Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., et.al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2014. 32(29): p. 3307-29.

995. Wilcken, N., Hornbuckle, J., Ghersi, D., Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer, Cochrane Database Syst Rev, 2003. p. Cd002747.

996. De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., et.al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clin Cancer Res, 2005. 11(13): p. 4741-8.

997. Gibson, L., Lawrence, D., Dawson, C., Bliss, J., Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women, Cochrane Database Syst Rev, 2009. p. Cd003370.

998. Ferretti, G., Bria, E., Giannarelli, D., Felici, A., Papaldo, P., Fabi, A., et.al. Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials, Br J Cancer, 2006. 94(12): p. 1789-96.

999. Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., et.al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group, J Clin Oncol, 2000. 18(22): p. 3758-67.

1000. Thurlimann, B., Robertson, J. F., Nabholtz, J. M., Buzdar, A., Bonneterre, J., Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women, Eur J Cancer, 2003. 39(16): p. 2310-7.

1001. Bonneterre, J., Buzdar, A., Nabholtz, J. M., Robertson, J. F., Thurlimann, B., von Euler, M., et.al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma, Cancer, 2001. 92(9): p. 2247-58.

1002. Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., et.al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate, J Clin Oncol, 2001. 19(14): p. 3357-66.

1003. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., et.al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol, 2003. 21(11): p. 2101-9.

1004. Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Cervek, J., et.al. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial, Eur J Cancer, 2000. 36 Suppl 4: p. S86-7.

1005. Paridaens, R., Dirix, L., Lohrisch, C., Beex, L., Nooij, M., Cameron, D., et.al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer, Ann Oncol, 2003. 14(9): p. 1391-8.

1006. Mauri, D., Pavlidis, N., Polyzos, N. P., Ioannidis, J. P., Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis, J Natl Cancer Inst, 2006. 98(18): p. 1285-91.

1007. Carrick, S., Parker, S., Wilcken, N., Ghersi, D., Marzo, M., Simes, J., Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev, 2005. p. Cd003372.

1008. Sledge, G. W., Jr., Hu, P., Falkson, G., Tormey, D., Abeloff, M., Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study, J Clin Oncol, 2000. 18(2): p. 262-6.

1009. Sledge, G W, Toi, M, Neven, P, Sohn, J, Inoue, K, Pivot, X, et.al. LBA6_PRMONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer, Annals of Oncology, 2019. 30(Supplement_5):, https://doi.org/10.1093/annonc/mdz394.006

1010. Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., et.al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy, J Clin Oncol, 2017. 35(25): p. 2875-2884.

1011. Lilly Deutschland GmbH, Abemaciclib (Verzenios®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4B, 2019., https://www.g-ba.de/downloads/92-975-2707/2018-10-26_Modul4B_Abemaciclib.pdf

1012. Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., et.al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer, N Engl J Med, 2018. 379(20): p. 1926-1936., https://www.ncbi.nlm.nih.gov/pubmed/30345905

1013. Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., et.al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med, 2015. 373(3): p. 209-19.

1014. Pfizer Pharma GmbH, Palbociclib (IBRANCE®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4 B, 2018., https://www.g-ba.de/downloads/92-975-2609/2018-09-28_Modul4B_Palbociclib.pdf

1015. Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., et.al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer, N Engl J Med, 2019. 381(4): p. 307-316.

1016. Tripathy, D., Im, S. A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., et.al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial, Lancet Oncol, 2018. 19(7): p. 904-915.

1017. Novartis Pharma Gmbh, Ribociclib (Kisqali®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4B, 2019., https://www.g-ba.de/downloads/92-975-2866/2019-01-11_Modul4B_Ribociclib.pdf

1018. Klijn, J. G., Blamey, R. W., Boccardo, F., Tominaga, T., Duchateau, L., Sylvester, R., Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials, J Clin Oncol, 2001. 19(2): p. 343-53.

1019. (NBOCC)., National Breast and Ovarian Cancer Centre, Recommendations for use of Chemotherapy for the treatment of advanced breast cancer., 2010.

1020. Taylor, C. W., Green, S., Dalton, W. S., Martino, S., Rector, D., Ingle, J. N., et.al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study, J Clin Oncol, 1998. 16(3): p. 994-9.

1021. Loibl, S, Turner, NC, Ro, J, Cristofanilli, M, Iwata, H, Im, SA, Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3, J Clin Oncol, 2016. 34(suppl): p. abstr 524.

1022. Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., et.al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women, J Clin Oncol, 1998. 16(10): p. 3439-60.

1023. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Bericht Nr. 781 - Ribociclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Addendum zum Auftrag A19-06, 2019., https://www.g-ba.de/downloads/92-975-3033/2019-07-04_Addendum_Ribociclib-Aromatasehemmer_D-430.pdf

1024. Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., et.al. Palbociclib and Letrozole in Advanced Breast Cancer, N Engl J Med, 2016. 375(20): p. 1925-1936.

1025. Johnston, Stephen, Martin, Miguel, Di Leo, Angelo, Im, Seock-Ah, Awada, Ahmad, Forrester, Tammy, et.al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer, npj Breast Cancer, 2019. 5(1): p. 5., https://doi.org/10.1038/s41523-018-0097-z

1026. Yardley, D. A., MONALEESA clinical program: a review of ribociclib use in different clinical settings, Future Oncol, 2019. 15(23): p. 2673-2686.

1027. Osoba, D., Rodrigues, G., Myles, J., Zee, B., Pater, J., Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 1998. 16(1): p. 139-44.

1028. Gemeinsamer Bundesausschuss (G-BA), Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V - Crizotinib (neues Anwendungsgebiet), 2016., https://www.g-ba.de/downloads/40-268-3830/2016-06-16_AM-Rl-XII_Crizotinib_nAWG_D-205_TrG.pdf?

1029. Cazzaniga, M. E., Danesi, R., Girmenia, C., Invernizzi, P., Elvevi, A., Uguccioni, M., Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success, Breast Cancer Res Treat, 2019. 176(3): p. 483-494.

1030. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Ribociclib (neues Anwendungsgebiet: Mammakarzinom, Kombination mit Fulvestrant / prä-, perimenopausale Frauen), 2019., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/430

1031. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Ribociclib, 2019., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/311/

1032. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Palbociclib, 2018., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/269/

1033. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Palbociclib (Neubewertung nach Fristablauf – Patientenpopulation b1 und b2), 2019., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/394/

1034. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Abemaciclib (in Kombination mit einem Aromatasehemmer), 2019., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/410/

1035. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Abemaciclib (in Kombination mit Fulvestrant), 2019., hhttps://www.g-ba.de/bewertungsverfahren/nutzenbewertung/409/

1036. Klijn, J. G., Beex, L. V., Mauriac, L., van Zijl, J. A., Veyret, C., Wildiers, J., et.al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study, J Natl Cancer Inst, 2000. 92(11): p. 903-11.

1037. Jonat, W., Kaufmann, M., Blamey, R. W., Howell, A., Collins, J. P., Coates, A., et.al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer, Eur J Cancer, 1995. 31a(2): p. 137-42.

1038. Boccardo, F., Rubagotti, A., Perrotta, A., Amoroso, D., Balestrero, M., De Matteis, A., et.al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study, Ann Oncol, 1994. 5(4): p. 337-42.

1039. Forward, D. P., Cheung, K. L., Jackson, L., Robertson, J. F., Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer, Br J Cancer, 2004. 90(3): p. 590-4.

1040. Bartsch, R., Bago-Horvath, Z., Berghoff, A., DeVries, C., Pluschnig, U., Dubsky, P., et.al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer, Eur J Cancer, 2012. 48(13): p. 1932-8.

1041. Ellis, MJ, Hayes, DF, Lippman, ME, Treatment of metastatic breast cancer, Cancer, 2000. 2000: p. 749-797.

1042. Hayes, D. F., Henderson, I. C., Shapiro, C. L., Treatment of metastatic breast cancer: present and future prospects, Semin Oncol, 1995. 22(2 Suppl 5): p. 5-19; discussion 19-21.

1043. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., et.al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group, J Clin Oncol, 2001. 19(10): p. 2596-606.

1044. Mouridsen, H, Sun, Y, Gershanovich, M, Perez-Carrion, R, Becquart, D, Chaudri-Ross, HA, et.al. First-line therapy with letrozole (femara®) for advanced breast cancer prolongs time to worsening of Karnofsky Performance Status compared with tamoxifen, Breast Cancer Research and Treatment, 2001. 69(3): p. 291.

1045. NICE, The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment, 2009 [addendum 2014]., https://www.nice.org.uk/guidance/cg81/evidence/addendum-242246990

1046. Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., et.al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women, J Clin Oncol, 1998. 16(10): p. 3439-60.

1047. Stockler, M, Wilcken, N, Ghersi, D, Simes, RJ, The management of advanced breast cancer: systemic reviews of randomised controlled trials regarding the use of cytotoxic chemotherapy and endocrine therapy, Woolloomooloo, NHMRC National Breast Cancer Centre, 1997.

1048. Stockler, M., Wilcken, N. R., Ghersi, D., Simes, R. J., Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer, Cancer Treat Rev, 2000. 26(3): p. 151-68.

1049. Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., et.al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline, J Clin Oncol, 2016. 34(25): p. 3069-103.

1050. Cancer Australia. Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation, 2014., http://guidelines.canceraustralia.gov.au/guidelines/guideline_17.pdf

1051. Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., et.al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2014. 32(29): p. 3307-29.

1052. Sledge, G. W., Jr., Hu, P., Falkson, G., Tormey, D., Abeloff, M., Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study, J Clin Oncol, 2000. 18(2): p. 262-6.

1053. Carrick, S., Parker, S., Wilcken, N., Ghersi, D., Marzo, M., Simes, J., Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev, 2005. p. Cd003372.

1054. Lilly Deutschland GmbH, Abemaciclib (Verzenios®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4A, 2019., https://www.g-ba.de/downloads/92-975-2701/2018-10-26_Modul4A_Abemaciclib.pdf

1055. Pfizer Pharma GmbH, Palbociclib (IBRANCE®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4 A, 2016., https://www.g-ba.de/downloads/92-975-1744/2016-11-22_Palbociclib_Modul4A.pdf

1056. Novartis Pharma GmbH, Ribociclib (Kisqali®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4, 2017., https://www.g-ba.de/downloads/92-975-2078/2017-08-29_Modul4_Ribociclib.pdf

1057. Slamon, Dennis J., Neven, Patrick, Chia, Stephen, Fasching, Peter A., De Laurentiis, Michelino, Im, Seock-Ah, et.al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer, New England Journal of Medicine, 2019., https://doi.org/10.1056/NEJMoa1911149

1058. Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., et.al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3, J Clin Oncol, 2018. 36(24): p. 2465-2472.

1059. Novartis Pharma Gmbh, Ribociclib (Kisqali®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4A, 2019., https://www.g-ba.de/downloads/92-975-2865/2019-01-11_Modul4A_Ribociclib.pdf

1060. Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., et.al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy, J Clin Oncol, 2017. 35(25): p. 2875-2884.

1061. Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., et.al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med, 2015. 373(3): p. 209-19.

1062. Gibson, L., Lawrence, D., Dawson, C., Bliss, J., Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women, Cochrane Database Syst Rev, 2009. p. Cd003370.

1063. Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., et.al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3), Ann Oncol, 1998. 9(6): p. 639-45.

1064. Robertson, J. F., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., et.al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials, Cancer, 2003. 98(2): p. 229-38.

1065. Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., et.al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17, J Natl Cancer Inst, 2005. 97(17): p. 1262-71.

1066. Loibl, S, Turner, NC, Ro, J, Cristofanilli, M, Iwata, H, Im, SA, Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3, J Clin Oncol, 2016. 34(suppl): p. abstr 524.

1067. Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., et.al. Palbociclib and Letrozole in Advanced Breast Cancer, N Engl J Med, 2016. 375(20): p. 1925-1936.

1068. Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., et.al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 2015. 16(1): p. 25-35.

1069. Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., et.al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol, 2016. 17(4): p. 425-439.

1070. Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., Andre, F., et.al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 2016. 27(6): p. 1047-54.

1071. Bell, T., Crown, J. P., Lang, I., Bhattacharyya, H., Zanotti, G., Randolph, S., et.al. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment, Curr Med Res Opin, 2016. 32(5): p. 959-65.

1072. Finn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Lang, I., et.al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18, Breast Cancer Res, 2016. 18(1): p. 67.

1073. Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., et.al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3), Oncologist, 2016. 21(10): p. 1165-1175.

1074. Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., et.al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer, N Engl J Med, 2016. 375(18): p. 1738-1748.

1075. Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahmoud, T., et.al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 2012. 366(6): p. 520-9.

1076. Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., et.al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger, Ann Oncol, 2014. 25(12): p. 2357-62.

1077. Dear, R. F., McGeechan, K., Jenkins, M. C., Barratt, A., Tattersall, M. H., Wilcken, N., Combination versus sequential single agent chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev, 2013. p. Cd008792.

1078. Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., et.al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193), J Clin Oncol, 2003. 21(4): p. 588-92.

1079. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., et.al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 2007. 357(26): p. 2666-76.

1080. Gray, R., Bhattacharya, S., Bowden, C., Miller, K., Comis, R. L., Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer, J Clin Oncol, 2009. 27(30): p. 4966-72.

1081. Robert, Nicholas J, Diéras, Véronique, Glaspy, John, Brufsky, Adam M, Bondarenko, Igor, Lipatov, Oleg N, et.al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer, Journal of Clinical Oncology, 2011. 29(10): p. 1252-1260.

1082. Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C. C., Koehler, A., et.al. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial, Breast Cancer Res Treat, 2016. 156(1): p. 97-107.

1083. Lang, I., Brodowicz, T., Ryvo, L., Kahan, Z., Greil, R., Beslija, S., et.al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial, Lancet Oncol, 2013. 14(2): p. 125-33.

1084. Zielinski, C., Lang, I., Inbar, M., Kahan, Z., Greil, R., Beslija, S., et.al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial, Lancet Oncol, 2016. 17(9): p. 1230-9.

1085. Ghersi, D., Willson, M. L., Chan, M. M., Simes, J., Donoghue, E., Wilcken, N., Taxane-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev, 2015. p. Cd003366.

1086. Nabholtz, J. M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., et.al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial, J Clin Oncol, 2003. 21(6): p. 968-75.

1087. Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N., et.al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer, Ann Oncol, 2004. 15(10): p. 1527-34.

1088. Luck, H. J., Du Bois, A., Loibl, S., Schrader, I., Huober, J., Heilmann, V., et.al. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group, Breast Cancer Res Treat, 2013. 139(3): p. 779-87.

1089. Hu, X. C., Zhang, J., Xu, B. H., Cai, L., Ragaz, J., Wang, Z. H., et.al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial, Lancet Oncol, 2015. 16(4): p. 436-46.

1090. Harvey, V., Mouridsen, H., Semiglazov, V., Jakobsen, E., Voznyi, E., Robinson, B. A., et.al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer, J Clin Oncol, 2006. 24(31): p. 4963-70.

1091. Chan, S., Friedrichs, K., Noel, D., Pinter, T., Van Belle, S., Vorobiof, D., et.al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, J Clin Oncol, 1999. 17(8): p. 2341-54.

1092. Rivera, E., Mejia, J. A., Arun, B. K., Adinin, R. B., Walters, R. S., Brewster, A., et.al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer, Cancer, 2008. 112(7): p. 1455-61.

1093. Malinovszky, K., Johnston, S., Barrett-Lee, P., Howell, A., Verrill, M., O'Reilly, S., et.al. TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC, Cancer Chemother Pharmacol, 2007. 59(3): p. 413-8.

1094. Langley, R. E., Carmichael, J., Jones, A. L., Cameron, D. A., Qian, W., Uscinska, B., et.al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01, J Clin Oncol, 2005. 23(33): p. 8322-30.

1095. Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., et.al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 2011. 377(9769): p. 914-23.

1096. Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., et.al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, 2015. 33(6): p. 594-601.

1097. Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., et.al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger, Ann Oncol, 2014. 25(12): p. 2357-62.

1098. Beck, J. T., Hortobagyi, G. N., Campone, M., Lebrun, F., Deleu, I., Rugo, H. S., et.al. Everolimus plus exemestane as first-line therapy in HR(+), HER2(-) advanced breast cancer in BOLERO-2, Breast Cancer Res Treat, 2014. 143(3): p. 459-67.

1099. Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., et.al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer, J Clin Oncol, 2010. 28(30): p. 4594-600.

1100. Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., et.al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial, J Natl Cancer Inst, 2014. 106(1): p. djt337.

1101. Yardley, D. A., Burris, H. A., 3rd, Simons, L., Spigel, D. R., Greco, F. A., Barton, J. H., et.al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer, Clin Breast Cancer, 2008. 8(5): p. 425-31.

1102. Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., et.al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med, 2006. 355(26): p. 2733-43.

1103. Yardley, D. A., Brufsky, A., Coleman, R. E., Conte, P. F., Cortes, J., Gluck, S., et.al. Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial, Trials, 2016. 17: p. 63.

1104. Hamilton, E., Kimmick, G., Hopkins, J., Marcom, P. K., Rocha, G., Welch, R., et.al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer, Clin Breast Cancer, 2013. 13(6): p. 416-20.

1105. Mirtsching, B., Cosgriff, T., Harker, G., Keaton, M., Chidiac, T., Min, M., A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer, Clin Breast Cancer, 2011. 11(2): p. 121-8.

1106. Blum, J. L., Savin, M. A., Edelman, G., Pippen, J. E., Robert, N. J., Geister, B. V., et.al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes, Clin Breast Cancer, 2007. 7(11): p. 850-6.

1107. Brodowicz, T., Lang, I., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., et.al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses, Br J Cancer, 2014. 111(11): p. 2051-7.

1108. Lang, I., Inbar, M. J., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., et.al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer, Eur J Cancer, 2012. 48(17): p. 3140-9.

1109. Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart, A. C., Pluzanska, A., et.al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment, J Clin Oncol, 2008. 26(24): p. 3950-7.

1110. Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., et.al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol, 2016. 17(4): p. 425-39.

1111. Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., et.al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3), Oncologist, 2016. 21(10): p. 1165-1175.

1112. Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., et.al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med, 2015. 373(3): p. 209-19.

1113. Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., et.al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 2012. 366(2): p. 109-19.

1114. Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., et.al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study, J Clin Oncol, 2011. 29(3): p. 264-71.

1115. Huober, J., Fasching, P. A., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., et.al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial, Breast, 2012. 21(1): p. 27-33.

1116. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., et.al. Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 2012. 367(19): p. 1783-91.

1117. Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M., et.al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial, Lancet Oncol, 2014. 15(7): p. 689-99.

1118. Mross, K, Rüther, A, Gierlich, T, Unger, C, Tumor growth control by oral trofosfamide in patients with metastatic breast cancer, Oncology Research and Treatment, 1998. 21(1): p. 52-56.

1119. Zelek, L., Barthier, S., Riofrio, M., Fizazi, K., Rixe, O., Delord, J. P., et.al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, Cancer, 2001. 92(9): p. 2267-72.

1120. Weber, B. L., Vogel, C., Jones, S., Harvey, H., Hutchins, L., Bigley, J., et.al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer, J Clin Oncol, 1995. 13(11): p. 2722-30.

1121. Martin, M., Ruiz, A., Munoz, M., Balil, A., Garcia-Mata, J., Calvo, L., et.al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial, Lancet Oncol, 2007. 8(3): p. 219-25.

1122. Addeo, R., Sgambato, A., Cennamo, G., Montella, L., Faiola, V., Abbruzzese, A., et.al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer, Clin Breast Cancer, 2010. 10(4): p. 301-6.

1123. Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., et.al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 2014. 32(19): p. 2078-99.

1124. Balduzzi, S., Mantarro, S., Guarneri, V., Tagliabue, L., Pistotti, V., Moja, L., et.al. Trastuzumab-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev, 2014. p. Cd006242.

1125. Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C. H., et.al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3), Ann Oncol, 2016.

1126. Heindel, Walter, Gübitz, Raphael, Vieth, Volker, Weckesser, Matthias, Schober, Otmar, Schäfers, Michael, The diagnostic imaging of bone metastases, Deutsches Ärzteblatt International, 2014. 111(44): p. 741.

1127. Chow, E, Zeng, L, Salvo, N, Dennis, K, Tsao, M, Lutz, S, Update on the systematic review of palliative radiotherapy trials for bone metastases, Clinical oncology, 2012. 24(2): p. 112-124.

1128. Chow, Edward, van der Linden, Yvette M, Roos, Daniel, Hartsell, William F, Hoskin, Peter, Wu, Jackson SY, et.al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial, The Lancet Oncology, 2014. 15(2): p. 164-171.

1129. Lutz, Stephen, Berk, Lawrence, Chang, Eric, Chow, Edward, Hahn, Carol, Hoskin, Peter, et.al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, International Journal of Radiation Oncology* Biology* Physics, 2011. 79(4): p. 965-976.

1130. Roque, I. Figuls M., Martinez-Zapata, M. J., Scott-Brown, M., Alonso-Coello, P., Radioisotopes for metastatic bone pain, Cochrane Database Syst Rev, 2011. p. Cd003347.

1131. Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366(9486): p. 643-8.

1132. Leithner, Andreas, Maurer-Ertl, Werner, Windhager, Reinhard, Biopsy of bone and soft tissue tumours: hints and hazards, Treatment of bone and soft tissue sarcomas, 2009. p. 3-10.

1133. Berenson, J., Pflugmacher, R., Jarzem, P., Zonder, J., Schechtman, K., Tillman, J. B., et.al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial, Lancet Oncol, 2011. 12(3): p. 225-35.

1134. Eck, J. C., Nachtigall, D., Humphreys, S. C., Hodges, S. D., Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature, Spine J, 2008. 8(3): p. 488-97.

1135. Wong, Matthew HF, Stockler, Martin R, Pavlakis, Nick, Bisphosphonates and other bone agents for breast cancer, The Cochrane Library, 2012.

1136. Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., et.al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials, Eur J Cancer, 2012. 48(16): p. 3082-92.

1137. Ibrahim, MFK, Mazzarello, S, Shorr, R, Vandermeer, L, Jacobs, C, Hilton, J, et.al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis, Annals of Oncology, 2015. 26(11): p. 2205-2213.

1138. Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., et.al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 2010. 28(35): p. 5132-9.

1139. Grötz, KA, Piesold, JU, Al-Nawas, B, Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen, AWMF online, 2012. 4: p. 2012.

1140. Kalkanis, S. N., Kondziolka, D., Gaspar, L. E., Burri, S. H., Asher, A. L., Cobbs, C. S., et.al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 2010. 96(1): p. 33-43.

1141. Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., et.al. A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 1990. 322(8): p. 494-500.

1142. Vecht, Charles J, Haaxma‐Reiche, Hanny, Noordijk, Evert M, Padberg, George W, Voormolen, Joan HC, Hoekstra, Foppe H, et.al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery, Annals of neurology, 1993. 33(6): p. 583-590.

1143. Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., et.al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial, Jama, 1998. 280(17): p. 1485-9.

1144. Kondziolka, D., Patel, A., Lunsford, L. D., Kassam, A., Flickinger, J. C., Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases, Int J Radiat Oncol Biol Phys, 1999. 45(2): p. 427-34.

1145. Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et.al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 2004. 363(9422): p. 1665-72.

1146. Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., et.al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, Jama, 2006. 295(21): p. 2483-91.

1147. Chang, Eric L, Wefel, Jeffrey S, Hess, Kenneth R, Allen, Pamela K, Lang, Frederick F, Kornguth, David G, et.al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, The lancet oncology, 2009. 10(11): p. 1037-1044.

1148. Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et.al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study, J Clin Oncol, 2011. 29(2): p. 134-41.

1149. Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., et.al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial, Jama, 2016. 316(4): p. 401-9.

1150. Mehta, M. P., Paleologos, N. A., Mikkelsen, T., Robinson, P. D., Ammirati, M., Andrews, D. W., et.al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 2010. 96(1): p. 71-83.

1151. Lin, N. U., Bellon, J. R., Winer, E. P., CNS metastases in breast cancer, J Clin Oncol, 2004. 22(17): p. 3608-17.

1152. Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., et.al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours, Ann Oncol, 2017. 28(suppl_4): p. iv84-iv99.

1153. Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., et.al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO), Neuro Oncol, 2017. 19(2): p. 162-174.

1154. Scott, B. J., Oberheim-Bush, N. A., Kesari, S., Leptomeningeal metastasis in breast cancer - a systematic review, Oncotarget, 2016. 7(4): p. 3740-7.

1155. Boogerd, Willem, Van den Bent, MJ, Koehler, PJ, Heimans, JJ, Van der Sande, JJ, Aaronson, NK, et.al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study, European Journal of Cancer, 2004. 40(18): p. 2726-2733.

1156. Lin, N. U., Dieras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H. J., et.al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer, Clin Cancer Res, 2009. 15(4): p. 1452-9.

1157. Jones, Jeremy, Takeda, Andrea, Picot, Joanna, von Keyserlingk, Camilla, Clegg, A, Lapatinib for the treatment of HER2-overexpressing breast cancer, Health technology assessment (Winchester, England), 2009. 13: p. 1-6.

1158. Lin, N. U., Eierman, W., Greil, R., Campone, M., Kaufman, B., Steplewski, K., et.al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases, J Neurooncol, 2011. 105(3): p. 613-20.

1159. Kaplan, M. A., Isikdogan, A., Koca, D., Kucukoner, M., Gumusay, O., Yildiz, R., et.al. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology, Breast Cancer, 2014. 21(6): p. 677-83.

1160. Bachelot, T., Romieu, G., Campone, M., Dieras, V., Cropet, C., Dalenc, F., et.al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study, Lancet Oncol, 2013. 14(1): p. 64-71.

1161. Pivot, X., Manikhas, A., Zurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., et.al. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer, J Clin Oncol, 2015. 33(14): p. 1564-73.

1162. Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., et.al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA, Ann Oncol, 2015. 26(1): p. 113-9.

1163. Larsen, P. B., Kumler, I., Nielsen, D. L., A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer, Cancer Treat Rev, 2013. 39(7): p. 720-7.

1164. Witzel, I., Oliveira-Ferrer, L., Pantel, K., Muller, V., Wikman, H., Breast cancer brain metastases: biology and new clinical perspectives, Breast Cancer Res, 2016. 18(1): p. 8.

1165. Leone, J. P., Leone, B. A., Breast cancer brain metastases: the last frontier, Exp Hematol Oncol, 2015. 4: p. 33.

1166. Aversa, C., Rossi, V., Geuna, E., Martinello, R., Milani, A., Redana, S., et.al. Metastatic breast cancer subtypes and central nervous system metastases, Breast, 2014. 23(5): p. 623-8.

1167. Gaspar, Laurie E, Scott, Charles, Murray, Kevin, Curran, Walter, Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases, International Journal of Radiation Oncology* Biology* Physics, 2000. 47(4): p. 1001-1006.

1168. Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., et.al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 2012. 30(4): p. 419-25.

1169. Mintz, A. H., Kestle, J., Rathbone, M. P., Gaspar, L., Hugenholtz, H., Fisher, B., et.al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis, Cancer, 1996. 78(7): p. 1470-6.

1170. Rades, D., Kieckebusch, S., Haatanen, T., Lohynska, R., Dunst, J., Schild, S. E., Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis, Int J Radiat Oncol Biol Phys, 2008. 70(5): p. 1319-24.

1171. Yamamoto, Masaaki, Serizawa, Toru, Shuto, Takashi, Akabane, Atsuya, Higuchi, Yoshinori, Kawagishi, Jun, et.al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, The Lancet Oncology, 2014. 15(4): p. 387-395.

1172. Li, X. P., Meng, Z. Q., Guo, W. J., Li, J., Treatment for liver metastases from breast cancer: results and prognostic factors, World J Gastroenterol, 2005. 11(24): p. 3782-7.

1173. Mariani, P, Servois, V, De Rycke, Y, Bennett, SP, Feron, JG, Almubarak, MM, et.al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients, European Journal of Surgical Oncology (EJSO), 2013. 39(12): p. 1377-1383.

1174. Tasci, Y., Aksoy, E., Taskin, H. E., Aliyev, S., Moore, H., Agcaoglu, O., et.al. A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver, HPB (Oxford), 2013. 15(10): p. 789-93.

1175. Fairhurst, K., Leopardi, L., Satyadas, T., Maddern, G., The safety and effectiveness of liver resection for breast cancer liver metastases: A systematic review, Breast, 2016. 30: p. 175-184.

1176. Sadot, E., Lee, S. Y., Sofocleous, C. T., Solomon, S. B., Gonen, M., Peter Kingham, T., et.al. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients, Ann Surg, 2016. 264(1): p. 147-54.

1177. Ruiz, A., Wicherts, D. A., Sebagh, M., Giacchetti, S., Castro-Benitez, C., van Hillegersberg, R., et.al. Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results, Ann Surg Oncol, 2017. 24(2): p. 535-545.

1178. Ruiz, A., Castro-Benitez, C., Sebagh, M., Giacchetti, S., Castro-Santa, E., Wicherts, D. A., et.al. Repeat Hepatectomy for Breast Cancer Liver Metastases, Ann Surg Oncol, 2015. 22 Suppl 3: p. S1057-66.

1179. Zhou, J. H., Rosen, D., Andreou, A., Brouquet, A., Abbott, D., Loyer, E., et.al. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer, Ann Diagn Pathol, 2014. 18(5): p. 266-70.

1180. Polistina, F., Costantin, G., Febbraro, A., Robusto, E., Ambrosino, G., Aggressive treatment for hepatic metastases from breast cancer: results from a single center, World J Surg, 2013. 37(6): p. 1322-32.

1181. van Walsum, G. A., de Ridder, J. A., Verhoef, C., Bosscha, K., van Gulik, T. M., Hesselink, E. J., et.al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors, Eur J Surg Oncol, 2012. 38(10): p. 910-7.

1182. Abbott, D. E., Brouquet, A., Mittendorf, E. A., Andreou, A., Meric-Bernstam, F., Valero, V., et.al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome, Surgery, 2012. 151(5): p. 710-6.

1183. Spolverato, G., Vitale, A., Bagante, F., Connolly, R., Pawlik, T. M., Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis, Ann Surg, 2016.

1184. Wang, M., Zhang, J., Ji, S., Shao, G., Zhao, K., Wang, Z., et.al. Transarterial chemoembolisation for breast cancer with liver metastasis: A systematic review, Breast, 2017. 36: p. 25-30.

1185. Gordon, A. C., Gradishar, W. J., Kaklamani, V. G., Thuluvath, A. J., Ryu, R. K., Sato, K. T., et.al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy, J Vasc Interv Radiol, 2014. 25(10): p. 1523-32, 1532.e1-2.

1186. Caralt, M., Bilbao, I., Cortes, J., Escartin, A., Lazaro, J. L., Dopazo, C., et.al. Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer, Ann Surg Oncol, 2008. 15(10): p. 2804-10.

1187. Chua, T. C., Saxena, A., Liauw, W., Chu, F., Morris, D. L., Hepatic resection for metastatic breast cancer: a systematic review, Eur J Cancer, 2011. 47(15): p. 2282-90.

1188. Groeschl, Ryan T, Nachmany, Ido, Steel, Jennifer L, Reddy, Srinevas K, Glazer, Evan S, De Jong, Mechteld C, et.al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis, Journal of the American College of Surgeons, 2012. 214(5): p. 769-777.

1189. Hoffmann, Katrin, Franz, Clemens, Hinz, Ulf, Schirmacher, Peter, Herfarth, Christian, Eichbaum, Michael, et.al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors, Annals of surgical oncology, 2010. 17(6): p. 1546-1554.

1190. Fan, J., Chen, D., Du, H., Shen, C., Che, G., Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis, J Thorac Dis, 2015. 7(8): p. 1441-51.

1191. Meimarakis, G., Ruttinger, D., Stemmler, J., Crispin, A., Weidenhagen, R., Angele, M., et.al. Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer, Ann Thorac Surg, 2013. 95(4): p. 1170-80.

1192. Kycler, W., Laski, P., Surgical approach to pulmonary metastases from breast cancer, Breast J, 2012. 18(1): p. 52-7.

1193. García-Yuste, Mariano, Cassivi, Stephen, Paleru, Cristian, Pulmonary metastasectomy in breast cancer, Journal of Thoracic Oncology, 2010. 5(6): p. S170-S171.

1194. Yhim, H. Y., Han, S. W., Oh, D. Y., Han, W., Im, S. A., Kim, T. Y., et.al. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy, Cancer, 2010. 116(12): p. 2890-901.

1195. Clive, A. O., Jones, H. E., Bhatnagar, R., Preston, N. J., Maskell, N., Interventions for the management of malignant pleural effusions: a network meta-analysis, Cochrane Database Syst Rev, 2016. p. Cd010529.

1196. Leonard, R., Hardy, J., van Tienhoven, G., Houston, S., Simmonds, P., David, M., et.al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer, J Clin Oncol, 2001. 19(21): p. 4150-9.

1197. Spratt, D. E., Gordon Spratt, E. A., Wu, S., DeRosa, A., Lee, N. Y., Lacouture, M. E., et.al. Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis, J Clin Oncol, 2014. 32(28): p. 3144-55.

1198. Adderley, U. J., Holt, I. G., Topical agents and dressings for fungating wounds, Cochrane Database Syst Rev, 2014. p. Cd003948.

1199. Cabula, C., Campana, L. G., Grilz, G., Galuppo, S., Bussone, R., De Meo, L., et.al. Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis, Ann Surg Oncol, 2015. 22 Suppl 3: p. S442-50.

1200. Campana, L. G., Galuppo, S., Valpione, S., Brunello, A., Ghiotto, C., Ongaro, A., et.al. Bleomycin electrochemotherapy in elderly metastatic breast cancer patients: clinical outcome and management considerations, J Cancer Res Clin Oncol, 2014. 140(9): p. 1557-65.

1201. Matthiessen, L. W., Johannesen, H. H., Hendel, H. W., Moss, T., Kamby, C., Gehl, J., Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial, Acta Oncol, 2012. 51(6): p. 713-21.

1202. Jarvis, Virginia, The range and role of palliative interventions for locally advanced breast cancer, Current opinion in supportive and palliative care, 2014. 8(1): p. 70-76.

1203. Lund-Nielsen, B., Adamsen, L., Kolmos, H. J., Rorth, M., Tolver, A., Gottrup, F., The effect of honey-coated bandages compared with silver-coated bandages on treatment of malignant wounds-a randomized study, Wound Repair Regen, 2011. 19(6): p. 664-70.

1204. Jull, Andrew B, Cullum, Nicky, Dumville, Jo C, Westby, Maggie J, Deshpande, Sohan, Walker, Natalie, Honey as a topical treatment for wounds, The Cochrane Library, 2015.

1205. Tryfonidis, K., Senkus, E., Cardoso, M. J., Cardoso, F., Management of locally advanced breast cancer-perspectives and future directions, Nat Rev Clin Oncol, 2015. 12(3): p. 147-62.

1206. Radbruch, Lukas, Payne, Sheila, White Paper on standards and norms for hospice and palliative care in Europe: part 2, European journal of palliative care, 2010. 17(1): p. 22-33.

1207. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30(8): p. 880-7.

1208. Radbruch, Lukas, Payne, Sheila, White paper on standards and norms for hospice and palliative care in Europe: part 1, European journal of palliative care, 2009. 16(6): p. 278-289.

1209. Douglas, C., Murtagh, F. E., Chambers, E. J., Howse, M., Ellershaw, J., Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group, Palliat Med, 2009. 23(2): p. 103-10.

1210. Griffin, J. P., Koch, K. A., Nelson, J. E., Cooley, M. E., Palliative care consultation, quality-of-life measurements, and bereavement for end-of-life care in patients with lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 2007. 132(3 Suppl): p. 404s-422s.

1211. Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 5: Palliative CareCopyright (c) World Health Organization, 2007.

1212. Supportive, Improving, Palliative Care for Adults with Cancer NICE London http://www. nice. org. ukCSGSP, 2004.

1213. NIH State-of-the-Science Conference Statement on improving end-of-life care, NIH Consens State Sci Statements, 2004. 21(3): p. 1-26.

1214. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29(6): p. 755-60.

1215. Levy, M. H., Adolph, M. D., Back, A., Block, S., Codada, S. N., Dalal, S., et.al. Palliative care, J Natl Compr Canc Netw, 2012. 10(10): p. 1284-309.

1216. (WHO)., World Health Organization, Palliative care., 2007.

1217. Improvement., Institute for Clinical Systems, Health care guidelines: palliative care, 2009.

1218. Committee, O.G.A., Palliative Care: Recognizing Eligible Patients and Starting the Discussion., 2008.

1219. Committee, O.G.A., Palliative Care: Improving Palliative Care Planning for Identified Patients., 2007.

1220. Project, N.C., Clinical Practice Guidelines for Quality Palliative Care ., 2012.

1221. NIfC, Excellence, Guidance on Cancer Services Improving Supportive and Palliative Care for Adults with Cancer-Research Evidence, Health Do, editor. London: Department of Health, 2004.

1222. Lindenfeld, J., Albert, N. M., Boehmer, J. P., Collins, S. P., Ezekowitz, J. A., Givertz, M. M., et.al. HFSA 2010 Comprehensive Heart Failure Practice Guideline, J Card Fail, 2010. 16(6): p. e1-194.

1223. Gaertner, J., Frechen, S., Sladek, M., Ostgathe, C., Voltz, R., Palliative care consultation service and palliative care unit: why do we need both?, Oncologist, 2012. 17(3): p. 428-35.

1224. Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et.al. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 2010. 363(8): p. 733-42.

1225. Bruera, E., Hui, D., Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care, J Clin Oncol, 2010. 28(25): p. 4013-7.

1226. Bruera, E., Yennurajalingam, S., Palliative care in advanced cancer patients: how and when?, Oncologist, 2012. 17(2): p. 267-73.

1227. Levy, M. H., Back, A., Benedetti, C., Billings, J. A., Block, S., Boston, B., et.al. NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr Canc Netw, 2009. 7(4): p. 436-73.

1228. Gaertner, J., Wuerstlein, R., Klein, U., Scheicht, D., Frechen, S., Wolf, J., et.al. Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project, Breast Care (Basel), 2011. 6(3): p. 215-220.

1229. Partridge, A. H., Seah, D. S., King, T., Leighl, N. B., Hauke, R., Wollins, D. S., et.al. Developing a service model that integrates palliative care throughout cancer care: the time is now, J Clin Oncol, 2014. 32(29): p. 3330-6.

1230. Gaertner, J., Wolf, J., Hallek, M., Glossmann, J. P., Voltz, R., Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach, Support Care Cancer, 2011. 19(7): p. 1037-43.

1231. Dudgeon, D., King, S., Howell, D., Green, E., Gilbert, J., Hughes, E., et.al. Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening, Psychooncology, 2012. 21(4): p. 357-64.

1232. Carlson, L. E., Waller, A., Groff, S. L., Zhong, L., Bultz, B. D., Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage, Br J Cancer, 2012. 107(4): p. 617-25.

1233. Billings, J. A., The need for safeguards in advance care planning, J Gen Intern Med, 2012. 27(5): p. 595-600.

1234. Aranda, S., Schofield, P., Weih, L., Yates, P., Milne, D., Faulkner, R., et.al. Mapping the quality of life and unmet needs of urban women with metastatic breast cancer, Eur J Cancer Care (Engl), 2005. 14(3): p. 211-22.

1235. Griesser, A. C., Vlastos, G., Morel, L., Beaume, C., Sappino, A. P., Haller, G., Socio-demographic predictors of high support needs in newly diagnosed breast cancer patients, Eur J Cancer Care (Engl), 2011. 20(4): p. 466-74.

1236. Fiszer, C., Dolbeault, S., Sultan, S., Bredart, A., Prevalence, intensity, and predictors of the supportive care needs of women diagnosed with breast cancer: a systematic review, Psychooncology, 2014. 23(4): p. 361-74.

1237. Bausewein, C., Daveson, B. A., Currow, D. C., Downing, J., Deliens, L., Radbruch, L., et.al. EAPC White Paper on outcome measurement in palliative care: Improving practice, attaining outcomes and delivering quality services - Recommendations from the European Association for Palliative Care (EAPC) Task Force on Outcome Measurement, Palliat Med, 2016. 30(1): p. 6-22.

1238. Simon, S. T., Higginson, I. J., Harding, R., Daveson, B. A., Gysels, M., Deliens, L., et.al. Enhancing patient-reported outcome measurement in research and practice of palliative and end-of-life care, Support Care Cancer, 2012. 20(7): p. 1573-8.

1239. Network, National Comprehensive Cancer, Distress management, NCCN Clinical Practice Guidelines in Oncology, 2008.

1240. NCCN, NCCN Clinical Practice Guidelines in Oncology: Palliative Care., 2012.

1241. Stiel, S., Pollok, A., Elsner, F., Lindena, G., Ostgathe, C., Nauck, F., et.al. Validation of the Symptom and Problem Checklist of the German Hospice and Palliative Care Evaluation (HOPE), J Pain Symptom Manage, 2012. 43(3): p. 593-605.

1242. Stiel, S., Matthes, M. E., Bertram, L., Ostgathe, C., Elsner, F., Radbruch, L., [Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS)], Schmerz, 2010. 24(6): p. 596-604.

1243. Mehnert, Anja, Müller, Diana, Lehmann, Claudia, Koch, Uwe, Die deutsche version des NCCN distress-thermometers: empirische Prüfung eines screening-instruments zur erfassung psychosozialer belastung bei krebspatienten, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 2006. 54(3): p. 213-223.

1244. Bausewein, C., Fegg, M., Radbruch, L., Nauck, F., von Mackensen, S., Borasio, G. D., et.al. Validation and clinical application of the german version of the palliative care outcome scale, J Pain Symptom Manage, 2005. 30(1): p. 51-62.

1245. Gilbert, J. E., Howell, D., King, S., Sawka, C., Hughes, E., Angus, H., et.al. Quality improvement in cancer symptom assessment and control: the Provincial Palliative Care Integration Project (PPCIP), J Pain Symptom Manage, 2012. 43(4): p. 663-78.

1246. Herschbach, Peter, Heußner, Pia, Einführung in die psychoonkologische BehandlungspraxisKlett-Cotta, 2008. 215:

1247. Holland, J. C., History of psycho-oncology: overcoming attitudinal and conceptual barriers, Psychosom Med, 2002. 64(2): p. 206-21.

1248. Weis, Joachim, Schwarz, Reinhold, Blettner, Gabriele, Psychoonkologische Versorgung in Deutschland: Qualität und Quantität/Psychooncological care in Germany: Quality and quantity, Zeitschrift für Psychosomatische Medizin und Psychotherapie, 2000. 46(1): p. 4-17.

1249. Weis, J, Schumacher, A, Blettner, G, Determann, M, Reinert, E, Rüffer, JU, et.al. Psychoonkologie, Der Onkologe, 2007. 13(2): p. 185-194.

1250. Koch, Uwe, Weis, Joachim, Krankheitsbewältigung bei Krebs und Möglichkeiten der Unterstützung, Stuttgart: Schattauer, 1998.

1251. Turner, Jane, Zapart, Siggi, Pedersen, Karen, Rankin, Nicole, Luxford, Karen, Fletcher, Jane, Clinical practice guidelines for the psychosocial care of adults with cancer, Psycho‐Oncology, 2005. 14(3): p. 159-173.

1252. (NHMRC)., National Health and Medical Research Council, Psychosocial practice guidelines: information, support and counselling for women with breast cancer., 1999.

1253. Edwards, A. G., Hailey, S., Maxwell, M., Psychological interventions for women with metastatic breast cancer, Cochrane Database Syst Rev, 2004. p. CD004253.

1254. Burish, T. G., Snyder, S. L., Jenkins, R. A., Preparing patients for cancer chemotherapy: effect of coping preparation and relaxation interventions, J Consult Clin Psychol, 1991. 59(4): p. 518-25.

1255. Burton, Mary V, Parker, Ronald W, Farrell, Anita, Bailey, Dianne, Conneely, Julia, Booth, Sue, et.al. A randomized controlled trial of preoperative psychological preparation for mastectomy, Psycho‐Oncology, 1995. 4(1): p. 1-19.

1256. Flam, B., Spice-Cherry, P., Amsel, R., Effects of preparatory information of a myelogram on patients' expectations and anxiety levels, Patient Educ Couns, 1989. 14(2): p. 115-26.

1257. Hathaway, D., Effect of preoperative instruction on postoperative outcomes: a meta-analysis, Nurs Res, 1986. 35(5): p. 269-75.

1258. Johnston, Marie, Vögele, Claus, Benefits of psychological preparation for surgery: a meta-analysis, Annals of Behavioral Medicine, 1993. 15: p. 245-245.

1259. Meyer, T. J., Mark, M. M., Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments, Health Psychol, 1995. 14(2): p. 101-8.

1260. Hall, Angela, Fallowfield, Lesley J, A'Hern, Roger P, When Breast Cancer Recurs: A 3‐Year Prospective Study of Psychological Morbidity, The Breast Journal, 1996. 2(3): p. 197-203.

1261. Jenkins, P. L., May, V. E., Hughes, L. E., Psychological morbidity associated with local recurrence of breast cancer, Int J Psychiatry Med, 1991. 21(2): p. 149-55.

1262. Pinder, K. L., Ramirez, A. J., Black, M. E., Richards, M. A., Gregory, W. M., Rubens, R. D., Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors, Eur J Cancer, 1993. 29a(4): p. 524-7.

1263. McArdle, J. M., George, W. D., McArdle, C. S., Smith, D. C., Moodie, A. R., Hughson, A. V., et.al. Psychological support for patients undergoing breast cancer surgery: a randomised study, Bmj, 1996. 312(7034): p. 813-6.

1264. Christ, G. H., Siegel, K., Freund, B., Langosch, D., Hendersen, S., Sperber, D., et.al. Impact of parental terminal cancer on latency-age children, Am J Orthopsychiatry, 1993. 63(3): p. 417-25.

1265. Nelson, D. V., Friedman, L. C., Baer, P. E., Lane, M., Smith, F. E., Subtypes of psychosocial adjustment to breast cancer, J Behav Med, 1994. 17(2): p. 127-41.

1266. Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., Kuffner, R., Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis, J Clin Oncol, 2013. 31(6): p. 782-93.

1267. Devine, E. C., Westlake, S. K., The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies, Oncol Nurs Forum, 1995. 22(9): p. 1369-81.

1268. Sheard, T., Maguire, P., The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses, Br J Cancer, 1999. 80(11): p. 1770-80.

1269. Antoni, M. H., Wimberly, S. R., Lechner, S. C., Kazi, A., Sifre, T., Urcuyo, K. R., et.al. Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer, Am J Psychiatry, 2006. 163(10): p. 1791-7.

1270. Edgar, L., Rosberger, Z., Collet, J. P., Lessons learned: Outcomes and methodology of a coping skills intervention trial comparing individual and group formats for patients with cancer, Int J Psychiatry Med, 2001. 31(3): p. 289-304.

1271. Gaston-Johansson, F., Fall-Dickson, J. M., Nanda, J., Ohly, K. V., Stillman, S., Krumm, S., et.al. The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation, Cancer Nurs, 2000. 23(4): p. 277-85.

1272. Albert, U. S., Koller, M., Lorenz, W., Kopp, I., Heitmann, C., Stinner, B., et.al. Quality of life profile: from measurement to clinical application, Breast, 2002. 11(4): p. 324-34.

1273. Burke, Susan, Kissane, David William, Psychosocial support for breast cancer patients provided by members of the treatment team: A summary of the literature 1976-1996NHMRC National Breast Cancer Centre, 1998.

1274. Kalaitzi, C., Papadopoulos, V. P., Michas, K., Vlasis, K., Skandalakis, P., Filippou, D., Combined brief psychosexual intervention after mastectomy: effects on sexuality, body image, and psychological well-being, J Surg Oncol, 2007. 96(3): p. 235-40.

1275. Schover, L. R., Yetman, R. J., Tuason, L. J., Meisler, E., Esselstyn, C. B., Hermann, R. E., et.al. Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality, Cancer, 1995. 75(1): p. 54-64.

1276. Aranda, S., Schofield, P., Weih, L., Milne, D., Yates, P., Faulkner, R., Meeting the support and information needs of women with advanced breast cancer: a randomised controlled trial, Br J Cancer, 2006. 95(6): p. 667-73.

1277. Dowsett, S. M., Saul, J. L., Butow, P. N., Dunn, S. M., Boyer, M. J., Findlow, R., et.al. Communication styles in the cancer consultation: preferences for a patient-centred approach, Psychooncology, 2000. 9(2): p. 147-56.

1278. Pistrang, N., Barker, C., The partner relationship in psychological response to breast cancer, Soc Sci Med, 1995. 40(6): p. 789-97.

1279. Goedendorp, M. M., Gielissen, M. F., Verhagen, C. A., Bleijenberg, G., Psychosocial interventions for reducing fatigue during cancer treatment in adults, Cochrane Database Syst Rev, 2009. p. CD006953.

1280. Fillion, L., Gagnon, P., Leblond, F., Gelinas, C., Savard, J., Dupuis, R., et.al. A brief intervention for fatigue management in breast cancer survivors, Cancer Nurs, 2008. 31(2): p. 145-59.

1281. Jacobsen, P. B., Donovan, K. A., Vadaparampil, S. T., Small, B. J., Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue, Health Psychol, 2007. 26(6): p. 660-7.

1282. Montgomery, G. H., Kangas, M., David, D., Hallquist, M. N., Green, S., Bovbjerg, D. H., et.al. Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis, Health Psychol, 2009. 28(3): p. 317-22.

1283. Yates, P., Aranda, S., Hargraves, M., Mirolo, B., Clavarino, A., McLachlan, S., et.al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer, J Clin Oncol, 2005. 23(25): p. 6027-36.

1284. Loscalzo, M., Psychological approaches to the management of pain in patients with advanced cancer, Hematol Oncol Clin North Am, 1996. 10(1): p. 139-55.

1285. Fields, Howard L, Core curriculum for professional education in pain, RevIASP press, 1991.

1286. Poppelreuter, M, Weis, J, Schmid, J, Bartsch, HH, Neuropsychologische Folgestörungen nach adjuvanter Therapie des Mammakarzinoms, Der Onkologe, 2006. 12(1): p. 27-35.

1287. Moorey, Stirling, Greer, Steven, Watson, Maggie, Baruch, John DR, Robertson, Bernadette M, Mason, Anne, et.al. Adjuvant psychological therapy for patients with cancer: outcome at one year, Psycho‐Oncology, 1994. 3(1): p. 39-46.

1288. Ley, P. Llewelyn, S., Improving patients understanding, recall, satisfaction and compliance., 1992.

1289. Kissane, D. W., Bloch, S., Smith, G. C., Miach, P., Clarke, D. M., Ikin, J., et.al. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial, Psychooncology, 2003. 12(6): p. 532-46.

1290. Kissane, D. W., Love, A., Hatton, A., Bloch, S., Smith, G., Clarke, D. M., et.al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer, J Clin Oncol, 2004. 22(21): p. 4255-60.

1291. Kissane, D. W., Grabsch, B., Clarke, D. M., Smith, G. C., Love, A. W., Bloch, S., et.al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial, Psychooncology, 2007. 16(4): p. 277-86.

1292. Dolbeault, S., Cayrou, S., Bredart, A., Viala, A. L., Desclaux, B., Saltel, P., et.al. The effectiveness of a psycho-educational group after early-stage breast cancer treatment: results of a randomized French study, Psychooncology, 2009. 18(6): p. 647-56.

1293. Bindemann, S., Soukop, M., Kaye, S. B., Randomised controlled study of relaxation training, Eur J Cancer, 1991. 27(2): p. 170-4.

1294. Cohen, Miri, Fried, Georgeta, Comparing relaxation training and cognitive-behavioral group therapy for women with breast cancer, Research on Social Work Practice, 2007. 17(3): p. 313-323.

1295. Lengacher, C. A., Johnson-Mallard, V., Post-White, J., Moscoso, M. S., Jacobsen, P. B., Klein, T. W., et.al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer, Psychooncology, 2009. 18(12): p. 1261-72.

1296. Nidich, S. I., Fields, J. Z., Rainforth, M. V., Pomerantz, R., Cella, D., Kristeller, J., et.al. A randomized controlled trial of the effects of transcendental meditation on quality of life in older breast cancer patients, Integr Cancer Ther, 2009. 8(3): p. 228-34.

1297. Yoo, H. J., Ahn, S. H., Kim, S. B., Kim, W. K., Han, O. S., Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life, Support Care Cancer, 2005. 13(10): p. 826-33.

1298. Baucom, D. H., Porter, L. S., Kirby, J. S., Gremore, T. M., Wiesenthal, N., Aldridge, W., et.al. A couple-based intervention for female breast cancer, Psychooncology, 2009. 18(3): p. 276-83.

1299. Manne, S. L., Ostroff, J. S., Winkel, G., Fox, K., Grana, G., Miller, E., et.al. Couple-focused group intervention for women with early stage breast cancer, J Consult Clin Psychol, 2005. 73(4): p. 634-46.

1300. Northouse, L., Kershaw, T., Mood, D., Schafenacker, A., Effects of a family intervention on the quality of life of women with recurrent breast cancer and their family caregivers, Psychooncology, 2005. 14(6): p. 478-91.

1301. Scott, J. L., Halford, W. K., Ward, B. G., United we stand? The effects of a couple-coping intervention on adjustment to early stage breast or gynecological cancer, J Consult Clin Psychol, 2004. 72(6): p. 1122-35.

1302. Kesler, S., Hadi Hosseini, S. M., Heckler, C., Janelsins, M., Palesh, O., Mustian, K., et.al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors, Clin Breast Cancer, 2013. 13(4): p. 299-306.

1303. Ercoli, L. M., Petersen, L., Hunter, A. M., Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial, 2015. 24(11): p. 1360-7.

1304. Bradt, J., Dileo, C., Magill, L., Teague, A., Music interventions for improving psychological and physical outcomes in cancer patients, Cochrane Database Syst Rev, 2016. p. Cd006911.

1305. Burns, D. S., The effect of the bonny method of guided imagery and music on the mood and life quality of cancer patients, J Music Ther, 2001. 38(1): p. 51-65.

1306. Hanser, S. B., Bauer-Wu, S., Kubicek, L., Healey, M., Manola, J., Hernandez, M., et.al. Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer, J Soc Integr Oncol, 2006. 4(3): p. 116-24.

1307. Puig, Ana, Lee, Sang Min, Goodwin, Linda, Sherrard, Peter AD, The efficacy of creative arts therapies to enhance emotional expression, spirituality, and psychological well-being of newly diagnosed Stage I and Stage II breast cancer patients: A preliminary study, The Arts in Psychotherapy, 2006. 33(3): p. 218-228.

1308. Svensk, A. C., Oster, I., Thyme, K. E., Magnusson, E., Sjodin, M., Eisemann, M., et.al. Art therapy improves experienced quality of life among women undergoing treatment for breast cancer: a randomized controlled study, Eur J Cancer Care (Engl), 2009. 18(1): p. 69-77.

1309. Mehnert, A., Lehmann, C., Cao, P., Koch, U., [Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56(12): p. 462-79.

1310. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 1993. 85(5): p. 365-76.

1311. Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et.al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure, J Clin Oncol, 1993. 11(3): p. 570-9.

1312. Albert, U. S., Koller, M., Lorenz, W., Kopp, I., Heitmann, C., Stinner, B., et.al. Quality of life profile: from measurement to clinical application, Breast, 2002. 11(4): p. 324-34.

1313. Engel, J., Eckel, R., Aydemir, U., Aydemir, S., Kerr, J., Schlesinger-Raab, A., et.al. Determinants and prognoses of locoregional and distant progression in breast cancer, Int J Radiat Oncol Biol Phys, 2003. 55(5): p. 1186-95.

1314. Lemieux, J., Goodwin, P. J., Bordeleau, L. J., Lauzier, S., Theberge, V., Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009), J Natl Cancer Inst, 2011. 103(3): p. 178-231.

1315. Velikova, G., Wright, E. P., Smith, A. B., Cull, A., Gould, A., Forman, D., et.al. Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires, J Clin Oncol, 1999. 17(3): p. 998-1007.

1316. Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et.al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial, J Clin Oncol, 2004. 22(4): p. 714-24.

1317. Klinkhammer-Schalke, M., Koller, M., Steinger, B., Ehret, C., Ernst, B., Wyatt, J. C., et.al. Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer, Br J Cancer, 2012. 106(5): p. 826-38.

1318. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 1993. 85(5): p. 365-76.

1319. Mehnert, A., Lehmann, C., Cao, P., Koch, U., [Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56(12): p. 462-79.

1320. Onkologie, Leitlinienprogramm, S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Langversion 1.1, 2015. AWMF-Registernummer: 128/001OL, 2016.

1321. (NCI)., National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE Version 4.03)., 2010.

1322. Markes, M., Brockow, T., Resch, K. L., Exercise for women receiving adjuvant therapy for breast cancer, Cochrane Database Syst Rev, 2006. p. Cd005001.

1323. Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., et.al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 2011. 29(31): p. 4189-98.

1324. Hesketh, P. J., Bohlke, K., Lyman, G. H., Basch, E., Chesney, M., Clark-Snow, R. A., et.al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update, J Clin Oncol, 2016. 34(4): p. 381-6.

1325. (MASCC), Mulitnational Association of Supportive Care in Cancer, Updated antiemetic consensus guidelines by MASCC/ESMO, 2016.

1326. Roila, F, Herrstedt, Jørn, Aapro, M, Gralla, RJ, Einhorn, LH, Ballatori, E, et.al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference, Annals of Oncology, 2010. 21(suppl 5): p. v232-v243.

1327. Warr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., et.al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy, J Clin Oncol, 2005. 23(12): p. 2822-30.

1328. Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I., et.al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy, Ann Oncol, 2014. 25(7): p. 1328-33.

1329. Morrow, GR, Roscoe, JA, Anticipatory nausea and vomiting: models, mechanisms and management, Medical management of cancer treatment induced emesis. London: Martin Dunitz, 1997. p. 149-166.

1330. Navari, R. M., Nagy, C. K., Gray, S. E., The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, Support Care Cancer, 2013. 21(6): p. 1655-63.

1331. Tipton, J. M., McDaniel, R. W., Barbour, L., Johnston, M. P., Kayne, M., LeRoy, P., et.al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting, Clin J Oncol Nurs, 2007. 11(1): p. 69-78.

1332. Aapro, M. S., Molassiotis, A., Olver, I., Anticipatory nausea and vomiting, Support Care Cancer, 2005. 13(2): p. 117-21.

1333. Maranzano, E., De Angelis, V., Pergolizzi, S., Lupattelli, M., Frata, P., Spagnesi, S., et.al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres, Radiother Oncol, 2010. 94(1): p. 36-41.

1334. Wong, R. K., Paul, N., Ding, K., Whitehead, M., Brundage, M., Fyles, A., et.al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19), J Clin Oncol, 2006. 24(21): p. 3458-64.

1335. Enblom, A., Bergius Axelsson, B., Steineck, G., Hammar, M., Borjeson, S., One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient, Support Care Cancer, 2009. 17(1): p. 23-32.

1336. Ruhlmann, C. H., Christensen, T. B., Dohn, L. H., Paludan, M., Ronnengart, E., Halekoh, U., et.al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial, Lancet Oncol, 2016. 17(4): p. 509-18.

1337. Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., et.al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients, Ann Oncol, 2016. 27(suppl 5): p. v119-v133.

1338. Lyman, G. H., Dale, D. C., Culakova, E., Poniewierski, M. S., Wolff, D. A., Kuderer, N. M., et.al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials, Ann Oncol, 2013. 24(10): p. 2475-84.

1339. Link, H., Maschmeyer, G., Meyer, P., Hiddemann, W., Stille, W., Helmerking, M., et.al. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy, Ann Hematol, 1994. 69(5): p. 231-43.

1340. Link, H., Bohme, A., Cornely, O. A., Hoffken, K., Kellner, O., Kern, W. V., et.al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society), Ann Hematol, 2003. 82 Suppl 2: p. S105-17.

1341. Schiel, X., Link, H., Maschmeyer, G., Glass, B., Cornely, O. A., Buchheidt, D., et.al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II, Infection, 2006. 34(3): p. 118-26.

1342. Link, H, Buchheidt, D, Maschmeyer, G, Böhme, A, Mahlberg, R, Mousset, S, et.al. Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) dDGfHuOeVD, Sektion Infektionen in der Hämatologie und Onkologie dP-E-GfCeVP, Arbeitsgemeinschaft Supportivmaßnahmen in der Onkologie dDKeVA, Deutschsprachige Mykologische Gesellschaft eV (DMykG)(2006) Infektionen bei Neutropenie–Diagnostik und Therapie 2006–Empfehlungen für die Praxis, 2006.

1343. Bodey, G. P., Buckley, M., Sathe, Y. S., Freireich, E. J., Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia, Ann Intern Med, 1966. 64(2): p. 328-40.

1344. Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., Lyman, G. H., Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, 2006. 106(10): p. 2258-66.

1345. Elting, L. S., Rubenstein, E. B., Rolston, K. V., Bodey, G. P., Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials, Clin Infect Dis, 1997. 25(2): p. 247-59.

1346. Knight, K., Wade, S., Balducci, L., Prevalence and outcomes of anemia in cancer: a systematic review of the literature, Am J Med, 2004. 116 Suppl 7A: p. 11s-26s.

1347. Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., et.al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur J Cancer, 2004. 40(15): p. 2293-306.

1348. Weiss, G., Goodnough, L. T., Anemia of chronic disease, N Engl J Med, 2005. 352(10): p. 1011-23.

1349. Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D., Spivak, J. L., Decreased erythropoietin response in patients with the anemia of cancer, N Engl J Med, 1990. 322(24): p. 1689-92.

1350. Fleming, R. E., Bacon, B. R., Orchestration of iron homeostasis, N Engl J Med, 2005. 352(17): p. 1741-4.

1351. Ganz, T., Hepcidin and iron regulation, 10 years later, Blood, 2011. 117(17): p. 4425-33.

1352. Kautz, L, Jung, G, Nemeth, E, Ganz, T, The Erythroid Factor Erythroferrone and Its Role In Iron Homeostasis, Blood, 2013. 122(4):

1353. Harrison, L. B., Shasha, D., White, C., Ramdeen, B., Radiotherapy-Associated Anemia: The Scope of the Problem, Oncologist, 2000. 5 Suppl 2: p. 1-7.

1354. Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., et.al. Erythropoietin or darbepoetin for patients with cancer, Cochrane Database Syst Rev, 2012. 12: p. Cd003407.

1355. Machtay, M, Zhang, Q, Suntharalingam, M, Hershock, D, Lustig, R, Nabid, A, et.al. Long-term Outcomes from RTOG 99-03: Radiation Therapy With or Without Erythropoietin for Anemic Head-and-Neck Cancer Patients, International Journal of Radiation Oncology* Biology* Physics, 2012. 84(3): p. S21.

1356. Moebus, V., Jackisch, C., Schneeweiss, A., Huober, J., Lueck, H. J., du Bois, A., et.al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial, J Natl Cancer Inst, 2013. 105(14): p. 1018-26.

1357. Debus, J., Drings, P., Baurecht, W., Angermund, R., Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa, Radiother Oncol, 2014. 112(1): p. 23-9.

1358. Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., et.al. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer, Ann Oncol, 2014. 25(1): p. 75-80.

1359. Ludwig, H., Muldur, E., Endler, G., Hubl, W., Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia, Ann Oncol, 2013. 24(7): p. 1886-92.

1360. Hastka, J, Heimpel, H, Metzgeroth, G, Deutsche Gesellschaft für Hämatologie und medizinische Onkologie (DGHO). Eisenmangel und Eisenmangelanämie–Leitlinie 2011, 2011.

1361. Carson, J. L., Carless, P. A., Hebert, P. C., Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion, Cochrane Database Syst Rev, 2012. p. Cd002042.

1362. Retter, A., Wyncoll, D., Pearse, R., Carson, D., McKechnie, S., Stanworth, S., et.al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients, Br J Haematol, 2013. 160(4): p. 445-64.

1363. Hoppe, J.-D., Scriba, P. C., Klüter, H., Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten 4. überarbeitete und aktualisierte Auflage 2014., 2014.

1364. Carson, J. L., Sieber, F., Cook, D. R., Hoover, D. R., Noveck, H., Chaitman, B. R., et.al. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial, Lancet, 2015. 385(9974): p. 1183-9.

1365. Berger, M. D., Gerber, B., Arn, K., Senn, O., Schanz, U., Stussi, G., Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation, Haematologica, 2012. 97(1): p. 116-22.

1366. Yerrabothala, S., Desrosiers, K. P., Szczepiorkowski, Z. M., Dunbar, N. M., Significant reduction in red blood cell transfusions in a general hospital after successful implementation of a restrictive transfusion policy supported by prospective computerized order auditing, Transfusion, 2014. 54(10 Pt 2): p. 2640-5.

1367. Hicks, L. K., Bering, H., Carson, K. R., Kleinerman, J., Kukreti, V., Ma, A., et.al. The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question, Blood, 2013. 122(24): p. 3879-83.

1368. Park, Susanna B, Goldstein, David, Krishnan, Arun V, Lin, Cindy S‐Y, Friedlander, Michael L, Cassidy, James, et.al. Chemotherapy‐induced peripheral neurotoxicity: A critical analysis, CA: a cancer journal for clinicians, 2013. 63(6): p. 419-437.

1369. Lee, J. J., Swain, S. M., Peripheral neuropathy induced by microtubule-stabilizing agents, J Clin Oncol, 2006. 24(10): p. 1633-42.

1370. Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., et.al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840, J Clin Oncol, 2008. 26(10): p. 1642-9.

1371. Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et.al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J Clin Oncol, 2005. 23(31): p. 7794-803.

1372. Ibrahim, N. K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R. L., Rivera, E., et.al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel, Clin Cancer Res, 2002. 8(5): p. 1038-44.

1373. Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., et.al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer, J Clin Oncol, 2009. 27(22): p. 3611-9.

1374. Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., et.al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival, Clin Breast Cancer, 2012. 12(5): p. 313-21.

1375. Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et.al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 2014. 32(18): p. 1941-67.

1376. Streckmann, F., Zopf, E. M., Lehmann, H. C., May, K., Rizza, J., Zimmer, P., et.al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review, Sports Med, 2014. 44(9): p. 1289-304.

1377. Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., et.al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, Jama, 2013. 309(13): p. 1359-67.

1378. Garassino, M. C., Piva, S., La Verde, N., Spagnoletti, I., Iorno, V., Carbone, C., et.al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients, PLoS One, 2013. 8(4): p. e59981.

1379. Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., et.al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting, J Clin Oncol, 2006. 24(31): p. 5091-7.

1380. Saphner, T., Tormey, D. C., Gray, R., Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, 1996. 14(10): p. 2738-46.

1381. Rojas, M. P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., et.al. Follow-up strategies for women treated for early breast cancer, Cochrane Database Syst Rev, 2005. p. Cd001768.

1382. Gulliford, T., Opomu, M., Wilson, E., Hanham, I., Epstein, R., Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study, Bmj, 1997. 314(7075): p. 174-7.

1383. Hurria, A., Hudis, C., Follow-up care of breast cancer survivors, Crit Rev Oncol Hematol, 2003. 48(1): p. 89-99.

1384. Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del Turco, M., Distante, V., et.al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up, Jama, 1999. 281(17): p. 1586.

1385. Pestalozzi, B. C., Luporsi-Gely, E., Jost, L. M., Bergh, J., ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer, Ann Oncol, 2005. 16 Suppl 1: p. i7-9.

1386. Rosselli Del Turco, M., Palli, D., Cariddi, A., Ciatto, S., Pacini, P., Distante, V., Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up, Jama, 1994. 271(20): p. 1593-7.

1387. Ferzoco, R. M., Ruddy, K. J., Optimal delivery of male breast cancer follow-up care: improving outcomes, Breast Cancer (Dove Med Press), 2015. 7: p. 371-9.

1388. Selby, P., Gillis, C., Haward, R., Benefits from specialised cancer care, Lancet, 1996. 348(9023): p. 313-8.

1389. (NBOCC)., National Breast and Ovarian Cancer Centre, Recommendations for follow-up of women with early breast cancer., 2010.

1390. Dalberg, K., Mattsson, A., Sandelin, K., Rutqvist, L. E., Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer, Breast Cancer Res Treat, 1998. 49(1): p. 69-78.

1391. Riebe, E., Gunther, K., Schulz, K., Kohler, G., Schimming, A., Schwesinger, G., et.al. Recurrent disease after breast preserving therapy (BPT) and radiation therapy for breast cancer--diagnostic yield of palpation, mammography and ultrasonography, Ultraschall Med, 2007. 28(4): p. 394-400.

1392. Wojcinski, S., Farrokh, A., Hille, U., Hirschauer, E., Schmidt, W., Hillemanns, P., et.al. Optimizing breast cancer follow-up: diagnostic value and costs of additional routine breast ultrasound, Ultrasound Med Biol, 2011. 37(2): p. 198-206.

1393. Muuller, R. D., Barkhausen, J., Sauerwein, W., Langer, R., Assessment of local recurrence after breast-conserving therapy with MRI, J Comput Assist Tomogr, 1998. 22(3): p. 408-12.

1394. Viehweg, P., Heinig, A., Lampe, D., Buchmann, J., Heywang-Kobrunner, S. H., Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy, Magma, 1998. 7(3): p. 141-52.

1395. Kollias, J., Evans, A. J., Wilson, A. R., Ellis, I. O., Elston, C. W., Blamey, R. W., Value of contralateral surveillance mammography for primary breast cancer follow-up, World J Surg, 2000. 24(8): p. 983-7; discussion 988-9.

1396. Kuhl, C., Weigel, S., Schrading, S., Arand, B., Bieling, H., Konig, R., et.al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial, J Clin Oncol, 2010. 28(9): p. 1450-7.

1397. Auvinen, A., Curtis, R. E., Ron, E., Risk of subsequent cancer following breast cancer in men, J Natl Cancer Inst, 2002. 94(17): p. 1330-2.

1398. Aguiar-Bujanda, D., Bohn-Sarmiento, U., Aguiar-Morales, J., False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer, Breast J, 2004. 10(4): p. 375-6.

1399. Bornhak, Sven, Heidemann, Else, Herschlein, H-J, Simon, Wolfgang, Merkle, Elisabeth, Widmaier, Guenter, et.al. Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study, Oncology Research and Treatment, 2007. 30(8-9): p. 443-449.

1400. Hayes, D. F., Clinical practice. Follow-up of patients with early breast cancer, N Engl J Med, 2007. 356(24): p. 2505-13.

1401. Rojas, M. P., Telaro, E., Russo, A., Fossati, R., Confalonieri, C., Liberati, A., Follow-up strategies for women treated for early breast cancer, Cochrane Database Syst Rev, 2000. p. Cd001768.

1402. Brennan, M. J., Lymphedema following the surgical treatment of breast cancer: a review of pathophysiology and treatment, J Pain Symptom Manage, 1992. 7(2): p. 110-6.

1403. Armer, J., Fu, M. R., Wainstock, J. M., Zagar, E., Jacobs, L. K., Lymphedema following breast cancer treatment, including sentinel lymph node biopsy, Lymphology, 2004. 37(2): p. 73-91.

1404. Bani, H. A., Fasching, P. A., Lux, M. M., Rauh, C., Willner, M., Eder, I., et.al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit, Patient Educ Couns, 2007. 66(3): p. 311-8.

1405. Francis, W. P., Abghari, P., Du, W., Rymal, C., Suna, M., Kosir, M. A., Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection, Am J Surg, 2006. 192(5): p. 636-9.

1406. Golshan, M., Martin, W. J., Dowlatshahi, K., Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection, Am Surg, 2003. 69(3): p. 209-11; discussion 212.

1407. Hamner, J. B., Fleming, M. D., Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer, Ann Surg Oncol, 2007. 14(6): p. 1904-8.

1408. Harris, S. R., Hugi, M. R., Olivotto, I. A., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema, Cmaj, 2001. 164(2): p. 191-9.

1409. Hayes, S., Cornish, B., Newman, B., Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up, Breast Cancer Res Treat, 2005. 89(3): p. 221-6.

1410. Moseley, A. L., Carati, C. J., Piller, N. B., A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment, Ann Oncol, 2007. 18(4): p. 639-46.

1411. Sanjuan, A., Vidal-Sicart, S., Zanon, G., Pahisa, J., Velasco, M., Fernandez, P. L., et.al. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients, Eur J Nucl Med Mol Imaging, 2005. 32(8): p. 932-6.

1412. Torrenga, H., Fabry, H., van der Sijp, J. R., van Diest, P. J., Pijpers, R., Meijer, S., Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis, J Surg Oncol, 2004. 88(1): p. 4-7; discussion 7-8.

1413. Clark, B., Sitzia, J., Harlow, W., Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study, Qjm, 2005. 98(5): p. 343-8.

1414. Kokke, M. C., Jannink, I., Barneveld, P. C., van der Linden, J. C., Gelderman, W. A., Wissing, J. C., et.al. Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study, Eur J Surg Oncol, 2005. 31(3): p. 221-5.

1415. Mansel, R. E., Fallowfield, L., Kissin, M., Goyal, A., Newcombe, R. G., Dixon, J. M., et.al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial, J Natl Cancer Inst, 2006. 98(9): p. 599-609.

1416. Purushotham, A. D., Upponi, S., Klevesath, M. B., Bobrow, L., Millar, K., Myles, J. P., et.al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial, J Clin Oncol, 2005. 23(19): p. 4312-21.

1417. McNeely, M. L., Campbell, K., Ospina, M., Rowe, B. H., Dabbs, K., Klassen, T. P., et.al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment, Cochrane Database Syst Rev, 2010. p. Cd005211.

1418. Devoogdt, N., Van Kampen, M., Geraerts, I., Coremans, T., Christiaens, M. R., Different physical treatment modalities for lymphoedema developing after axillary lymph node dissection for breast cancer: a review, Eur J Obstet Gynecol Reprod Biol, 2010. 149(1): p. 3-9.

1419. Schmitz, K. H., Ahmed, R. L., Troxel, A., Cheville, A., Smith, R., Lewis-Grant, L., et.al. Weight lifting in women with breast-cancer-related lymphedema, N Engl J Med, 2009. 361(7): p. 664-73.

1420. Bonneterre, J., Roche, H., Kerbrat, P., Fumoleau, P., Goudier, M. J., Fargeot, P., et.al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group, J Clin Oncol, 2004. 22(15): p. 3070-9.

1421. Jensen, B. V., Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer, Semin Oncol, 2006. 33(3 Suppl 8): p. S15-21.

1422. Perez, E. A., Rodeheffer, R., Clinical cardiac tolerability of trastuzumab, J Clin Oncol, 2004. 22(2): p. 322-9.

1423. Le Deley, M. C., Suzan, F., Cutuli, B., Delaloge, S., Shamsaldin, A., Linassier, C., et.al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer, J Clin Oncol, 2007. 25(3): p. 292-300.

1424. Smith, R. E., Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience, Clin Breast Cancer, 2003. 4(4): p. 273-9.

1425. Stearns, V., Ullmer, L., Lopez, J. F., Smith, Y., Isaacs, C., Hayes, D., Hot flushes, Lancet, 2002. 360(9348): p. 1851-61.

1426. Mom, C. H., Buijs, C., Willemse, P. H., Mourits, M. J., de Vries, E. G., Hot flushes in breast cancer patients, Crit Rev Oncol Hematol, 2006. 57(1): p. 63-77.

1427. Pritchard, K. I., Khan, H., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer, Cmaj, 2002. 166(8): p. 1017-22.

1428. Caine, G. J., Stonelake, P. S., Rea, D., Lip, G. Y., Coagulopathic complications in breast cancer, Cancer, 2003. 98(8): p. 1578-86.

1429. Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., et.al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer, J Natl Cancer Inst, 1999. 91(21): p. 1829-46.

1430. Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., et.al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol, 2003. 21(21): p. 4042-57.

1431. Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., et.al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004, J Clin Oncol, 2005. 23(3): p. 619-29.

1432. Edmonds, M., McGuire, H., Price, J., Exercise therapy for chronic fatigue syndrome, Cochrane Database Syst Rev, 2004. p. Cd003200.

1433. Servaes, P., Prins, J., Verhagen, S., Bleijenberg, G., Fatigue after breast cancer and in chronic fatigue syndrome: similarities and differences, J Psychosom Res, 2002. 52(6): p. 453-9.

1434. Petrek, J., Seltzer, V., Breast cancer in pregnant and postpartum women, J Obstet Gynaecol Can, 2003. 25(11): p. 944-50.

1435. Velentgas, P., Daling, J. R., Malone, K. E., Weiss, N. S., Williams, M. A., Self, S. G., et.al. Pregnancy after breast carcinoma: outcomes and influence on mortality, Cancer, 1999. 85(11): p. 2424-32.

1436. Sankila, R., Heinavaara, S., Hakulinen, T., Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect", Am J Obstet Gynecol, 1994. 170(3): p. 818-23.

1437. Donnelly, J., Mack, P., Donaldson, L. A., Follow-up of breast cancer: time for a new approach?, Int J Clin Pract, 2001. 55(7): p. 431-3.

1438. Renton, J. P., Twelves, C. J., Yuille, F. A., Follow-up in women with breast cancer: the patients' perspective, Breast, 2002. 11(3): p. 257-61.

1439. Doubeni, C. A., Field, T. S., Ulcickas Yood, M., Rolnick, S. J., Quessenberry, C. P., Fouayzi, H., et.al. Patterns and predictors of mammography utilization among breast cancer survivors, Cancer, 2006. 106(11): p. 2482-8.

1440. Grunfeld, E., Noorani, H., McGahan, L., Paszat, L., Coyle, D., van Walraven, C., et.al. Surveillance mammography after treatment of primary breast cancer: a systematic review, Breast, 2002. 11(3): p. 228-35.

1441. Hollowell, K., Olmsted, C. L., Richardson, A. S., Pittman, H. K., Bellin, L., Tafra, L., et.al. American Society of Clinical Oncology-recommended surveillance and physician specialty among long-term breast cancer survivors, Cancer, 2010. 116(9): p. 2090-8.

1442. Katz, M. L., Donohue, K. A., Alfano, C. M., Day, J. M., Herndon, J. E., 2nd, Paskett, E. D., Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804, Cancer, 2009. 115(3): p. 480-8.

1443. Scott, D. A., Mills, M., Black, A., Cantwell, M., Campbell, A., Cardwell, C. R., et.al. Multidimensional rehabilitation programmes for adult cancer survivors, Cochrane Database Syst Rev, 2013. p. Cd007730.

1444. Fong, D. Y., Ho, J. W., Hui, B. P., Lee, A. M., Macfarlane, D. J., Leung, S. S., et.al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials, Bmj, 2012. 344: p. e70.

1445. Berger, A. M., Mooney, K., Alvarez-Perez, A., Breitbart, W. S., Carpenter, K. M., Cella, D., et.al. Cancer-Related Fatigue, Version 2.2015, J Natl Compr Canc Netw, 2015. 13(8): p. 1012-39.

1446. Weis, J., Cancer-related fatigue: prevalence, assessment and treatment strategies, Expert Rev Pharmacoecon Outcomes Res, 2011. 11(4): p. 441-6.

1447. Cella, D., Peterman, A., Passik, S., Jacobsen, P., Breitbart, W., Progress toward guidelines for the management of fatigue, Oncology (Williston Park), 1998. 12(11a): p. 369-77.

1448. Heim, Manfred E, Weis, Joachim, Fatigue bei Krebserkrankungen: Erkennen–Behandeln–VorbeugenSchattauer Verlag, 2014.

1449. Network, National Comprehensive Cancer, NCCN GUIDELINES FOR SUPPORTIVE CARE-Cancer Related Fatigue, Version 1, 2015

1450. Brown, J. C., Huedo-Medina, T. B., Pescatello, L. S., Pescatello, S. M., Ferrer, R. A., Johnson, B. T., Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2011. 20(1): p. 123-33.

1451. Puetz, T. W., Herring, M. P., Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis, Am J Prev Med, 2012. 43(2): p. e1-24.

1452. McMillan, E. M., Newhouse, I. J., Exercise is an effective treatment modality for reducing cancer-related fatigue and improving physical capacity in cancer patients and survivors: a meta-analysis, Appl Physiol Nutr Metab, 2011. 36(6): p. 892-903.

1453. Speck, R. M., Courneya, K. S., Masse, L. C., Duval, S., Schmitz, K. H., An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis, J Cancer Surviv, 2010. 4(2): p. 87-100.

1454. Tomlinson, D., Diorio, C., Beyene, J., Sung, L., Effect of exercise on cancer-related fatigue: a meta-analysis, Am J Phys Med Rehabil, 2014. 93(8): p. 675-86.

1455. Duijts, S. F., Faber, M. M., Oldenburg, H. S., van Beurden, M., Aaronson, N. K., Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis, Psychooncology, 2011. 20(2): p. 115-26.

1456. Kangas, M., Bovbjerg, D. H., Montgomery, G. H., Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients, Psychol Bull, 2008. 134(5): p. 700-41.

1457. Buffart, L. M., van Uffelen, J. G., Riphagen, II, Brug, J., van Mechelen, W., Brown, W. J., et.al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials, BMC Cancer, 2012. 12: p. 559.

1458. Cramp, F., Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2008. p. Cd006145.

1459. Cavaletti, G., Cornblath, D. R., Merkies, I. S., Postma, T. J., Rossi, E., Frigeni, B., et.al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings, Ann Oncol, 2013. 24(2): p. 454-62.

1460. Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., Standefer, J. C., Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies, Cancer, 1984. 54(7): p. 1269-75.

1461. Argyriou, A. A., Bruna, J., Marmiroli, P., Cavaletti, G., Chemotherapy-induced peripheral neurotoxicity (CIPN): an update, Crit Rev Oncol Hematol, 2012. 82(1): p. 51-77.

1462. Wiederholt, W. C., Threshold and conduction velocity in human median nerve sensory fibers, Electroencephalogr Clin Neurophysiol, 1969. 27(7): p. 718.

1463. Bock, W. J., Liesegang, J., [Comparative measurement of neural conduction velocity using surface and needle electrodes], Zentralbl Neurochir, 1972. 33(1): p. 45-51.

1464. Geiger, G., Mikus, E., Dertinger, H., Rick, O., Low frequency magnetic field therapy in patients with cytostatic-induced polyneuropathy: a phase II pilot study, Bioelectromagnetics, 2015. 36(3): p. 251-4.

1465. Rick, O, Mikus, E, Dertinger, H, Geiger, G, Treatment of chemotherapy-induced polyneuropathy with magnetic field therapy: A randomized, double-blind placebo-controlled comparative phase Iii study, Oncology Research and Treatment, 2014. 37: p. 189.

1466. Franconi, G., Manni, L., Schroder, S., Marchetti, P., Robinson, N., A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy, Evid Based Complement Alternat Med, 2013. 2013: p. 516916.

1467. Pachman, D. R., Weisbrod, B. L., Seisler, D. K., Barton, D. L., Fee-Schroeder, K. C., Smith, T. J., et.al. Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy, Support Care Cancer, 2015. 23(4): p. 943-51.

1468. oder Chemobrain, Kognitive Dysfunktion, GMS Onkologische Rehabilitation und Sozialmedizin

1469. Shilling, V., Jenkins, V., Trapala, I. S., The (mis)classification of chemo-fog--methodological inconsistencies in the investigation of cognitive impairment after chemotherapy, Breast Cancer Res Treat, 2006. 95(2): p. 125-9.

1470. Kohli, S., Griggs, J. J., Roscoe, J. A., Jean-Pierre, P., Bole, C., Mustian, K. M., et.al. Self-reported cognitive impairment in patients with cancer, J Oncol Pract, 2007. 3(2): p. 54-9.

1471. Ahles, T. A., Root, J. C., Ryan, E. L., Cancer- and cancer treatment-associated cognitive change: an update on the state of the science, J Clin Oncol, 2012. 30(30): p. 3675-86.

1472. Vardy, J., Wefel, J. S., Ahles, T., Tannock, I. F., Schagen, S. B., Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop, Ann Oncol, 2008. 19(4): p. 623-9.

1473. Kalbe, E., Kessler, J., Calabrese, P., Smith, R., Passmore, A. P., Brand, M., et.al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia, Int J Geriatr Psychiatry, 2004. 19(2): p. 136-43.

1474. Erzigkeit, H, Kurztest zur Erfassung von Gedächtnis-und Aufmerksamkeitssterungen, SKT-Manual (24. Auflage), Herzogenaurach: Geromed, 2001.

1475. König, V., Chemobrain – Was kann ich dagegen tun?, GMS Onkologische Rehabilitation und Sozialmedizin., 2014.

1476. Chan, D. N., Lui, L. Y., So, W. K., Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review, J Adv Nurs, 2010. 66(9): p. 1902-14.

1477. Chung, C., Lee, S., Hwang, S., Park, E., Systematic review of exercise effects on health outcomes in women with breast cancer, Asian Nurs Res (Korean Soc Nurs Sci), 2013. 7(3): p. 149-59.

1478. Lasinski, B. B., McKillip Thrift, K., Squire, D., Austin, M. K., Smith, K. M., Wanchai, A., et.al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011, Pm r, 2012. 4(8): p. 580-601.

1479. Dayes, I. S., Whelan, T. J., Julian, J. A., Parpia, S., Pritchard, K. I., D'Souza, D. P., et.al. Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer, J Clin Oncol, 2013. 31(30): p. 3758-63.

1480. Ahles, T. A., Saykin, A. J., Noll, W. W., Furstenberg, C. T., Guerin, S., Cole, B., et.al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy, Psychooncology, 2003. 12(6): p. 612-9.

1481. Janelsins, M. C., Peppone, L. J., Heckler, C. E., Kesler, S. R., Sprod, L. K., Atkins, J., et.al. YOCAS(c)(R) Yoga Reduces Self-reported Memory Difficulty in Cancer Survivors in a Nationwide Randomized Clinical Trial: Investigating Relationships Between Memory and Sleep, Integr Cancer Ther, 2016. 15(3): p. 263-71.

1482. Scherwath, A., Poppelreuter, M., Weis, J., Schulz-Kindermann, F., Koch, U., Mehnert, A., [Psychometric evaluation of a neuropsychological test battery measuring cognitive dysfunction in cancer patients--recommendations for a screening tool], Fortschr Neurol Psychiatr, 2008. 76(10): p. 583-93.

1483. Bray, V. J., Dhillon, H. M., Bell, M. L., Kabourakis, M., Fiero, M. H., Yip, D., et.al. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy, J Clin Oncol, 2017. 35(2): p. 217-225.

1484. Ferguson, R. J., McDonald, B. C., Rocque, M. A., Furstenberg, C. T., Horrigan, S., Ahles, T. A., et.al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial, Psychooncology, 2012. 21(2): p. 176-86.

1485. Mustian, Karen Michelle, Janelsins, Michelle Christine, Peppone, Luke Joseph, Kamen, Charles Stewart, Guido, Joseph John, Heckler, Charles E, EXCAP exercise effects on cognitive impairment and inflammation: A URCC NCORP RCT in 479 cancer patientsAmerican Society of Clinical Oncology, 2015.

1486. Derry, H. M., Jaremka, L. M., Bennett, J. M., Peng, J., Andridge, R., Shapiro, C., et.al. Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial, Psychooncology, 2015. 24(8): p. 958-66.

1487. Horneber, M. A., Bueschel, G., Huber, R., Linde, K., Rostock, M., Mistletoe therapy in oncology, Cochrane Database Syst Rev, 2008. p. Cd003297.

1488. Kalder, M., Muller, T., Fischer, D., Muller, A., Bader, W., Beckmann, M. W., et.al. A Review of Integrative Medicine in Gynaecological Oncology, Geburtshilfe Frauenheilkd, 2016. 76(2): p. 150-155.

1489. Horneber, M., Bueschel, G., Dennert, G., Less, D., Ritter, E., Zwahlen, M., How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis, Integr Cancer Ther, 2012. 11(3): p. 187-203.

1490. Micke, Oliver, Bruns, Frank, Glatzel, Michael, Schönekaes, Klaus, Micke, Patrick, Mücke, Ralph, et.al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology, European Journal of Integrative Medicine, 2009. 1(1): p. 19-25.

1491. Zeller, T., Muenstedt, K., Stoll, C., Schweder, J., Senf, B., Ruckhaeberle, E., et.al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center, J Cancer Res Clin Oncol, 2013. 139(3): p. 357-65.

1492. Huebner, J., Muenstedt, K., Prott, F. J., Stoll, C., Micke, O., Buentzel, J., et.al. Online survey of patients with breast cancer on complementary and alternative medicine, Breast Care (Basel), 2014. 9(1): p. 60-3.

1493. Greenlee, H., Balneaves, L. G., Carlson, L. E., Cohen, M., Deng, G., Hershman, D., et.al. Erratum. Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer, J Natl Cancer Inst Monogr, 2015. 2015(51): p. 98.

1494. Molassiotis, A., Bardy, J., Finnegan-John, J., Mackereth, P., Ryder, D. W., Filshie, J., et.al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial, J Clin Oncol, 2012. 30(36): p. 4470-6.

1495. Montgomery, G. H., David, D., Kangas, M., Green, S., Sucala, M., Bovbjerg, D. H., et.al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer, J Clin Oncol, 2014. 32(6): p. 557-63.

1496. Barton, D. L., Liu, H., Dakhil, S. R., Linquist, B., Sloan, J. A., Nichols, C. R., et.al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2, J Natl Cancer Inst, 2013. 105(16): p. 1230-8.

1497. Deng, G., Chan, Y., Sjoberg, D., Vickers, A., Yeung, K. S., Kris, M., et.al. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial, Support Care Cancer, 2013. 21(6): p. 1735-41.

1498. Bower, J. E., Garet, D., Sternlieb, B., Ganz, P. A., Irwin, M. R., Olmstead, R., et.al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial, Cancer, 2012. 118(15): p. 3766-75.

1499. Hershman, D. L., Unger, J. M., Crew, K. D., Minasian, L. M., Awad, D., Moinpour, C. M., et.al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy, J Clin Oncol, 2013. 31(20): p. 2627-33.

1500. da Costa Miranda, V., Trufelli, D. C., Santos, J., Campos, M. P., Nobuo, M., da Costa Miranda, M., et.al. Effectiveness of guarana (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study, J Altern Complement Med, 2009. 15(4): p. 431-3.

1501. Bairati, I., Meyer, F., Gelinas, M., Fortin, A., Nabid, A., Brochet, F., et.al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients, J Clin Oncol, 2005. 23(24): p. 5805-13.

1502. Bairati, I., Meyer, F., Gelinas, M., Fortin, A., Nabid, A., Brochet, F., et.al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients, J Natl Cancer Inst, 2005. 97(7): p. 481-8.

1503. Camphausen, K., Citrin, D., Krishna, M. C., Mitchell, J. B., Implications for tumor control during protection of normal tissues with antioxidants, J Clin Oncol, 2005. 23(24): p. 5455-7.

1504. Argyriou, A. A., Chroni, E., Koutras, A., Iconomou, G., Papapetropoulos, S., Polychronopoulos, P., et.al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results, Support Care Cancer, 2006. 14(11): p. 1134-40.

1505. Argyriou, A. A., Chroni, E., Koutras, A., Iconomou, G., Papapetropoulos, S., Polychronopoulos, P., et.al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation, J Pain Symptom Manage, 2006. 32(3): p. 237-44.

1506. Thompson, I., Jr., Kristal, A., Platz, E. A., Prevention of prostate cancer: outcomes of clinical trials and future opportunities, Am Soc Clin Oncol Educ Book, 2014. p. e76-80.

1507. Dennert, G., Horneber, M., Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients, Cochrane Database Syst Rev, 2006. p. Cd005037.

1508. Vinceti, M., Dennert, G., Crespi, C. M., Zwahlen, M., Brinkman, M., Zeegers, M. P., et.al. Selenium for preventing cancer, Cochrane Database Syst Rev, 2014. p. Cd005195.

1509. Ogunleye, Adeyemi A, Xue, Fei, Michels, Karin B, Green tea consumption and breast cancer risk or recurrence: a meta-analysis, Breast cancer research and treatment, 2010. 119(2): p. 477.

1510. Ernst, E., Schmidt, K., Steuer-Vogt, M. K., Mistletoe for cancer? A systematic review of randomised clinical trials, Int J Cancer, 2003. 107(2): p. 262-7.

1511. Kienle, G. S., Kiene, H., Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies, Integr Cancer Ther, 2010. 9(2): p. 142-57.

1512. Taixiang, W., Munro, A. J., Guanjian, L., Chinese medical herbs for chemotherapy side effects in colorectal cancer patients, Cochrane Database Syst Rev, 2005. p. Cd004540.

1513. Zhang, M., Liu, X., Li, J., He, L., Tripathy, D., Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients, Cochrane Database Syst Rev, 2007. p. Cd004921.

1514. Sun, C. L., Yuan, J. M., Koh, W. P., Yu, M. C., Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies, Carcinogenesis, 2006. 27(7): p. 1310-5.

1515. Yiannakopoulou, ECh, Effect of green tea catechins on breast carcinogenesis: a systematic review of in-vitro and in-vivo experimental studies, Eur J Cancer Prev, 2014. 23(2): p. 84-9.

1516. Chi, F., Wu, R., Zeng, Y. C., Xing, R., Liu, Y., Xu, Z. G., Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies, Asian Pac J Cancer Prev, 2013. 14(4): p. 2407-12.

1517. Nechuta, S. J., Caan, B. J., Chen, W. Y., Lu, W., Chen, Z., Kwan, M. L., et.al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women, Am J Clin Nutr, 2012. 96(1): p. 123-32.

1518. Henneicke-von Zepelin, H. H., Meden, H., Kostev, K., Schroder-Bernhardi, D., Stammwitz, U., Becher, H., Isopropanolic black cohosh extract and recurrence-free survival after breast cancer, Int J Clin Pharmacol Ther, 2007. 45(3): p. 143-54.

1519. Hirschberg, A. L., Edlund, M., Svane, G., Azavedo, E., Skoog, L., von Schoultz, B., An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women, Menopause, 2007. 14(1): p. 89-96.

1520. Liske, E., Hanggi, W., Henneicke-von Zepelin, H. H., Boblitz, N., Wustenberg, P., Rahlfs, V. W., Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect, J Womens Health Gend Based Med, 2002. 11(2): p. 163-74.

1521. Raus, K., Brucker, C., Gorkow, C., Wuttke, W., First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055, Menopause, 2006. 13(4): p. 678-91.

1522. Rebbeck, T. R., Troxel, A. B., Norman, S., Bunin, G. R., DeMichele, A., Baumgarten, M., et.al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer, Int J Cancer, 2007. 120(7): p. 1523-8.

1523. Reed, S. D., Newton, K. M., LaCroix, A. Z., Grothaus, L. C., Grieco, V. S., Ehrlich, K., Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study, Menopause, 2008. 15(1): p. 51-8.

1524. Ruhlen, R. L., Haubner, J., Tracy, J. K., Zhu, W., Ehya, H., Lamberson, W. R., et.al. Black cohosh does not exert an estrogenic effect on the breast, Nutr Cancer, 2007. 59(2): p. 269-77.

1525. Walji, R., Boon, H., Guns, E., Oneschuk, D., Younus, J., Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients, Support Care Cancer, 2007. 15(8): p. 913-21.

1526. Hernandez Munoz, G., Pluchino, S., Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer, Maturitas, 2003. 44 Suppl 1: p. S59-65.

1527. Jacobson, J. S., Troxel, A. B., Evans, J., Klaus, L., Vahdat, L., Kinne, D., et.al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer, J Clin Oncol, 2001. 19(10): p. 2739-45.

1528. Crane-Okada, R., Kiger, H., Sugerman, F., Uman, G. C., Shapiro, S. L., Wyman-McGinty, W., et.al. Mindful movement program for older breast cancer survivors: a pilot study, Cancer Nurs, 2012. 35(4): p. E1-13.

1529. Henderson, V. P., Clemow, L., Massion, A. O., Hurley, T. G., Druker, S., Hebert, J. R., The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial, Breast Cancer Res Treat, 2012. 131(1): p. 99-109.

1530. Henderson, V. P., Massion, A. O., Clemow, L., Hurley, T. G., Druker, S., Hebert, J. R., A randomized controlled trial of mindfulness-based stress reduction for women with early-stage breast cancer receiving radiotherapy, Integr Cancer Ther, 2013. 12(5): p. 404-13.

1531. Hoffman, C. J., Ersser, S. J., Hopkinson, J. B., Nicholls, P. G., Harrington, J. E., Thomas, P. W., Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial, J Clin Oncol, 2012. 30(12): p. 1335-42.

1532. Garssen, B., Boomsma, M. F., Meezenbroek Ede, J., Porsild, T., Berkhof, J., Berbee, M., et.al. Stress management training for breast cancer surgery patients, Psychooncology, 2013. 22(3): p. 572-80.

1533. Andersen, S. R., Wurtzen, H., Steding-Jessen, M., Christensen, J., Andersen, K. K., Flyger, H., et.al. Effect of mindfulness-based stress reduction on sleep quality: results of a randomized trial among Danish breast cancer patients, Acta Oncol, 2013. 52(2): p. 336-44.

1534. Chandwani, K. D., Thornton, B., Perkins, G. H., Arun, B., Raghuram, N. V., Nagendra, H. R., et.al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer, J Soc Integr Oncol, 2010. 8(2): p. 43-55.

1535. Danhauer, S. C., Mihalko, S. L., Russell, G. B., Campbell, C. R., Felder, L., Daley, K., et.al. Restorative yoga for women with breast cancer: findings from a randomized pilot study, Psychooncology, 2009. 18(4): p. 360-8.

1536. Mustian, K. M., Sprod, L. K., Janelsins, M., Peppone, L. J., Palesh, O. G., Chandwani, K., et.al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors, J Clin Oncol, 2013. 31(26): p. 3233-41.

1537. Post-White, J., Kinney, M. E., Savik, K., Gau, J. B., Wilcox, C., Lerner, I., Therapeutic massage and healing touch improve symptoms in cancer, Integr Cancer Ther, 2003. 2(4): p. 332-44.

1538. Barsevick, A., Beck, S. L., Dudley, W. N., Wong, B., Berger, A. M., Whitmer, K., et.al. Efficacy of an intervention for fatigue and sleep disturbance during cancer chemotherapy, J Pain Symptom Manage, 2010. 40(2): p. 200-16.

1539. Li, X. M., Yan, H., Zhou, K. N., Dang, S. N., Wang, D. L., Zhang, Y. P., Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial, Breast Cancer Res Treat, 2011. 128(2): p. 411-9.

1540. Binns-Turner, P. G., Wilson, L. L., Pryor, E. R., Boyd, G. L., Prickett, C. A., Perioperative music and its effects on anxiety, hemodynamics, and pain in women undergoing mastectomy, Aana j, 2011. 79(4 Suppl): p. S21-7.

1541. Cantarero-Villanueva, I., Fernandez-Lao, C., Fernandez-de-Las-Penas, C., Lopez-Barajas, I. B., Del-Moral-Avila, R., de la-Llave-Rincon, A. I., et.al. Effectiveness of water physical therapy on pain, pressure pain sensitivity, and myofascial trigger points in breast cancer survivors: a randomized, controlled clinical trial, Pain Med, 2012. 13(11): p. 1509-19.

1542. Fernandez-Lao, C., Cantarero-Villanueva, I., Fernandez-de-Las-Penas, C., del Moral-Avila, R., Castro-Sanchez, A. M., Arroyo-Morales, M., Effectiveness of a multidimensional physical therapy program on pain, pressure hypersensitivity, and trigger points in breast cancer survivors: a randomized controlled clinical trial, Clin J Pain, 2012. 28(2): p. 113-21.

1543. Montgomery, G. H., Bovbjerg, D. H., Schnur, J. B., David, D., Goldfarb, A., Weltz, C. R., et.al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients, J Natl Cancer Inst, 2007. 99(17): p. 1304-12.

1544. Montgomery, G. H., Weltz, C. R., Seltz, M., Bovbjerg, D. H., Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients, Int J Clin Exp Hypn, 2002. 50(1): p. 17-32.

1545. Crew, K. D., Capodice, J. L., Greenlee, H., Apollo, A., Jacobson, J. S., Raptis, G., et.al. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients, J Cancer Surviv, 2007. 1(4): p. 283-91.

1546. Bao, T., Cai, L., Giles, J. T., Gould, J., Tarpinian, K., Betts, K., et.al. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors, Breast Cancer Res Treat, 2013. 138(1): p. 167-74.

1547. Oh, B., Kimble, B., Costa, D. S., Davis, E., McLean, A., Orme, K., et.al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study, Acupunct Med, 2013. 31(3): p. 264-71.

1548. Mao, J. J., Xie, S. X., Farrar, J. T., Stricker, C. T., Bowman, M. A., Bruner, D., et.al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use, Eur J Cancer, 2014. 50(2): p. 267-76.

1549. Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., et.al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial, BMC Cancer, 2012. 12: p. 355.

1550. Hanf, V., Schutz, F., Liedtke, C., Thill, M., AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015, Breast Care (Basel), 2015. 10(3): p. 189-97.

1551. Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Senologie., Jahresbericht der zertifizierten Brustkrebszentren. Kennzahlenauswertung 2017., 2017.

1552. Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Senologie., Individueller Jahresbericht der zertifizierten Brustkrebszentren. Kennzahlenauswertung 2017., 2017.

1553. Azim, H. A., Jr., Kroman, N., Paesmans, M., Gelber, S., Rotmensz, N., Ameye, L., et.al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study, J Clin Oncol, 2013. 31(1): p. 73-9.

1554. Azim, H. A., Jr., Santoro, L., Pavlidis, N., Gelber, S., Kroman, N., Azim, H., et.al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies, Eur J Cancer, 2011. 47(1): p. 74-83.

1555. Valachis, A., Tsali, L., Pesce, L. L., Polyzos, N. P., Dimitriadis, C., Tsalis, K., et.al. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies, Obstet Gynecol Surv, 2010. 65(12): p. 786-93.

1556. Goldrat, O., Kroman, N., Peccatori, F. A., Cordoba, O., Pistilli, B., Lidegaard, O., et.al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome, Eur J Cancer, 2015. 51(12): p. 1490-6.

1557. Lambertini, M., Del Mastro, L., Pescio, M. C., Andersen, C. Y., Azim, H. A., Jr., Peccatori, F. A., et.al. Cancer and fertility preservation: international recommendations from an expert meeting, BMC Med, 2016. 14: p. 1.

1558. Gennari, A., Costa, M., Puntoni, M., Paleari, L., De Censi, A., Sormani, M. P., et.al. Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies, Breast Cancer Res Treat, 2015. 150(2): p. 405-13.

1559. Luke, B., Brown, M. B., Missmer, S. A., Spector, L. G., Leach, R. E., Williams, M., et.al. Assisted reproductive technology use and outcomes among women with a history of cancer, Hum Reprod, 2016. 31(1): p. 183-9.

1560. Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., et.al. Treatment of breast cancer during pregnancy: an observational study, Lancet Oncol, 2012. 13(9): p. 887-96.

1561. Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., et.al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients, JAMA Oncol, 2015. 1(8): p. 1145-53.

1562. NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy, NTP Monogr, 2013. p. i-214.

1563. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Papadimitriou, C. A., Dimopoulos, M. A., Bartsch, R., Trastuzumab administration during pregnancy: a systematic review and meta-analysis, Breast Cancer Res Treat, 2013. 137(2): p. 349-57.

1564. Del Mastro, L., Rossi, G., Lambertini, M., Poggio, F., Pronzato, P., New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients, Cancer Treat Rev, 2016. 42: p. 18-23.

1565. Vitek, W. S., Shayne, M., Hoeger, K., Han, Y., Messing, S., Fung, C., Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis, Fertil Steril, 2014. 102(3): p. 808-815.e1.

1566. Moore, H. C., Unger, J. M., Phillips, K. A., Boyle, F., Hitre, E., Porter, D., et.al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy, N Engl J Med, 2015. 372(10): p. 923-32.

1567. Del Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S., et.al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial, Jama, 2011. 306(3): p. 269-76.

1568. Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., et.al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial, Jama, 2015. 314(24): p. 2632-40.

1569. Gerber, B., von Minckwitz, G., Stehle, H., Reimer, T., Felberbaum, R., Maass, N., et.al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study, J Clin Oncol, 2011. 29(17): p. 2334-41.

1570. Munster, P. N., Moore, A. P., Ismail-Khan, R., Cox, C. E., Lacevic, M., Gross-King, M., et.al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer, J Clin Oncol, 2012. 30(5): p. 533-8.

1571. Kalsi, T., Babic-Illman, G., Ross, P. J., Maisey, N. R., Hughes, S., Fields, P., et.al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people, Br J Cancer, 2015. 112(9): p. 1435-44.

1572. Hall, D. E., Arya, S., Schmid, K. K., Carlson, M. A., Lavedan, P., Bailey, T. L., et.al. Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365 Days, JAMA Surg, 2017. 152(3): p. 233-240.

1573. Le Saux, O., Ripamonti, B., Bruyas, A., Bonin, O., Freyer, G., Bonnefoy, M., et.al. Optimal management of breast cancer in the elderly patient: current perspectives, Clin Interv Aging, 2015. 10: p. 157-74.

1574. Decoster, L., Van Puyvelde, K., Mohile, S., Wedding, U., Basso, U., Colloca, G., et.al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger, Ann Oncol, 2015. 26(2): p. 288-300.

1575. Clough-Gorr, K. M., Stuck, A. E., Thwin, S. S., Silliman, R. A., Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up, J Clin Oncol, 2010. 28(3): p. 380-6.

1576. Mislang, A. R., Biganzoli, L., Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?, Cancers (Basel), 2015. 7(3): p. 1191-214.

1577. Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., et.al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), Lancet Oncol, 2012. 13(4): p. e148-60.

1578. Thavarajah, N., Menjak, I., Trudeau, M., Mehta, R., Wright, F., Leahey, A., et.al. Towards an optimal multidisciplinary approach to breast cancer treatment for older women, Can Oncol Nurs J, 2015. 25(4): p. 384-408.

1579. Perrone, F., Nuzzo, F., Di Rella, F., Gravina, A., Iodice, G., Labonia, V., et.al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial, Ann Oncol, 2015. 26(4): p. 675-82.

1580. Hamaker, M. E., Seynaeve, C., Wymenga, A. N., van Tinteren, H., Nortier, J. W., Maartense, E., et.al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group, Breast, 2014. 23(1): p. 81-7.

1581. Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., et.al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol, 2011. 29(25): p. 3457-65.

1582. Morgan, Jenna, Wyld, Lynda, Collins Karen, A., Reed Malcolm, W., Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus), Cochrane Database of Systematic Reviews, 2014.

1583. Christiansen, P., Bjerre, K., Ejlertsen, B., Jensen, M. B., Rasmussen, B. B., Laenkholm, A. V., et.al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark, J Natl Cancer Inst, 2011. 103(18): p. 1363-72.

1584. Ono, M., Ogilvie, J. M., Wilson, J. S., Green, H. J., Chambers, S. K., Ownsworth, T., et.al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer, Front Oncol, 2015. 5: p. 59.

1585. Biganzoli, L., Aapro, M., Loibl, S., Wildiers, H., Brain, E., Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force, Cancer Treat Rev, 2016. 43: p. 19-26.

1586. Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., et.al. Adjuvant chemotherapy in older women with early-stage breast cancer, N Engl J Med, 2009. 360(20): p. 2055-65.

1587. Freyer, G., Campone, M., Peron, J., Facchini, T., Terret, C., Berdah, J. F., et.al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study, Crit Rev Oncol Hematol, 2011. 80(3): p. 466-73.

1588. Loibl, S., von Minckwitz, G., Harbeck, N., Janni, W., Elling, D., Kaufmann, M., et.al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials, Breast Cancer Res, 2008. 10(5): p. R77.

1589. Swain, S. M., Whaley, F. S., Ewer, M. S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer, 2003. 97(11): p. 2869-79.

1590. Freedman, R. A., Seisler, D. K., Foster, J. C., Sloan, J. A., Lafky, J. M., Kimmick, G. G., et.al. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511), Breast Cancer Res Treat, 2017. 161(2): p. 363-373.

1591. Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H., Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer, J Clin Oncol, 2007. 25(25): p. 3808-15.

1592. Dall, P., Lenzen, G., Gohler, T., Lerchenmuller, C., Feisel-Schwickardi, G., Koch, T., et.al. Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany, J Geriatr Oncol, 2015. 6(6): p. 462-9.

1593. Brollo, J., Curigliano, G., Disalvatore, D., Marrone, B. F., Criscitiello, C., Bagnardi, V., et.al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials, Cancer Treat Rev, 2013. 39(1): p. 44-50.

1594. Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., et.al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer, J Clin Oncol, 2006. 24(34): p. 5381-7.

1595. Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., et.al. Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 2011. 365(14): p. 1273-83.

1596. Dang, C., Guo, H., Najita, J., Yardley, D., Marcom, K., Albain, K., et.al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer, JAMA Oncol, 2016. 2(1): p. 29-36.

1597. Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., et.al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 2015. 372(2): p. 134-41.

1598. Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., et.al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 2013. 31(14): p. 1748-57.

1599. BfArM, Bulletin zur Arzneimittelsicherheit, 2010.

1600. Patten, D. K., Sharifi, L. K., Fazel, M., New approaches in the management of male breast cancer, Clin Breast Cancer, 2013. 13(5): p. 309-14.

1601. Harlan, L. C., Zujewski, J. A., Goodman, M. T., Stevens, J. L., Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival, Cancer, 2010. 116(15): p. 3558-68.

1602. Caruso, G., Ienzi, R., Piovana, G., Ricotta, V., Cirino, A., Salvaggio, G., et.al. High-frequency ultrasound in the study of male breast palpable masses, Radiol Med, 2004. 108(3): p. 185-93.

1603. Hines, S. L., Tan, W. W., Yasrebi, M., DePeri, E. R., Perez, E. A., The role of mammography in male patients with breast symptoms, Mayo Clin Proc, 2007. 82(3): p. 297-300.

1604. Chau, A., Jafarian, N., Rosa, M., Male Breast: Clinical and Imaging Evaluations of Benign and Malignant Entities with Histologic Correlation, Am J Med, 2016. 129(8): p. 776-91.

1605. Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., et.al. Multidisciplinary meeting on male breast cancer: summary and research recommendations, J Clin Oncol, 2010. 28(12): p. 2114-22.

1606. Cardoso, Fatima, Bartlett, John, Slaets, Leen, van Deurzen, Carolien, van Leewen-Stok, Elise, Porter, Peggy, et.al. Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC ProgramAACR, 2015.

1607. Javidiparsijani, S., Rosen, L. E., Gattuso, P., Male Breast Carcinoma: A Clinical and Pathological Review, Int J Surg Pathol, 2017. 25(3): p. 200-205.

1608. Deb, S., Lakhani, S. R., Ottini, L., Fox, S. B., The cancer genetics and pathology of male breast cancer, Histopathology, 2016. 68(1): p. 110-8.

1609. Sousa, B., Moser, E., Cardoso, F., An update on male breast cancer and future directions for research and treatment, Eur J Pharmacol, 2013. 717(1-3): p. 71-83.

1610. Fentiman, I. S., Male breast cancer is not congruent with the female disease, Crit Rev Oncol Hematol, 2016. 101: p. 119-24.

1611. Mitri, Z. I., Jackson, M., Garby, C., Song, J., Giordano, S. H., Hortobagyi, G. N., et.al. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing, Oncologist, 2015. 20(6): p. 593-7.

1612. Ruddy, K. J., Winer, E. P., Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship, Ann Oncol, 2013. 24(6): p. 1434-43.

1613. Serdy, K. M., Leone, J. P., Dabbs, D. J., Bhargava, R., Male Breast Cancer, Am J Clin Pathol, 2017. 147(1): p. 110-119.

1614. Cutuli, B., Le-Nir, C. C., Serin, D., Kirova, Y., Gaci, Z., Lemanski, C., et.al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases, Crit Rev Oncol Hematol, 2010. 73(3): p. 246-54.

1615. Eggemann, H., Ignatov, A., Stabenow, R., von Minckwitz, G., Rohl, F. W., Hass, P., et.al. Male breast cancer: 20-year survival data for post-mastectomy radiotherapy, Breast Care (Basel), 2013. 8(4): p. 270-5.

1616. Flynn, L. W., Park, J., Patil, S. M., Cody, H. S., 3rd, Port, E. R., Sentinel lymph node biopsy is successful and accurate in male breast carcinoma, J Am Coll Surg, 2008. 206(4): p. 616-21.

1617. Cloyd, J. M., Hernandez-Boussard, T., Wapnir, I. L., Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009, Ann Surg Oncol, 2013. 20(5): p. 1545-50.

1618. Fogh, S., Kachnic, L. A., Goldberg, S. I., Taghian, A. G., Powell, S. N., Hirsch, A. E., Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation, Clin Breast Cancer, 2013. 13(5): p. 344-9.

1619. Zaenger, D., Rabatic, B. M., Dasher, B., Mourad, W. F., Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?, Clin Breast Cancer, 2016. 16(2): p. 101-4.

1620. Giordano, S. H., Perkins, G. H., Broglio, K., Garcia, S. G., Middleton, L. P., Buzdar, A. U., et.al. Adjuvant systemic therapy for male breast carcinoma, Cancer, 2005. 104(11): p. 2359-64.

1621. Wibowo, E., Pollock, P. A., Hollis, N., Wassersug, R. J., Tamoxifen in men: a review of adverse events, Andrology, 2016. 4(5): p. 776-88.

1622. Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Rohl, F. W., et.al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients, Breast Cancer Res Treat, 2013. 137(2): p. 465-70.

1623. Board, PDQ Adult Treatment Editorial, Male Breast Cancer Treatment (PDQ®), 2016.

1624. Mauras, N., O'Brien, K. O., Klein, K. O., Hayes, V., Estrogen suppression in males: metabolic effects, J Clin Endocrinol Metab, 2000. 85(7): p. 2370-7.

1625. Di Lauro, L., Vici, P., Del Medico, P., Laudadio, L., Tomao, S., Giannarelli, D., et.al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer, Breast Cancer Res Treat, 2013. 141(1): p. 119-23.

1626. Zagouri, F., Sergentanis, T. N., Koutoulidis, V., Sparber, C., Steger, G. G., Dubsky, P., et.al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series, Br J Cancer, 2013. 108(11): p. 2259-63.

1627. Khan, M. H., Allerton, R., Pettit, L., Hormone Therapy for Breast Cancer in Men, Clin Breast Cancer, 2015. 15(4): p. 245-50.

1628. Kuba, S., Ishida, M., Oikawa, M., Nakamura, Y., Yamanouchi, K., Tokunaga, E., et.al. Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature, Breast Cancer, 2016. 23(6): p. 945-949.

1629. Masci, G., Gandini, C., Zuradelli, M., Pedrazzoli, P., Torrisi, R., Lutman, F. R., et.al. Fulvestrant for advanced male breast cancer patients: a case series, Ann Oncol, 2011. 22(4): p. 985.

1630. Giotta, F., Acito, L., Candeloro, G., Del Medico, P., Gadaleta-Caldarola, G., Giordano, G., et.al. Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes, Oncologist, 2016.

1631. Wernberg, J. A., Yap, J., Murekeyisoni, C., Mashtare, T., Wilding, G. E., Kulkarni, S. A., Multiple primary tumors in men with breast cancer diagnoses: a SEER database review, J Surg Oncol, 2009. 99(1): p. 16-9.

1632. (ÄZQ), Ärztliches Zentrum für Qualität in der Medizin, E, Gramsch, JD, Hoppe, G, Jonitz, A, Köhler, al., Ollenschläger G et, Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.

1633. Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm OnkologieLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), 2017.

1634. Gesundheitswesen, IQTIG - Institut für Qualitätssicherung und Transparenz im, Bundesauswertung zum Erfassungsjahr 2016 Mammachirurgie. Qualitätsindikatoren., 2017.

1635. Page, D. L., Salhany, K. E., Jensen, R. A., Dupont, W. D., Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma, Cancer, 1996. 78(2): p. 258-66.

1636. Tavassoli, F.A., Pathology of the breastAppleton & Lange, 1999.

1637. Lebeau, A., Kriegsmann, M., Burandt, E., Sinn, H. P., [Invasive breast cancer: the current WHO classification], Pathologe, 2014. 35(1): p. 7-17.

1638. Ellis, I. O., Al-Sam, S., Anderson, N., Carder, P., Deb, R., Girling, A., et.al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. G 148 LRThe Royal College of Pathologists, 2016. p. 1-160.

1639. Balslev, I., Axelsson, C. K., Zedeler, K., Rasmussen, B. B., Carstensen, B., Mouridsen, H. T., The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG), Breast Cancer Res Treat, 1994. 32(3): p. 281-90.

1640. D'Eredita, G., Giardina, C., Martellotta, M., Natale, T., Ferrarese, F., Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution, Eur J Cancer, 2001. 37(5): p. 591-6.

1641. Galea, M. H., Blamey, R. W., Elston, C. E., Ellis, I. O., The Nottingham Prognostic Index in primary breast cancer, Breast Cancer Res Treat, 1992. 22(3): p. 207-19.

1642. Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C., Curigliano, G., et.al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann Oncol, 2015. 26(7): p. 1280-91.

1643. Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C., Curigliano, G., et.al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann Oncol, 2015. 26(7): p. 1280-91.

1644. Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., et.al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol, 2007. 25(28): p. 4414-22.

1645. Marme, F., Aigner, J., Lorenzo Bermejo, J., Sinn, P., Sohn, C., Jager, D., et.al. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials, Int J Cancer, 2013. 133(4): p. 1006-15.

1646. Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A., Newman, L. A., Gonzalez-Angulo, A. M., et.al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy, J Clin Oncol, 2011. 29(15): p. 1956-62.

1647. Vila, J., Teshome, M., Tucker, S. L., Woodward, W. A., Chavez-MacGregor, M., Hunt, K. K., et.al. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer, Ann Surg, 2017. 265(3): p. 574-580.

1648. Vila, J., Teshome, M., Tucker, S. L., Woodward, W. A., Chavez-MacGregor, M., Hunt, K. K., et.al. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer, Ann Surg, 2017. 265(3): p. 574-580.

1649. D'Eredita, G., Giardina, C., Martellotta, M., Natale, T., Ferrarese, F., Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution, Eur J Cancer, 2001. 37(5): p. 591-6.

1650. Galea, M. H., Blamey, R. W., Elston, C. E., Ellis, I. O., The Nottingham Prognostic Index in primary breast cancer, Breast Cancer Res Treat, 1992. 22(3): p. 207-19.

1651. Vila, J., Teshome, M., Tucker, S. L., Woodward, W. A., Chavez-MacGregor, M., Hunt, K. K., et.al. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer, Ann Surg, 2017. 265(3): p. 574-580.

1652. TNM classification of malignant tumoursJohn Wiley & Sons, Inc., 2017. p. p..

1653. TNM-Klassifikation maligner TumorenWiley-VCH, 2017.

1654. NICE, Early and locally advanced breast cancer: diagnosis and treatment. CG80National Institute for Health and Care Excellence (NICE), 2009 (last update 2017). p. 1-26.